

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MANITOBA PUBLIC UTILITIES BOARD

Re: MANITOBA PUBLIC INSURANCE COMPANY (MPI)
GENERAL RATE APPLICATION
FOR 2012/13 INSURANCE YEAR

Before Board Panel:

- Susan Proven - Board Chairman
- Len Evans - Board Member
- Regis Gosselin - Board Member

HELD AT:

Public Utilities Board
400, 330 Portage Avenue
Winnipeg, Manitoba
October 18, 2011
Pages 1047 to 1301

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

APPEARANCES

Candace Grammond) Board Counsel
Nicole Hamilton (np))
Kathy Kalinowsky) MPI
Raymond Oakes) CMMG
Byron Williams) CAC/MSOS (MPI) Manitoba
Nick Roberts (np)) MUCDA
Liz Peters) CAA Manitoba
Jerry Kruk)
Dave Schioler (np)) IBAM

	TABLE OF CONTENTS	
		Page No.
1		
2		
3	List of Exhibits	1051
4	List of Undertakings	1052
5		
6	MPI PANEL, Resumed:	
7	MARILYN MCLAREN, Resumed	
8	DONALD PALMER, Resumed	
9	Continued Cross-examination by Ms. Candace Grammond	1054
10		
11	MPI PANEL 2:	
12	JIM CHRISTIE, Sworn	
13	Examination-in-chief by Ms. Kathy Kalinowsky (Qual.)	1066
14	Ruling (Qual.)	1074
15	Examination-in-chief by Ms. Kathy Kalinowsky	1074
16	Cross-examination by Ms. Candace Grammond	1133
17	Cross-examination by Mr. Byron Williams	1164
18	Cross-examination by Mr. Raymond Oakes	1192
19		
20	MPI PANEL 3:	
21	ROBERT KOWALCHUK, Sworn	
22	NEIL PARKINSON, Sworn	
23	Examination-in-chief by Ms. Kathy Kalinowsky (Qual.)	1206
24	Ruling (Qual.)	1212
25		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

TABLE OF CONTENTS (Con't)

Page No.

Examination-in-chief by Ms. Kathy Kalinowsky	1212
Cross-examination by Ms. Candace Grammond	1270
Cross-examination by Mr. Byron Williams	1290
Certificate of Transcript	1301

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

LIST OF EXHIBITS

NO.	DESCRIPTION	PAGE NO.
MPI-20	Handwritten exhibit with charts on one (1) side and numbers on the other	1088
CAC-10	Memo from Mr. Manktelow to Mr. Neil Parkinson dated April 22nd, 2010	1290

	LIST OF UNDERTAKINGS		
1			
2	NO.	DESCRIPTION	PAGE NO.
3	18	MPI to provide whether the February,	
4		2011, report was affected by this	
5		reserving issue	1060
6	19	Mr. Christie to review his reports with	
7		regard to Basic as at October 31st, 2005,	
8		through October 31st, 2009, for the	
9		purposes of identifying references to	
10		the 250 million	1187
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

1 --- Upon commencing at 9:30 a.m.

2

3 THE CHAIRPERSON: Good morning, everyone.
4 Hopefully everybody had a nice weekend. The weather was
5 fantastic. Great. We're going to start very shortly,
6 but I did want to give you some advance notice that
7 tomorrow we're going to have to finish at 4:00 not 4:30,
8 and that's because the Board -- not the whole Board, but
9 myself and some other members have another commitment in
10 the evening out doing water hearings. So I'll just give
11 you that notice.

12 So, Ms. Grammond...?

13 MS. CANDACE GRAMMOND: Thank you, Madam
14 Chair. Just by way of process for this morning, I'm
15 going to have a few questions for the MPI panel on a
16 couple of actuarial topics. Ms. Kalinowsky's aware of
17 that. And then once I'm done with that she will have a
18 direct examination of Mr. Christie, who's here from Ernst
19 & Young. And then we'll proceed with cross-examination
20 of Mr. Christie after that.

21

22 MPI PANEL:

23 DONALD PALMER, Resumed

24 MARILYN MCLAREN, Resumed

25

1 CONTINUED CROSS-EXAMINATION BY MS. CANDACE GRAMMOND:

2 MS. CANDACE GRAMMOND: So, Mr. Palmer,
3 the -- the questions that I have in the first instance
4 relate to MPI Exhibit 11. That's the internal actuary's
5 report as at July 31st, 2011. It was filed last week.
6 And for everyone else, it's a fairly thick document with
7 Tabs A through I. It's again MPI Exhibit 11.

8 Mr. Palmer, for starters, I'd ask you to
9 describe how this July, 2011, review compares in rigour
10 to the five (5) month review of previous years.

11 MR. DONALD PALMER: Because of our change
12 in reserving last year we thought it was very important
13 to ensure that the reserves were running off, were still
14 tracking to what we expected. So there was a complete
15 review of the existing factors for the PIPP lines of
16 business. Those are the two (2) lines where most of the
17 IBNR resides.

18 So really it was -- was taking a real hard
19 look, much harder than in the past years. In the pa --
20 in the past years, basically we took the factors as they
21 had been calculated as at February. And, of course,
22 there's adjustments for -- to adjust for the number of
23 months of development, but basically that was all that
24 was done.

25 This year, we really did take a harder

1 look at those development factors to make sure that they
2 -- the assumptions were still holding, and really they
3 are still holding. So we -- like other years, we did not
4 involve the external actuary. All the work that was done
5 was internal, as it has been done in the past years.

6 MS. CANDACE GRAMMOND: Thank you. I
7 understand as well that there were no changes to
8 methodologies or development assumptions other than with
9 respect to the accident benefits other indexed line of
10 business?

11

12 (BRIEF PAUSE)

13

14 MR. DONALD PALMER: There was no changes
15 to the factors, although at the beginning there -- there
16 could have been. So we didn't go in at the beginning
17 with the intent of not changing the factors as we had
18 done with previous years. So -- but we did not change
19 the factors.

20 With regard to the accident benefits other
21 indexed, there was large unexpected development and that
22 was due to a -- a system issue in terms of having
23 overstatement in the case reserves. So we made
24 adjustment for -- for that. But that really didn't
25 impact the case development factors, per se.

1 MS. CANDACE GRAMMOND: Thank you. Now I
2 understand, Mr. Palmer, that the review gave rise to a
3 total fiscal year to date net favourable runoff of about
4 4.7 million.

5 Is that right?

6 MR. DONALD PALMER: That's correct and
7 that can be found on page 4 of the report.

8 MS. CANDACE GRAMMOND: Now I understand
9 in terms of the various offsets that gave rise to that
10 4.7 million, that there was unfavourable runoff of about
11 1.2 million on collision, of about 5.4 million in
12 accident benefits weekly indemnity, and that unfavourable
13 runoff was more than offset by the favourable runoff on
14 all the other lines combined of about 11.3 million.

15 MR. DONALD PALMER: Subject to check, I
16 will agree with that.

17 MS. CANDACE GRAMMOND: One (1) more
18 detail of that, and again if you could confirm subject to
19 check, that the favourable runoff of the 11.3 million was
20 mostly concentrated in comprehensive, which was about 4.1
21 million, and accident benefits other indexed, which was
22 about 5.7 million.

23 MR. DONALD PALMER: Subject to check,
24 that sounds about right, yes.

25 MS. CANDACE GRAMMOND: Okay. Mr. Palmer,

1 I'd like you to turn back to page 2 of the report. You
2 commented in -- in your evidence a moment ago that there
3 was an overstatement in the case reserves. And we noted
4 on page 2, in the third paragraph, that there is
5 reference to a "reserving problem" in the BI3 claims
6 management system. Is that the -- the same issue that
7 you were speaking about?

8 MR. DONALD PALMER: Yes, it is.

9 MS. CANDACE GRAMMOND: Can you tell us
10 which line of business was affected by this reserving
11 problem?

12 MR. DONALD PALMER: It's all in PIPP, so
13 any of the PIPP coverages, but -- sorry, it's -- it's all
14 accident benefits other indexed.

15 MS. CANDACE GRAMMOND: And it's reflected
16 in this third full paragraph, that pursuant to the
17 analysis that was done -- I'm reading from the first
18 sentence:

19 "The incurred loss development
20 experience for accident benefits other
21 indexed was significantly higher than
22 predicted by the February, 2011, loss
23 development factors."

24 I take it that this reserving problem was
25 the -- the root cause that led to that observation?

1 MR. DONALD PALMER: Yes, that's correct.

2 MS. CANDACE GRAMMOND: Can you tell us
3 the extent to which the -- the PIPP line of business was
4 affected by this reserving problem and to what extent, if
5 any, the analysis was corrected because of this issue?

6 MR. DONALD PALMER: The analysis, once we
7 delved into the -- the data and -- and found the root
8 cause, that -- essentially there's a -- a trigger called
9 an auto-close trigger, that once reserves are open and
10 then don't have any activity on -- on them, they're
11 supposed to be automatically closed.

12 They weren't. So -- so they continued to
13 be open and grew and grew and grew, and -- and that was
14 essentially the -- the issue. And that was ab -- in
15 total of about \$25 million. Once we identified that and
16 were able to -- to isolate that we completely offset that
17 on the financial statement. So really the impact of that
18 as at the quarterly is nil.

19 There's -- there's an impact on the -- on
20 the case reserves, but then an offsetting impact on the
21 IBNR. So -- so really the overall financial impact on
22 the financial statements as at October 31 is nil.

23 In terms of going forward, I can report
24 that that issue has been fixed as at the first week of
25 October and the -- and the fixes to -- to get -- to fix

1 the systematic issue so the software works correctly, and
2 also a patch to the existing data, so the case reserves
3 were fixed in the first week of October.

4 MS. CANDACE GRAMMOND: And the -- the 25
5 million that you're speaking about is what's referenced
6 on page 3 of the report?

7 MR. DONALD PALMER: That's correct.

8

9 (BRIEF PAUSE)

10

11 MS. CANDACE GRAMMOND: So can you tell
12 us, Mr. Palmer, taking a step back from this July, 2011,
13 report, whether the February, 2011, report was affected
14 by this reserving issue?

15 MR. DONALD PALMER: There may have been
16 some minimal impact at that time. The effect of the
17 auto-close wasn't evident in the underlying data at that
18 point in time. It was only later that -- that really it
19 became so obvious to be material.

20 MS. CANDACE GRAMMOND: Are you in a
21 position to provide some kind of a quantum that would be
22 attached to that? I know you said it was fairly minimal,
23 or would that be a very significant undertaking to
24 determine?

25 MR. DONALD PALMER: It's -- would

1 definitely be an undertaking. I don't have that number.
2 We haven't gone to historically track -- track that. I
3 certainly can't promise it by the end of the hearings.

4 MS. CANDACE GRAMMOND: Okay. That --
5 that's fine.

6
7 --- UNDERTAKING NO. 18: MPI to provide whether the
8 February, 2011, report was
9 affected by this reserving
10 issue

11
12 CONTINUED BY MS. CANDACE GRAMMOND:

13 MS. CANDACE GRAMMOND: Okay. Thank you,
14 Mr. Palmer. Those are the questions with respect to that
15 report. I just have a few questions with respect to the
16 DCAT which was filed by the Corporation as Exhibit 12.
17 If you want to -- to turn it, that's fine. You may not
18 need to.

19 First of all, I'd ask you to confirm that
20 pursuant to this DCAT, the Corporation's recommended
21 minimum RSR target point has increased from 185 million
22 to 210 million.

23 MR. DONALD PALMER: That's correct.

24 MS. CANDACE GRAMMOND: And is it the view
25 of the Corporation that this increase is reflective of a

1 real change in the Corporation's risk level or does this
2 in -- instead reflective of a improvement in the
3 estimation process?

4 MR. DONALD PALMER: I would say that it's
5 a change in the risk level, and the main driver of that
6 is our equity por -- portfolio and the risk inherent in -
7 - in equities. From the time that last year's DCAT was
8 done to this year our total equity portfolio increased by
9 about a hundred million dollars, so it is that risk
10 inherent in that extra hundred million dollars that gives
11 rise to most of this change.

12 We also have had some change in
13 observations from -- from hail claims that has some
14 impact but not as big as the impact from the equities.

15 MS. CANDACE GRAMMOND: And, Mr. Palmer,
16 the increase in equities is due to the Corporation's
17 strategy to increase the amount of equities held within
18 its portfolio?

19 MR. DONALD PALMER: There was two (2)
20 sources of -- of that and more coming up to target
21 levels. Our US equity was only at about 3 percent of the
22 total portfolio and that has been increased to a total of
23 5 percent. We did change from an active strategy to a
24 passive strategy in -- in our US investments. When we
25 did that, we also increased the total -- we -- the total

1 was increased from 3 percent to 5 percent. And, of
2 course, that's under the -- the management of the
3 Minister of Finance. So -- so again, all the contracts
4 with all of the investment managers and the decision to
5 increase from the 3 percent exposure to the 5 percent was
6 from the Minister of Finance.

7 MS. CANDACE GRAMMOND: So we appreciate
8 that the Corporation didn't have the DCAT report at the
9 time that the rate application was filed in June. We
10 know that there's a significant rate reduction being
11 applied for.

12 Given the result of the DCAT, if the
13 Corporation were to -- to look back, and if it had the
14 DCAT now available in hand at the time that the rate
15 application was being prepared, would it have still
16 applied for the -- the same rate decrease? And now that
17 the DCAT is there, given what it reflects, is the
18 Corporation sticking with the application as pending?

19 MS. MARILYN MCLAREN: The Corporation
20 continues to be firmly behind the rate application as
21 filed. Not so much that the DCAT came up with a higher
22 number this year, but remembering that the Corporation
23 has -- clearly now, I think this is the second, maybe the
24 third year, that the Corporation has taken the position
25 that it will accept the PUB's upper target -- upper --

1 the upper range of the PUB target for rate setting
2 purposes, that has not changed.

3 I -- I will not say that the Corporation
4 completely rejects the notion of at some point revisiting
5 with the PUB the matter of the RSR target and what it
6 ought to be, but not this year. So we are firmly behind
7 the rate application. We know the RSR right now is below
8 the PUB target. We continue to be comfortable with that
9 largely because of the outlook that has been filed with
10 the Board.

11 We expect that we may very well be in a
12 position to fully replenish the RSR to the PUB target if,
13 in fact, that's what the cont -- the Corporation
14 continues to support a couple of years from now. And
15 maybe looking at rate decreases. So with that view, and
16 given the fact that we have had an unprecedented year for
17 hail this year that we don't expect to be repeated, we're
18 very comfortable with the rate application as -- as
19 filed. And that's what we are continuing to encord -
20 encourage the Board to approve.

21

22 (BRIEF PAUSE)

23

24 MS. CANDACE GRAMMOND: Mr. Palmer, you
25 told us a couple of minutes ago that the -- in your view,

1 the -- there were additional risks to the Corporation
2 inherent in the increase in the equities within the
3 Corporation.

4 In your view, or in the view of the
5 Corporation, is there a -- a distinction between equities
6 that are passibly - passively managed versus those that
7 are actively managed?

8 MR. DONALD PALMER: No, the -- the
9 difference is there -- there's an extra 2 percent that
10 the Minister of Finance has deemed to be appropriate for
11 the MPI portfolio. And it's that difference of 2
12 percent, plus the other source of the -- the gain of that
13 \$100 million was also capital gains within the investment
14 portfolio.

15 So because of that growth in the portfolio
16 that was the - that's the source of the risk. It's not
17 the fact that there's a different risk level if it's
18 actively managed or passively managed.

19 MS. CANDACE GRAMMOND: Okay. With
20 respect to the -- the DCAT then, can you confirm for the
21 Board whether the -- the document is prepared and
22 reviewed exclusively internally, or does the
23 Corporation's app -- external appointed actuary, Mr.
24 Christie, or his successor, have any role in that?

25 MR. DONALD PALMER: The -- the report is

1 prepared entirely internally and -- and signed by Mr.
2 Johnston, who is a Fellow of the Casualty Actuarial
3 Society and a Fellow of the Canadian Institute of
4 Actuaries. Part of the process is to have this document
5 peer-reviewed. It has not yet been peer-reviewed.

6 MS. CANDACE GRAMMOND: Okay. Thank you,
7 Madam Chair. Those are the questions that we have for
8 the MPI witnesses with respect to those issues. It -- it
9 occurs to me, and I didn't mention this in -- at the
10 beginning, but if any of the Intervenors have questions
11 for the MPI witnesses on these issues in fairness and in
12 -- pursuant to the agreement that we have with MPI, those
13 should probably be asked now. There may not be
14 questions, but we should probably give that opportunity.

15 THE CHAIRPERSON: We'll turn to Mr.
16 Williams, first.

17 MR. BYRON WILLIAMS: Thank you and good
18 morning, Madam Chair. I think I ran through my questions
19 last Thursday, so I'm satisfied with the record as it
20 currently stands.

21 THE CHAIRPERSON: Okay. Do we have other
22 Intervenors that would like to ask questions at this
23 point?

24 MR. RAYMOND OAKES: Not at this point,
25 Madam Chairman, I think that most of my questions follow

1 the interrogatories and can proceed in the ordinary
2 course.

3 MS. LIZ PETERS: No questions from CAA.

4 THE CHAIRPERSON: All right. We'll turn
5 back now to you, and you can tell us what's happening
6 next.

7 MS. CANDACE GRAMMOND: Sure, Madam Chair.

8 THE CHAIRPERSON: Thank you.

9 MS. CANDACE GRAMMOND: I think then, what
10 we'll have is Mr. Christie should be sworn by the Board
11 Secretary, and Ms. Kalinowsky can proceed with her direct
12 examination. Once that's concluded then I'll cross-
13 examine and so on and so forth with the Intervenors.

14 THE CHAIRPERSON: Thank you.

15

16 (PANEL STANDS DOWN)

17

18 MPI PANEL 2:

19 JIM CHRISTIE, Sworn

20

21 MR. JIM CHRISTIE: My name is James
22 Kenyan Christie.

23 THE CHAIRPERSON: Proceed.

24

25 EXAMINATION-IN-CHIEF BY MS. KATHY KALINOWSKY (QUAL.):

1 MS. KATHY KALINOWSKY: Good morning. I'm
2 very pleased to be able to present Mr. Jim Christie, as a
3 -- a witness this morning. He has testified previously
4 to the Public Utilities Board, but is back once again.

5 He also has, accompanying him in the back
6 row on the far -- my far right, is Mr. Liam McFarlane,
7 from Ernst and Young, who is also a member of both the --
8 I'm sorry, a Fellow of the Casualty Actuarial Society and
9 the Canadian Institute of Actuaries.

10 With that, I'd like to proceed with my
11 direct exam of Mr. Christie. I have prepared a fairly
12 lengthy and comprehensive direct examination of Mr.
13 Christie, in order to assist the Board members in their
14 understanding and placing the materials in context and
15 allowing for some education, also recognizing that two
16 (2) of the Board members, this foray into actuarial
17 science is a -- a first.

18 So, Mr. Christie, with that, I'll start
19 off by asking you, you're a Fellow of the Casualty
20 Actuarial Society. What type of specialization is that?

21 MR. JIM CHRISTIE: I am a Fellow of the
22 Casualty Actuarial Society. The Casualty Actuarial
23 Society specializes in training actuaries in areas of
24 non-life insurance casualty, typically referred to in
25 other jurisdictions as property casualty in Canada, or

1 cas -- or casualty insurance. So, auto insurance,
2 general liability, accident and health, home insurance,
3 those types of things.

4 MS. KATHY KALINOWSKY: You're also a
5 Fellow of the Canadian Institute of Actuaries.

6 MR. JIM CHRISTIE: I am a Fellow of the
7 Canadian Institute of Actuaries.

8 MS. KATHY KALINOWSKY: And what's the
9 difference between the CAS and the CIA, to use the
10 acronyms.

11 MR. JIM CHRISTIE: In broad terms, the
12 CAS, is an educational body, largely analogous to
13 universities. It specializes in training actuaries on an
14 international basis, although the organization is based
15 in the United States it does train actuaries throughout
16 the world.

17 The CIA, on the other hand, is the
18 professional body that represents actuaries in Canada.
19 It is the voice of the actuarial profession. It handles
20 the issues of discipline -- members. It advocates on
21 behalf of the public where there are issues that are of
22 an actuarial nature and other -- generally tries to help
23 the members of the cag -- the Canadian Institute of
24 Actuaries in their day-to-day work.

25 MS. KATHY KALINOWSKY: And how long have

1 you been involved in both the CIA and the CAS and can you
2 explain the nature of your participation?

3 MR. JIM CHRISTIE: I first became
4 involved with the CAS in 1976 when I started writing
5 actuarial exams, and I've been involved with the CIA
6 since 1981. Over the years, I've had a number of
7 capacities within both those organizations. Within the
8 CAS, the education body, I was, at one time, responsible
9 for Exam 7, which was the exam that specialized in
10 Canadian educational material, rules and regulations set
11 by public bodies, such as the PUB or other regulatory
12 bodies, taxation and legislation.

13 I later was vice-president of admissions
14 of the CAS ultimately responsible for all education
15 within the Casualty Actuarial Society, and I have also
16 served on the board of directors of the CAS.

17 Within the CIA I was chairman of the
18 Property Casualty Financial Reporting Committee. That is
19 the committee charged with reviewing standards of
20 practice for reporting with -- on property and casualty
21 issues, and addressing the establishment of claim
22 liabilities or policy liabilities in the property
23 casualty area.

24 I served as the secretary-treasurer of the
25 Canadian Institute of Actuaries, two (2) terms on the

1 board of directors, and a year ago I was elected
2 president of the Canadian Institute of Actuaries.

3 MS. KATHY KALINOWSKY: Can you explain
4 what your presidency of the Canadian Institute of
5 Actuaries entails, please?

6 MR. JIM CHRISTIE: I am the -- ultimately
7 responsible for actio -- I'm esse -- essentially the
8 chief executive officer of the CIA. We have a board of
9 directors of twelve (12) members that have the final
10 authority. I am a member of the board in my capacity as
11 president. So the board is the governing authority, but
12 the day-to-day operations are my responsibility, as well
13 as a paid executive director who is the administrative
14 officer, but I am setting policy.

15 MS. KATHY KALINOWSKY: Do you have
16 experience in the development of Canadian actuarial
17 standards?

18 MR. JIM CHRISTIE: Yes. Today, Canadian
19 actuarial standards are handled by Independent Actuarial
20 Standards Board, but until six (6) years ago they were
21 developed by the -- directly by the Canadian Institute of
22 Actuaries.

23 I personally was responsible for the
24 development of the standard of practice relating to pro -
25 - provisions for average deviations which allowed the

1 introduction in Canada of the present value of claim
2 liabilities, which is the standard of practice now in
3 this country.

4 As well, in the last year I've been active
5 -- I've been a member of the designated group developing
6 the new standard of practice for workers compensation.

7 MS. KATHY KALINOWSKY: And what about
8 international actuarial standards?

9 MR. JIM CHRISTIE: In my role as
10 president of the CIA I am a member of the council of the
11 International Actuarial Association. The International
12 Actuarial Association is in the process of developing
13 actuarial standards. "Standards" may be too strong a
14 word. Although they may look like standards because it's
15 an international organization that operates much like the
16 International Actu -- Accounting Standards Board, it only
17 has the power to adopt standards, but they don't come
18 into force until the various countries actually approve
19 the standard for use in their country.

20 MS. KATHY KALINOWSKY: Thank you, Mr.
21 Christie. Last time you testified to the Public
22 Utilities Board you were a partner at Ernst & Young. Can
23 you explain why you are no longer at Ernst & Young?

24 MR. JIM CHRISTIE: Yes. The partnership
25 agreement at Ernst & Young requires that partners retire

1 from the partnership when they turn sixty (60). I turned
2 sixty (60) in June of this year and retired at June 30th,
3 which was the end of our fiscal year.

4 MS. KATHY KALINOWSKY: And can you
5 explain what the nature of your practice was at Ernst &
6 Young?

7 MR. JIM CHRISTIE: I was in charge of the
8 property casualty actuarial practice for Canada at Ernst
9 & Young. I was there for roughly fifteen (15) years.
10 During that time we developed the practice into one (1)
11 of the larger actuarial practices in Canada.

12 I was also actively involved globally with
13 Ernst & Young in developing a strategy to deal with the
14 International Accounting Standards Boards -- the
15 International Financial Reporting Standard on insurance
16 contracts. That standard is still not finished, and so
17 despite the fact that I worked for ten (10) years on it
18 for Ernst & Young it ended up as -- I -- I'm no longer of
19 value to Ernst & Young on that side.

20 MS. KATHY KALINOWSKY: And a major part
21 of your practice would have been at Ernst & Young to
22 prepare opinions on unpaid claims liabilities?

23 MR. JIM CHRISTIE: Yes. Yes,
24 approximately 60 percent of my practice dealt with
25 establishing policy liabilities, that would be claim

1 liabilities and unearned premiums for various clients.

2 MS. KATHY KALINOWSKY: And approximately
3 how many opinions would you have signed in your
4 professional career as an actuary?

5 MR. JIM CHRISTIE: In excess of two
6 hundred and fifty (250).

7 MS. KATHY KALINOWSKY: And is that
8 correct that in -- that each opinion has a second
9 reviewer or a peer review undertaken at Ernst & Young?

10 MR. JIM CHRISTIE: Yes, that's our own --
11 Ernst & Young's internal standard, that all actuarial
12 reports are subject to a internal review before being
13 released to the client.

14 MS. KATHY KALINOWSKY: And approximately
15 how many opinions were you the second reviewer on, or did
16 you peer review for?

17 MR. JIM CHRISTIE: Approximately two
18 hundred and fifty (250) as either an internal reviewer
19 for reports issued by Ernst & Young, or as an external
20 peer reviewer.

21 In Canada many companies are required by
22 their -- their regulator to have their actuary's reports
23 externally reviewed on a triennial basis, and I have done
24 that for a number of clients as well.

25 MS. KATHY KALINOWSKY: Thank you. With

1 that I'd like to have Mr. Christie qualified as an expert
2 on actuarial science for these proceedings.

3 Ms. Grammond, if you have any questions or
4 concerns you could advise the Board on the procedure.

5 MS. CANDACE GRAMMOND: Yeah. No, I have
6 no objection. The Intervenors should be canvassed if
7 they do and we'll go from there.

8 THE CHAIRPERSON: Okay. We'll do that.
9 Mr. Williams, are -- are you prepared to accept this
10 witness?

11 MR. BYRON WILLIAMS: We have no challenge
12 to the qualifications, as framed.

13 THE CHAIRPERSON: I'll go back, are you
14 prepared as well?

15 MR. RAYMOND OAKES: Certainly, Madam
16 Chair.

17

18 RULING (QUAL.):

19 THE CHAIRPERSON: Thank you. Well, I
20 think we can proceed. We're willing to accept the
21 witness.

22

23 EXAMINATION-IN-CHIEF BY MS. KATHY KALINOWSKY:

24 MS. KATHY KALINOWSKY: Thank you very
25 much -- thank you very much for that.

1 I'd like to proceed now to ask some
2 questions, Mr. Christie, of you with respect to your
3 relationship with Manitoba Public Insurance.

4 Can you tell us how long you have acted as
5 the appointed actuary for MPI?

6 MR. JIM CHRISTIE: Approximately fifteen
7 (15) years. MPI appoints an actuary every five (5) years
8 as a result of an RFP I have been appointed once and then
9 reappointed two (2) times.

10 MS. KATHY KALINOWSKY: And in that period
11 of fifteen (15) years can you explain to the Board what
12 services you performed for MPI?

13 MR. JIM CHRISTIE: The bulk of my work
14 was as evaluation actuary. I -- evaluating the policy
15 liabilities as of October 30th and February 28th or 29th
16 each year -- each year for all fifteen (15) years.

17 In addition, for a period of about four
18 (4) years in the early 2000s I produced a -- dynamic
19 capital adequacy report for the Board, which is filed
20 today as the DCAT report. That is not a requirement of
21 the evaluation actuary to do that. MPI had not been
22 doing this on a regular basis, I started doing it for
23 them. And in -- then in due course they brought that
24 analysis in-house.

25 MS. KATHY KALINOWSKY: And as part of

1 your services performed for MPI you also meet with the
2 audit committee of the board of directors?

3 MR. JIM CHRISTIE: Yes, I do. I meet, at
4 least, annually in person with the board of directors to
5 discuss the results of my analysis.

6 MS. KATHY KALINOWSKY: And in fact your
7 appointment is to the board of directors of the
8 Corporation, not to the management of the Corporation?

9 MR. JIM CHRISTIE: That is correct.

10 MS. KATHY KALINOWSKY: Can you explain
11 why that's important?

12 MR. JIM CHRISTIE: It's important from a
13 risk management perspective that my obligation is to the
14 board and not to management. That gives the board some
15 additional comfort level that the report and the -- the
16 policy liabilities that I report on are appropriate and
17 are not unduly influenced by any management issues.

18 It also gives the board the -- having
19 someone external to the organization, the benefit of --
20 of a broader knowledge base than -- than someone who
21 might be internal to the organization and typically only
22 see what goes on in -- in one (1) corporation.

23 MS. KATHY KALINOWSKY: And for most
24 insurers, they are regulated so to speak by OSFI, and
25 that's a requirement. But MPI is not, is that correct?

1 MR. JIM CHRISTIE: MPI is not regulated
2 in the sense that most insurers in this country are. It
3 is not required to have an appointed actuary. It has
4 chosen to -- to do so, for I -- I -- I presume risk
5 management issues, or for board governance issues.

6 MS. KATHY KALINOWSKY: I'd like to ask
7 some questions on the purpose of having opinions prepared
8 on unpaid claims liabilities.

9 Your opinion is included in the annual
10 report, at page 47, and I think it would be helpful for
11 the Board members to turn to the annual report at --

12

13 (BRIEF PAUSE)

14

15 MS. KATHY KALINOWSKY: It is contained at
16 AI-7.

17 THE CHAIRPERSON: We all have it.

18 MS. KATHY KALINOWSKY: Thank you. It's
19 on page 47, and it's the bottom right hand corner. It's
20 short and sweet. "The Actuary's Report" is the title.

21 Perhaps, Mr. Christie, you could walk the
22 Board members through that and explain what your opinion
23 on.

24 MR. JIM CHRISTIE: Certainly. This is a
25 standard terminology. It's taken directly from the

1 standards and practice of the Canadian Institute of
2 Actuaries.

3 The -- first of all, the report is
4 addressed to the board of directors of Manitoba Public
5 Insurance Corporation. The addressee can change from one
6 (1) report to another, obviously, but -- then the first
7 paragraph says:

8 "I have evaluated the policy
9 liabilities [which means the claim
10 liabilities and the unearned premium
11 liabilities] and any associated
12 deferred acquisition expenses, at --
13 for its balance sheet at February
14 28th."

15 So we have to identify the date at which
16 this report is being done. So I'm evaluating those
17 numbers on the balance sheet and the change in those
18 liabilities from year to year as they flow through the
19 income statement. So, inferentially, I'm opining on the
20 income statement as well.

21 "I have done that in accordance with
22 accepted actuarial practice, including
23 the selection of appropriate
24 assumptions and methods."

25 The second paragraph states:

1 "In my opinion [and it's my opinion]
2 the amounts of policy liabilities make
3 appropriate provision for all
4 policyholder obligations and the
5 financial statements fairly present the
6 results of the valuation."

7 The latter part of that sentence allows
8 the company to carry a number slightly different than I
9 might have estimated, typically it's a rounding
10 difference. But in the case of MPI, it's exactly the
11 same, but it does allow for a mod -- non-material
12 difference there.

13 I then sign it personally, and identify
14 myself as a Fellow of the Canadian Institute of
15 Actuaries. And it's dated Winnipeg.

16 DR. LEN EVANS: Excuse me, is this a
17 normal type of actuary report, or...?

18 MR. JIM CHRISTIE: Absolutely. This is
19 the standard wording.

20 DR. LEN EVANS: Do you have some with a
21 lot of negative statements in them?

22 MR. JIM CHRISTIE: If there -- if there
23 were any change in these wordings, it would be classed as
24 a qualified opinion. And the only things that can change
25 are in the standards and practice there's a bracket

1 around the name of the company and the date. And I'm
2 allowed to call it -- in this -- Manitoba's case it's a
3 statement of operations. In some cases it's a financial
4 statement, whatever the term that is used in that
5 organization.

6 But there are -- can be no changes to this
7 without it being a qualified opinion. A qualified
8 opinion would set off some bells and whistles.

9 DR. LEN EVANS: So this is, more or less,
10 a standard type of actuarial report.

11 MR. JIM CHRISTIE: This is a standard
12 opinion, yes.

13 DR. LEN EVANS: Okay, thanks.

14

15 CONTINUED BY MS. KATHY KALINOWSKY:

16 MS. KATHY KALINOWSKY: And, in fact,
17 you've provided unqualified opinions since 2005 and every
18 year since to Manitoba Public Insurance?

19 MR. JIM CHRISTIE: I have.

20 MS. KATHY KALINOWSKY: Can you explain to
21 the Board, Mr. Christie, whether the finance -- final
22 selection of the unpaid claims reserve is that of MPI, or
23 is it that of the external appointed actuary?

24 MR. JIM CHRISTIE: The final selection is
25 the responsibility of the Corporation. I do my analysis,

1 and my opinion says that the financial statements fairly
2 present my analysis. So if there are non-material
3 differences I could still sign an unqualified opinion.

4 In most companies, the number on the
5 financial statements is identical to that nu -- the
6 number in the appointed actuary's analysis. But in some
7 organizations timing constraints require that some first-
8 order estimates be done and the number may be slightly
9 different.

10 MS. KATHY KALINOWSKY: Can you also
11 explain to the Board what would be the consequences if
12 MPI did not adopt the final amount that you've indicated
13 in your report?

14 MR. JIM CHRISTIE: Well, in the case of
15 MPI, we have a standard material -- materiality of \$6
16 million. So if the Corporation were to adopt a number
17 that was either higher or lower than my estimate by more
18 than \$6 million I would have to issue a qualified
19 opinion.

20 Issuing a qualified opinion would, first
21 of all, mean that the opinion in the financial statements
22 are qualified. And I can't speak for the auditors but,
23 typically, if the -- if the Corporation were to provide a
24 qualified actuarial opinion there would be concerns about
25 whether the audit could also -- could -- opinion could be

1 issued without being equally qualified.

2 Typically, what happens in the case where
3 management and the actuaries have a disagreement, those
4 nu -- that -- that is resolved before we get to the stage
5 of publishing financial statements.

6 MS. KATHY KALINOWSKY: And how is that
7 resolved?

8 MR. JIM CHRISTIE: Typically it's
9 resolved by adopting what the actuary says. That is
10 Canadian practice. In my role as the lead of the
11 actuarial practice in Ernst & Young I had to describe
12 Canadian practice to a number of senior VPs in American
13 corporations who were quite indignant that they could not
14 override their actuary. And my response was: If you
15 know something that the actuary doesn't know why don't
16 you tell them, and then they'll probably change their
17 opinion. And if you don't know anything that -- beyond
18 that you'd like it to be different, I'm going to stand
19 behind the actuary.

20 This is when I'm speaking as a member of
21 Ernst & Young as the audit team, not as Ernst & Young, an
22 actuary.

23 MS. KATHY KALINOWSKY: Over the past
24 week, maybe two (2) weeks now, Mr. Palmer has testified
25 that MPI is at times forecasting a runoff of PIPP claims

1 that could last forty (40), fifty (50), even sixty (60)
2 years, even though it only has at this point sixteen (16)
3 years experience because PIPP was introduced in 1994.

4 Can you explain at some length the
5 difficulties that this causes and why it is absolutely
6 crucial and important for your review of the unpaid
7 claims liabilities?

8 MR. JIM CHRISTIE: The -- the basic
9 premise of establishing claim liabilities is that the
10 future will resemble the past possibly with modifications
11 for what is known to be different now than what had
12 happened in the past. For instance, there might be an
13 adjustment for inflation. There might be a change in
14 reserving practices, something we'll talk about at length
15 later on.

16 But in broad terms, the assumption is that
17 what has happened in the past is likely to be replicated.
18 Now, claim development is a stochastic -- a probable --
19 probabilistic process. It's not guaranteed that a
20 particular event will happen each and every time. All we
21 do -- have with past observations is, in effect, sent --
22 observations of what might have happened.

23 They are equivalent to, if you will,
24 rolling a dice. You can -- if you don't know how many
25 faces there are on a dice, you just count them,

1 eventually you can figure it out, but there's no
2 guarantee of what a particular roll will produce. You --
3 you can describe what the process might be, but not what
4 the fi -- actual result will be.

5 In the case of PIPP, the product provides
6 for medical and rehabilitation expenses and for weekly
7 wage replacement from the time the individual is injured
8 until they die. In the case of a driver in their 20s,
9 that could be fifty (50) years. In the case of a
10 passenger who happens to be an infant, it could easily be
11 seventy (70) or eighty (80) years. Now, not everyone who
12 is injured is an infant, but there will certainly be
13 claims that will go on for -- for the lifetime of
14 individuals.

15 And as -- the basic process that actuaries
16 try to use is that the future is going to resemble the
17 past. Well, the fact is we don't have a history of -- of
18 all the people who are injured in a particular year
19 having finally died and know -- and knowing what might
20 have happened.

21 At this point, we have sixteen (16) years
22 of experience on the 1994 year. Now that will cover most
23 claims, but there will be a -- still, a significant
24 number of individuals who are act -- alive and are going
25 to be getting benefits for the rest of their life, which

1 might be a -- what's called an "impaired life." If
2 you're injured in -- some injuries can decrease your life
3 expectancy, others don't.

4 If you lose your leg, it probably doesn't
5 have a significant impact on your life expectancy. If
6 you are in a wheelchair, your ability of -- of your
7 internal organs to operate properly is im -- impaired and
8 you're likely to have some impaired life -- life
9 expectancy. We don't know for sure what that's going to
10 do for the claimants that MPI actually has from the 1994
11 year, and we know even less about the claimants they have
12 from the 2010 year.

13 One (1) of the approaches that actuarial
14 science uses is to look at surrogates. Is there another
15 base that's similar to what PIPP is that we might use
16 that's been around longer?

17 Well, the fact of the matter is that in
18 Canada there are only really three (3) jurisdictions that
19 have something like PIPP. We have the in -- in Manitoba
20 from 1994, we have it in Saskatchewan from roughly 1995,
21 and we have it in Ontario from about 1992. So they're
22 all roughly the same vintage, so we really don't have
23 another Canadian source to go to for automobile
24 accidents.

25 And we certainly don't -- and the next

1 thing would be to look south of the border, but in fact,
2 the Americans are much more litigious. They don't really
3 believe in a no-fault based system, so there really isn't
4 a no-fault based accident system in the -- or automobile
5 accident system that we can look at down there.

6 The other alternative is workers'
7 compensation. Workers' compensation is, broadly
8 speaking, been around since 1910, 1920, and it varies by
9 province, but broadly speaking. So it -- certainly you
10 could say you would have closed claim file -- claim years
11 in a workers' comp environment.

12 The problem there is the injuries that are
13 entailed in workers' comp are not necessarily similar --
14 or, identical to -- they're similar, but not identical
15 to, the kinds of trauma you would get in an automobile
16 accident.

17 First of all, it's workers' comp, so
18 everyone who's -- virtually everyone who's injured is
19 already, in some sense, physically able to work. When
20 you're involved in automobile accidents you have a number
21 of people in -- typically the passengers in the car who -
22 - who couldn't work, and you've also got younger children
23 who certainly aren't working, so it's not a -- it's not a
24 perfect match either. And PIPP is not identical to
25 workers -- so, well, we did look at that -- at that as a

1 possibility.

2 The other option that you might have is
3 disability insurance. Many life insurance companies in
4 this country sell a product that will pay you if you are
5 disabled or ill. The problem with that product is that,
6 first of all, before you get the policy you're
7 underwritten, so you -- they only pick people who have a
8 propensity to go back to work. Whereas, if you have an
9 automobile accident you can be anybody. So you've
10 already got what's called a select group of policy
11 holders in disability insurance.

12 And the second problem with disability
13 insurance is that it covers both accidental illness --
14 or, accidental trauma events plus normal illness: cancer,
15 flu -- influenza, whatever. So there are all kinds of
16 differences there. But there are a number of -- of
17 relatively good studies on disability insurance that
18 would -- you can use to create models.

19 So we looked at all of those. But really,
20 we still don't have anything beyond sixteen (16) years,
21 so the best that you can say is you've got sixteen (16)
22 years of experience. Do any of the models that are out
23 there, match for the first sixteen (16) years?

24 To the extent they do, there's -- you can
25 have some confidence that they are -- they're -- they may

1 be right. They're certainly maybe right for the first
2 sixteen (16) years, but there's absolutely no guarantee
3 that they're right for the 30th year or the 40th year.

4 That's the problem which they have.

5 MS. KATHY KALINOWSKY: Thank you for that
6 explanation, Mr. Christie. The next question I have is a
7 comment on the concept of a skewed distribution, and how
8 this impacts upon your opinion for MPI. I also note that
9 you have prepared an exhibit here, that we'd like to hand
10 out. And it's a handwritten exhibit with some charts on
11 one (1) side and numbers on the other -- other side. I
12 believe it should be MPI Exhibit number 20. So we'll
13 just hand these out right now if you'll just wait a
14 moment and then I'll ask the question once again.

15

16 (BRIEF PAUSE)

17

18 MS. KATHY KALINOWSKY: It's just going to
19 be confirmed in one (1) moment. Yes, confirmed. That is
20 number 20.

21

22 --- EXHIBIT NO. MPI-20: Handwritten exhibit with
23 charts on one (1) side and
24 numbers on the other

25

1 CONTINUED BY MS. KATHY KALINOWSKY:

2 MS. KATHY KALINOWSKY: Mr. Christie, can
3 you comment on the concept of skewed distribution, and
4 how this impacts upon your opinion for MPI?

5 MR. JIM CHRISTIE: Yes, I can. An
6 exhibit has been handed out that I drew quickly yesterday
7 for Kathy, in preparation for today. I'm -- I apologize
8 for it not being a very sophisticated diagram. And I
9 don't purport that this is exactly what happens at MPI,
10 it's just to describe the concept of skewedness.

11 Most people think about a distribution as
12 being -- that it's equally likely to have results on --
13 higher or lower. If you think about rolling a dice, the
14 -- each number is equally likely. Spinning a roulette
15 wheel, whatever, each number is equally likely. Those
16 are -- are -- are, in some sense, normal distributions.
17 The numbers close in around the middle.

18 Now every -- it's a law of statistics, or
19 a -- the more -- the larger the sample you take, the more
20 -- the closer to a -- a normal distribution you get. But
21 you'll never get exactly there, you'll just get a -- the
22 normal approximation of the results.

23 Now the problem in -- in insurance is that
24 the underlying distributions, claim size, are skewed.
25 That is, it's imp -- virt -- it's impossible to have a

1 claim below zero. I mean, I guess it's not impossible
2 but it would be a very -- it would be -- probably be a --
3 an error in the data system rather than a -- a real
4 claim. You -- you wouldn't have a claimant paying you
5 dollars if you are the insurance company.

6 On the other hand, while many -- most of
7 the claims are small, there are a few large ones. And
8 they are what we often refer to as outliers. They're
9 very large. So you look at the injuries that people have
10 received in automobile accidents. Most people are back
11 to work or back to whatever they were doing, within a few
12 weeks or certainly within a few months.

13 But some people are injured for the
14 remainder of their -- the injury will last to the
15 remainder of their life and they're going to have a
16 significantly larger claim.

17 So that's a skewed distribution. There
18 are -- there are few big claims and very few -- and there
19 are no negative claims. And that was what I was trying
20 to show with this example of a -- a normal distribution
21 and a skewed distribution, with a few claims out in the -
22 - the -- the right hand side -- the -- the -- typically
23 the large dollar amounts.

24 And then, what I tried to do is describe
25 that in -- in numeric terms. So, I just chose an example

1 of the numbers from one (1) to a hundred.

2 If you think of the numbers from one (1)
3 to a hundred, each one (1) being equally likely, the
4 mean, the average of those, is fifty (50). And the
5 median, that is half of the claims will be less than
6 fifty (50) and half of the claims will be more than fifty
7 (50).

8 So, that's a very nice distribution with a
9 mean and the median. The mean being the average and the
10 median being the -- the point where half of the claims
11 are above and below it is fifty (50) as well.

12 Now, if I choose a insurance distribution
13 -- and this particular example I simply replaced the
14 number one hundred (100) by ten (10) times that number, a
15 thousand, and assume all the other numbers are the same,
16 the numbers one (1) to ninety-nine (99) plus the number
17 one thousand (1,000) rather than one hundred (100).

18 Well, the mean of that distribution is
19 sixty (60), but the median, that is, half the
20 observations, are at fifty (50). So if you -- if you're
21 an actuary and you say the average is sixty (60), and
22 then you start testing it, you're more likely not going
23 to find that half the numbers are -- are below fifty
24 (50). You may not get a hundred observations, you may
25 only get twenty (20). Your -- you may not see the

1 hundredth observation.

2 And, in fact, even though the correct
3 average is sixty (60), the empirical evidence is going to
4 suggest that the -- the median, which many people take to
5 be the mean or average, is fifty (50).

6 And so people are going to suggest to you
7 that you have put some conservatism into your results
8 when in fact all you're doing is reflecting the true
9 value of the distribution.

10 Now, the problem we have in a system like
11 MPI's is that we don't have the whole distribution yet,
12 we only have sixteen (16) years worth of data. We may
13 not have seen in this example the one hundred (100) year
14 -- the one hundred (100) -- or one thousand do -- dollar
15 (\$1,000) event. We may only have seen the numbers
16 typically in the -- in the middle range, the forties to
17 sixties.

18 So when I am trying to establish claim
19 liabilities for an organization like this with unproven
20 future experience I try to be slightly conservative,
21 recognizing based on the observations I've got I'm
22 slightly conservative because there is probably a large
23 observation that hasn't yet been seen.

24 And that's why you try -- when I establish
25 these liabilities I try to pick various factors that are

1 slightly above the observed values for that particular
2 reason, largely because we haven't got all the experience
3 yet for MPI, and -- and we won't have it in my lifetime.

4 MS. KATHY KALINOWSKY: Thank you for that
5 explanation, Mr. Christie. I also want you to comment on
6 the concept of robustness, and particularly with regard
7 to your opinion for MPI.

8 MR. JIM CHRISTIE: Okay. We -- another
9 aspect governing the judgment that actuaries use, and
10 there is some judgment, this is not a mathematical
11 process, is that the selections you make should be
12 robust. That is that the addition of one (1) more
13 observation shouldn't change your estimate dramatically.

14 You should try to pick numbers or
15 selections that are -- or -- or design models that are as
16 best as possible robust. That's difficult to do when you
17 only have six (6), ten (10), fifteen (15) observations.
18 In a typical -- not a actuarial analysis, but in a
19 typical field test or something, like a vaccine, we would
20 tens of thousands of observations, and -- and adding one
21 (1) more observation isn't going to change the average
22 very much.

23 In the case of an actuarial analysis we,
24 at best, would have perhaps twenty-five (25) data points,
25 and we certainly don't have that for MPI. And so adding

1 one (1) point has the ability to change the average
2 significantly.

3 So you -- you try to pick numbers that
4 don't -- that are -- that won't be changed too much from
5 one (1) year to the next. And -- and that broad concept
6 of robustness is -- is underlying my selections
7 throughout the years.

8 Now, at some point, you have to start to
9 recognize reality or what you've seen, not re -- reality,
10 but empirical evidence, and so that is part of the reason
11 we're here today to talk about the \$250 million.

12 MS. KATHY KALINOWSKY: And that's a good
13 segue into the next session, which is can you explain
14 what occurred in the actuarial review as at October 31st,
15 2005.

16 MR. JIM CHRISTIE: Yes. Yes, I can. In
17 broad terms, a new process for establishing case
18 reserves, that is the value assigned to an individual
19 claim file, was set up in 2005.

20 Prior to that time, claim reserves were
21 largely established by the individual claim examiner
22 based on his or her personal experience and feelings
23 about the case. So they would look at an individual
24 claim and say, This person is likely to recover, not
25 likely to recover, likely to recover in five (5) years,

1 likely to recover in two (2) months, and put some
2 estimate on there.

3 Once claims ha -- prior to 2005, once
4 claims had reached ten (10) years of duration, they were
5 established using a tabular reserve, a formula approach
6 that looked at the attributes of a particular claimant,
7 their age, their gender, the severity of their accident,
8 how long ago had it been since the accident happened.

9 In 2005, that broad tabular approach was
10 mechanized and then applied to all claims. Initially the
11 plan had been all claims over ten (10) years within the
12 computer system, but in practical application it became
13 applied to all claims over three (3) -- three (3) years
14 since they had happened.

15 So there was a significant change in the
16 way individual case estimates were established, that is
17 the -- the raw data coming in that would come into the
18 actuary's datasets.

19 And an al -- and when that was implemented
20 we anticipated -- or MPI had anticipated that there would
21 some change. They weren't sure exactly what it was, but
22 it was closely monitored. And the -- the impact of that
23 change was in the order of \$250 million, that the case
24 estimates went down by \$250 million by applying this new
25 case reserving process.

1 Now, the bane on actuaries' existence
2 changes in the case -- in the way case estimates are
3 established. Yeah. I often tell my clients: I don't
4 care how you reserve as long as you do it the same year
5 in and year out. My models will correct for your -- any
6 error that you've been consistently making. But if
7 you're changing in the way you reserve the models are --
8 are strained. They're hard -- it's difficult to use the
9 models because you have to account for this change in the
10 -- the raw data coming into your system.

11 So we ha -- knew that coming -- the raw
12 data had produced roughly a \$250 million drop. In simple
13 terms, when companies change their case reserving
14 estimates, if the total estimate drops by some number,
15 then the IBNR goes up by the -- exactly the same number
16 so that you end up with the same final estimate.

17 So the -- the total -- the number on the
18 balance sheet is the sum of the case estimates in the
19 IBNR. Well, if the ultimate number, the case plus IBNR,
20 is correct and you've dropped the case down, then the
21 IBNR has to go up to produce the same number.

22 So there I am in 2005, not me
23 individually, but I'm at the end of the day signing this
24 thing, with a new reserving system that, on the face of
25 it, produces \$250 million less of claim liabilities.

1 All of the other techniques that I've been
2 using in prior years, in which I used in 2005, suggested
3 that wasn't the case. So my presumption at that point in
4 time was that this was -- there was something inherent in
5 the new claims reserving model that didn't reflect
6 reality and that I needed to put the two hundred (200) --
7 two and ha -- \$250 million back in as IBNR incurred but
8 not reported claims.

9 That's -- and the way we achieved that in
10 2005 was by selecting particularly conservative factors
11 that essentially produced an estimate \$250 million higher
12 than the tabular reserving method but produced numbers
13 that were reasonably close to those that had been
14 produced the year before and the year before that.

15 Now, we -- we did have this new method,
16 and we had checked it. We knew that it was calculating
17 correctly for each. We would take the individual
18 attributes for a claim, do the calculation on it and
19 calculate or whatever, and we would get the right -- the
20 same answer the computers were repu -- computing. We --
21 we had done that.

22 We had checked that the numbers coming in
23 were appropriately reflecting all of the attributes on
24 the claims file. That was a bit of an issue, because
25 some of the attributes that were needed had to be

1 gathered, because they hadn't been captured early on,
2 like an assessment of whether this was a moderate,
3 medium, or severe injury. Were in the claim file, but
4 weren't recorded in the -- the data points in the system.
5 They were in the paper file, so I had to go and get that
6 stuff.

7 So, that's -- that was the process that
8 was done in 2005. And -- and in -- in actuarial
9 parlance, that was applying zero credibility to the new
10 method and full credibility to the old methods.

11 And that's a common approach when you --
12 you have a number of methods that produce different
13 answers. You have to first of all assess, are each of
14 those methods equally reliable, or some less reliable
15 than others? And the ones that you believe are more
16 reliable, you put more weight on.

17 So I had a -- a new method, that was
18 theoretically appropriate, but -- and I looked at how the
19 -- the data then -- the model had been derived. It had
20 been derived from disability insurance claims wh -- where
21 the illness claims have been factored out, but it was
22 disability insurance claims in the US.

23 So first of all it was in the US, second
24 of all it was a -- what was called a preferred group. It
25 was people who had been underwritten as opposed to a --

1 this populace at large. And we -- and it basically dealt
2 with people who had bought insurance so that typically
3 meant they were in their twenties or thir -- more likely
4 in their thirties and forties and upward.

5 So it wasn't exactly the dataset of people
6 we had. We had people from -- well in fact, it's a fact
7 of life that the people who most get involved in
8 automobile injuries are in their sixteens to twenties.
9 Those people weren't covered in -- in our data -- in the
10 underlying dataset.

11 So I was not inclined to put much weight
12 on that analysis, and I didn't in 2005. But we did flag
13 it. It looked like a good approach and we watched it
14 over the years.

15 Again, in 2006, the analysis was run. The
16 tabular reserving approach predicted pretty accurately
17 what would happen in 2006 for each of the years. But I
18 still wasn't prepared after two (2) years to give any
19 weight to it.

20 We did it in 2008, the same thing
21 happened. It was producing pretty good results. So we
22 started -- I started allowing some credibility to that
23 method.

24 And I increased that in 2009. And in
25 2010, with five (5) years, where it had predicted

1 accurately what would happen from the third to the fourth
2 year and from the fourth to the fifth, and from the
3 twelfth to the thirteenth year and throughout, I felt we
4 should put a lot more credence on that.

5 And therefore, we adopted methods that
6 effectively gave full -- almost full credibility to the
7 tabular reserving approach with -- with effect in 2010.
8 And the result of that was that about \$250 million
9 claimed out of the claim liabilities in that year.

10 Now, why did we do that? Because we -- I
11 now felt that that was the best estimate. It had tracked
12 pretty closely what was happening, and our standards of
13 practice -- or actuarial standards, say that, once you've
14 decided that a particular estimate is the right one (1),
15 you take it into account right then. You don't -- you
16 don't get to phase it in over a period of years.

17 What you are allowed to do is use a
18 credibility weighting, which I had done for five (5)
19 years. But now I was of a mind that the new method --
20 well it was no longer new -- but the five (5) year old
21 method was accurately predicting and was a better
22 estimator than others. And therefore, we should go with
23 it.

24 So all of this happened in one (1) year
25 because of the way the standards are applied, is that you

1 -- once you've changed your mind, you have to go with
2 that new estimate.

3 MS. KATHY KALINOWSKY: Thank you for that
4 very comprehensive response, Mr. Christie. I'm just
5 going to break down some further questions, and probably
6 short responses on the next number of questions here.

7 But, in 2005, then, you held an expect --
8 a reasonable expectation that the reserves calculated,
9 using the new reserve calculator would still see incurred
10 claims development in the future.

11 Why would you think that?

12 MR. JIM CHRISTIE: I had until then -- or
13 until now I guess you would say, I had never seen a
14 disability income scheme that didn't have adverse
15 development in subsequent years. I live and work in
16 Ontario. The Ontario system had been plagued with
17 adverse development, good results in the first couple
18 years and adverse development year in, year out.

19 After that, then they changed in the
20 legislation, good results for a couple years then
21 terrible results again. And it seemed to be that it was
22 the -- not so much the claimant population but the
23 service industry supporting the claimant population that
24 found new ways to provide services that insurance
25 companies would have to pay for that hadn't been

1 contemplated in the earlier data because it wasn't there.

2 And, frankly, I -- it's to MPI's credit
3 that they -- that that didn't happen in this province.
4 But I was certainly not willing to, on the basis of my
5 experience, assume that there wouldn't be adverse
6 development going forward.

7 MS. KATHY KALINOWSKY: Then I want to
8 break down another question, which is can you describe
9 then how you actually came to revise your assumptions in
10 the actuary review to reflect the development patterns
11 that had indeed changed materially?

12 MR. JIM CHRISTIE: In simple terms, we
13 started using development fa -- patterns that were based
14 only on the last five (5) years of data, essentially
15 since the -- the new reserving process had been put in in
16 2005. So I have five (5) years of observations and,
17 therefore, four (4) data points for each row of the
18 triangles that have been described in -- in earlier
19 actuarial testimony.

20 MS. KATHY KALINOWSKY: Thanks. And one
21 (1) thing I want you to explain to the Board is you
22 stated that in 2005 you lacked credible data. But why
23 five (5) years later would you then have enough credible
24 data to adopt the new model when dealing with these very
25 long-term injury claims?

1 MR. JIM CHRISTIE: Well, I still not da -
2 - there's still no data beyond sixteen (16) years. But
3 we do have a model now that appears to track development
4 between the third and the fourth year, the fourth and the
5 fifth, the fifth and the sixth, the sixth and the
6 seventh, and so on, out to -- to the fourteenth or
7 fifteenth year, and track it very closely, surprisingly
8 closely, actually.

9 I have still picked factors that are
10 slightly conservative because I'm not convinced that
11 there isn't something lurking out there that there won't
12 at some point be a bad year, in some sense, or a claim
13 that goes sour, if I can use that expression.

14 The particular thing that worries me in
15 the MPI situation is that one (1) of the obligations of
16 MPI for -- to injured claimants is to pay for their
17 assistance, provide attendant care and that sort of
18 thing. In many cases, that attendant care is being
19 provided by the families of the injured claimant, often
20 by the parents.

21 Well, at some point, the parents are going
22 to be too old to provide that care and it's going to have
23 to be contracted out. And when you contract it out you
24 typically are paying more than you're paying the parents
25 for that. That's -- I don't think is in the dataset yet.

1 It's there to some extent because certainly there are
2 some people who are injured and immediately collect
3 attendant care from outside providers, but there are a
4 number of claimants where that isn't the case and will
5 eventually become the case.

6 And our model doesn't reflect that because
7 our model is -- is, broadly speaking, based on what is
8 your current expenditure and what is your assumption
9 around inflation.

10 So I've deliberately selected slightly
11 conservative factors out through the -- the data -- the
12 observed data we have. And then I have continued to add
13 a tail beyond that based on a 2005 study we did that
14 suggested there was still some upward development.

15 DR. LEN EVANS: Excuse me. I guess one
16 (1) of the factors - fluidity would be changing of
17 government regulations. And I'm just thinking -- I
18 understand in England, maybe it's changed, but the
19 government would pay relatives to look after their loved
20 ones who were injured or ill, or aged. Whereas that is
21 not the case, I know, in Manitoba.

22 If you're a relative, a sister or brother
23 of someone who needs care, you don't get paid. You're
24 not compensated by the government. I may be wrong, but I
25 understood in England there was this difference. The --

1 the -- the government would pay for that assistance.

2 So I'm just saying, if there's a change in
3 government reg -- I'm just using this as an example. If
4 there's a change in government regulations, that would be
5 one (1) factor affecting the fluidity of the situation.

6 MS. KATHY KALINOWSKY: Sure, I can just
7 give you the legal response, rather than putting Mr.
8 Christie on the spot to explain the intricacies of the
9 MPIC Act, particularly its benefits.

10 Yes, individuals that are loved ones,
11 spouses, parents, children, that do provide personal care
12 assistance to an individual that requires it are
13 compensated, are indeed paid. Additionally, if the in --
14 victim of the motor vehicle accident requires
15 professional compensation, the compensation is also paid
16 for that personal care assistance at the professional
17 rate.

18 DR. LEN EVANS: Excuse me. I guess I'm
19 thinking beyond that. I'm thinking of people who are not
20 involved in MPI claims. You know, people who are ill or
21 whatever, who need assistance at home, nothing to do with
22 automobile accidents, so maybe that's not a fair example
23 to use.

24 But I was just trying to think of
25 something that would affect the fluidity, if I can use

1 that term, the -- the situation of your calculations and
2 -- and one (1) of them I thought would be change in
3 government regulations.

4 MR. JIM CHRISTIE: Well, we try not to --
5 sorry -- we try not to re -- reflect changes in
6 legislation that haven't happened, or haven't been at
7 least announced. Because that -- although, inherent in
8 any dataset is some sort of regulatory -- I'll call it
9 regulatory creep. It is the expansion of coverage, that
10 broadly speaking, over the years coverage expands.

11 It's a rare situation where the courts
12 rule that coverage that individuals were -- or a benefit
13 that people were collecting is no longer available.
14 Typically, court rulings are that something that you
15 weren't paying for, you now have to pay for.

16 So there's some broad creep going on.
17 That kind of creep is typically reflected in the
18 empirical data, and so it's implicitly reflected in our
19 analysis, because we don't flag a particular claim as
20 being an increase because a particular judge ruled a
21 particular benefit had to be paid. It's just there now
22 and it's applied to all the policy hold -- or claimants
23 that are -- are covered by that particular benefit.

24 THE CHAIRPERSON: I'm just thinking, we
25 will want to take a break at some point, but before we

1 do, I just want to get some clarification from Mr.
2 Christie.

3 You were saying you had to think about the
4 future when these claimants would not have their parents
5 looking after them. And that could shock the system as
6 they move into a personal care home where the -- the
7 costs are higher than if they're at home.

8 But then I heard Ms. Kalinowsky say that
9 these parents or relatives or whoever they may be, are
10 receiving compensation under our existing system. So I'm
11 wondering -- I -- I'm getting a -- sort of two (2)
12 different messages here. So I just want to make sure I
13 heard it right.

14 MR. JIM CHRISTIE: You did hear it right.
15 There are two (2) things going on. Some of these in --
16 families, refuse to collect -- accept benefits. They say
17 this is my responsibility as a family member. Well, when
18 it turns to professional, you're not going to get that
19 response. The second one (1) is that, when you go to
20 professional care, it typically costs more than it does
21 in the family home.

22 So I am aware -- well aware of the fact
23 that MPI does pay benefits. And a number of people are
24 entitled to those benefits who choose not to accept them,
25 but...

1 THE CHAIRPERSON: Okay. That helps me a
2 lot to know that there's an overhead expense, obviously,
3 that's not being paid. It's just labour, and also some
4 are rejecting or not accessing it.

5 And on that note, I'm thinking can we
6 interrupt your line of questioning and just take a little
7 break? Would this be an appropriate time?

8 MS. KATHY KALINOWSKY: Certainly.

9 THE CHAIRPERSON: Okay. We'll stand
10 down, probably fifteen (15) minutes, which would take us
11 till five (5) after 11:00.

12

13 --- Upon recessing at 10:49 a.m.

14 --- Upon resuming at 11:05 a.m.

15

16 THE CHAIRPERSON: I think we're all in
17 place now.

18 MS. KATHY KALINOWSKY: Thank you very
19 much. I'd like to proceed with my direct examination of
20 Mr. Christie now.

21

22 CONTINUED BY MS. KATHY KALINOWSKY:

23 MS. KATHY KALINOWSKY: As required by
24 auditing standards, the auditor's actuary has reviewed
25 your opinion as at October 31st, 2010. And are you aware

1 that KPMG had no concerns with your review?

2 MR. JIM CHRISTIE: Yes, I am. I don't
3 receive formal notification of no concerns. What I would
4 typically get is concerns, or notification if there was a
5 concern, but -- so the absence of a notification is
6 indication that they had no concerns.

7 MS. KATHY KALINOWSKY: And you're also
8 aware, of course, that KPMG signed an unqualified opinion
9 on the financial statements, which, in effect, adopted
10 the results from your review of unpaid claims
11 liabilities?

12 MR. JIM CHRISTIE: Absolutely. Before I
13 sign my opinion, I make sure the auditors are prepared to
14 sign a -- an unqualified financial statement opinion.

15 MS. KATHY KALINOWSKY: So at the end of
16 the day then, for the 2005 and 2010 reviews on unpaid
17 claims liabilities, the opinions that you prepared were
18 agreed to be reasonable by the MPI internal actuaries,
19 yourself of course from Ernst and Young, a peer-reviewing
20 actuary from Ernst and Young, and also the auditor's
21 actuary from KPMG?

22 MR. JIM CHRISTIE: That is correct.

23 MS. KATHY KALINOWSKY: In trying to
24 assess the magnitude of this \$250 million release, are
25 you aware of other insurers who have experienced similar-

1 size releases?

2 MR. JIM CHRISTIE: Yes. One (1) of
3 recent vintage in 2010, the State Farm Insurance Company
4 announced that they had a \$1 billion operating loss in
5 the 2010 year, which appears to have been entirely due to
6 a charge to their financial statement -- an increase in
7 their liabilities, by \$1 billion.

8 MR. REGIS GOSSELIN: Sorry, who is that?
9 Which company was that?

10 MR. JIM CHRISTIE: State Farm Auto Insur
11 -- Mut -- State Farm Mutual Auto Insurance Company.

12

13 CONTINUED BY MS. KATHY KALINOWSKY:

14 MS. KATHY KALINOWSKY: And where does
15 State Farm operate? Perhaps you could put that on the
16 record.

17 MR. JIM CHRISTIE: They -- it operates --
18 this is the Canadian operations. It operates in three
19 (3) provinces. To the best of my knowledge: Alberta,
20 Ontario. and New Brunswick.

21 And to put it in context of magnitude, it
22 is roughly four (4) times the size of MPI, so the numbers
23 are comparable except the sign is reversed.

24 MS. KATHY KALINOWSKY: I'd like you and
25 the Board members to turn to one (1) Information Request.

1 And that is PUB-1-26.

2 MR. JIM CHRISTIE: I have it.

3 MS. KATHY KALINOWSKY: And perhaps when
4 the Board members do take -- do obtain that they just
5 review it themselves quickly. Won't read it into the
6 record or anything like that, but if you could just look
7 at PUB 1-26.

8 MR. REGIS GOSSELIN: You said 1-26?

9 MS. KATHY KALINOWSKY: Yes, PUB-1-26,
10 correct.

11

12 (BRIEF PAUSE)

13

14 CONTINUED BY MS. KATHY KALINOWSKY:

15 MS. KATHY KALINOWSKY: Thank you, Mr.
16 Chris -- Mr. Christie. I'll ask you a question now on
17 PUB-1-26. That's an Information Request posed by the
18 Board, and it was actually posed to MPI but requested
19 that you respond. And you have provide -- provided an
20 attached response to that.

21 But it asked you if whether the staged
22 recognition of the 2005 reserving methodology over
23 several fiscal years in any way impaired or diminished
24 the fairness of the presentation of the results of the
25 valuation in the financial statements over that period.

1 Do you just want to summarize your
2 response?

3 MR. JIM CHRISTIE: Well, the short answer
4 is, no. And as I tried to elaborate in my earlier
5 testimony, each year we use -- I selected what I thought
6 was the best estimate, apply li -- no credibility
7 initially, and then a small amount of credibility and
8 then a large amount of credibility over that five (5)
9 period in line with accepted actuarial practice in this
10 country.

11 MS. KATHY KALINOWSKY: Have you ever been
12 asked such a question previously?

13 MR. JIM CHRISTIE: No.

14 MS. KATHY KALINOWSKY: I'm going to move
15 to another ar -- a little bit of a different area now and
16 talk about some of the future directions, so where we're
17 going forward from here.

18 You've reviewed the Ernst & Young audit
19 memo in which their -- from their actuary, which states,
20 and I can just quote it, but it says:

21 "For -- for some lines of business
22 reviewed we consider that Mr.
23 Christie's estimates are slightly
24 conservative while remaining within the
25 range of reasonableness."

1 Do you know what Mr. Lam, who is the
2 actuary at Ernst & Young, is referring to here, as you
3 being slightly conservative?

4 MR. JIM CHRISTIE: First of all, a point
5 of clarification. Mr. Lam in that memoir from KPMG, the
6 auditors of MPI, and not from Ernst & Young, who is my
7 employer. But assuming you meant to ask --

8 MS. KATHY KALINOWSKY: Yes.

9 MR. JIM CHRISTIE: -- KPMG, I am -- I
10 have read the memo. I've read Mr. Lam's comment. It is
11 similar to what I would write if I were in his position,
12 and I have -- am reviewing the work of other actuaries.
13 It would be extremely odd that two (2) actuaries would
14 come up with exactly the same estimate.

15 So when writing the letter to the audit
16 partner responsible for the audit, language is used to
17 indicate either that the auditor's actuary has come up
18 with a lower number, in which case they would say
19 "slightly conservative" or "significantly conservative."
20 Or if the actuaries -- auditor's actuaries come up with a
21 number above the company's estimate they would indicate
22 "slightly aggressive" or "significantly aggressive."

23 I was not surprised that he said slightly
24 conservative. That was what I would have expected him to
25 say. And -- and more to the point was not that comment,

1 but the next one (1). It says the results are
2 reasonable.

3 And it is when you write a letter to the
4 audit partner that says the results are not reasonable
5 that all sorts of things happen. But a le -- this is
6 essentially, in my opinion, a normal letter that says the
7 results are -- results are slightly conservative and the
8 end result is reasonable.

9 MS. KATHY KALINOWSKY: Thank you for
10 that. And moving along in the -- talking about the
11 future direction, are you aware of any other possible
12 large scale actuarial adjustments, releases in the future
13 at MPI?

14 MR. JIM CHRISTIE: I'm not aware of any.
15 I don't anticipate any large-scale ones. I would
16 anticipate that there would be slight releases every
17 year. Simply as I described in the numerical example,
18 most of the time, the results will be slightly better
19 than average. It's only very occasionally you get a bad
20 result, in which case, it'll be awful. But in most
21 cases, they would be -- have -- have some slight release
22 each year, but I -- not -- not -- nothing of the order of
23 magnitude we saw this year.

24 MS. KATHY KALINOWSKY: So although you
25 are re -- retired now, you're no longer the appointed

1 actuary of MPI, what comfort or assurances can you
2 provide the Public Utilities Board that there will not be
3 a more significant favourable basic runoff of prior years
4 claims?

5 MR. JIM CHRISTIE: Well, I can't provide
6 any absolute assurance. I -- I believe the estimates
7 that were established in fe -- in October, 2010, and
8 February, 2011, are the best estimates that are -- that
9 are available with the data that's currently there.

10 I don't anticipate them to be -- the
11 final results to be significantly differently from those,
12 but there is no -- can be no guarantee. This is, after
13 all, an estimate of a future obligation.

14 MS. KATHY KALINOWSKY: And asking another
15 sim -- similar question with the pendulum swinging the
16 other way. What comfort can you provide the PUB that
17 there will not be a significant adverse runoff of Basic
18 prior years claims reversing this pattern of recent years
19 and potentially diminishing the RSR?

20 MR. JIM CHRISTIE: Again, no absolute
21 assurance. But by nature of the selections being on --
22 on the slightly conservative side my expectation -- and
23 that's my expectation, not a guarantee, is that there
24 would not be significant adverse development.

25 This Corporation -- I -- I've been around

1 it for fifteen (15) years one way or another, it has had
2 adverse development I would say about seventeen (17)
3 years ago. So we are aware of that -- that potential,
4 but I -- I'm -- do not expect it to happen.

5 MS. KATHY KALINOWSKY: And going back to
6 that KP -- KPMG Actuarial Review by Mr. Lam concludes
7 that you are slightly conservative.

8 Is that a more desirable conclusion than
9 perhaps being slightly aggressive?

10 MR. JIM CHRISTIE: Personally, I think
11 so. That is, sort of -- beauty is in the eye of the
12 beholder, whether you want to be aggressive or
13 conservative. I think an organization like MPI values
14 conservatism, I certainly personally do.

15 I just -- if -- I put myself in the
16 position of the board of the directors at MPI. Would
17 they rather be giving a 2 -- \$250 million rebate, or
18 asking this Board for a rate increase to -- to cover \$250
19 million. You know, it's the -- as one (1) of their
20 counterparts in another province is going to be -- have
21 to be doing.

22 MS. KATHY KALINOWSKY: So perhaps you
23 could explain to this Board what are the consequences of
24 being slightly conservative in the report on unpaid
25 claims liabilities?

1 MR. JIM CHRISTIE: The result is that the
2 balance sheet liabilities are -- are -- in most cases
3 likely to be overstated when the final results are known.
4 That overstatement will flow through the income statement
5 and appear as a favourable or a reduction in claims
6 incurred in the year that the release happens.

7 The actual -- to the extent that there is
8 historic favourable development, it is probably reflected
9 in the -- already in the estimates that MPI does for
10 producing their rate filing. I can't speak to that
11 because I'm not part of the rate filing, but I would
12 anticipate the actual results are incorporated in their
13 analysis that leads to the rate filing.

14 MS. KATHY KALINOWSKY: Okay. And then
15 the other question similar along that line is: What
16 would be the consequences of being slightly aggressive in
17 the report on unpaid claims liabilities?

18 MR. JIM CHRISTIE: Well, the likelihood
19 is that there would be unfavourable development each year
20 and that would have to be, in effect, charged to next
21 year's policyholders.

22 MS. KATHY KALINOWSKY: As an actuary that
23 has had a very extensive consulting practice at a
24 national level, are you aware of any actuarial reviews
25 that have an aggressive estimation of reserves? And what

1 has been the result in some of those instances?

2 MR. JIM CHRISTIE: Yes, I am aware of
3 such. Largely in my capacity as a -- an actuarial
4 support specialist for Ernst & Young when we are doing
5 the audit of other companies, I have identified on a few
6 occasions a report where I have written a letter, much
7 like Mr. Lam, and written where I have said, the reserves
8 are slightly aggressive.

9 MR. REGIS GOSSELIN: Could I probe a
10 little bit more, please?

11 In terms of being slightly conservative
12 you indicated that it would impact on the reserve levels.

13 MR. JIM CHRISTIE: Yes.

14 MR. REGIS GOSSELIN: In other words,
15 would increase the required reserves to protect against
16 adverse experiences.

17 Is the -- is the fact that you're doing
18 that, is that cumulative? In other words, is it, sort
19 of, being repeated year after year to the point where it
20 accumulates on the -- on the balance sheet?

21 MR. JIM CHRISTIE: No, it's not
22 cumulative. It's essentially replicating, so it's there
23 on the opening balance and its there in the closing
24 balance. And in general it doesn't have a significant
25 impact on the current operating results because there is

1 a release from prior years, but then a margin or
2 conservatism put up on the current year that, by and
3 large, off -- one (1) offsets the other.

4 That's not entirely true in the case of
5 MPI. There would be some growth simply because the MPI -
6 - the PIPP system is not what I'll call in steady-state.
7 It hasn't yet reached the position where the number of
8 claims closing is exactly offset by the number of claims
9 opening. I would expect it's close to that now, but it's
10 probably still not there.

11 MR. REGIS GOSSELIN: I -- I -- my
12 inclination is to think that if you're running a for-
13 profit corporation involving insurance you would probably
14 more likely be on the slightly aggressive side than would
15 be the case for a entity like MPI, and I -- let me -- let
16 me take that one (1) step further, and probably linked to
17 the levels of profit, you know, because it's -- I would
18 think that by being a bit aggressive you're actually
19 increasing revenues -- not revenue, profits, but -- and
20 also thereby increasing dividends and increasing
21 executive pay?

22 MR. JIM CHRISTIE: I agree with you in
23 the sense that the -- it's only a few observations. But
24 the -- the companies that I have seen with aggressive
25 operations were typically bottom-line-driven

1 organizations concerned about quarterly or annual
2 results.

3 MPI I would -- is one (1) of the few
4 publicly-owned insurance companies that I deal with, but
5 there are a number of mutual companies who are -- are in
6 fact owned by the policyholders and have no par -- no
7 shareholders, only policyholders. And they tend to be er
8 -- those kinds of organizations tend to view conservatism
9 as a positive attribute.

10 MR. REGIS GOSSELIN: Now, in respect of
11 the change in methodology, you indicated that you review
12 a number of methodologies on an ongoing basis to
13 determine the appropriateness of -- of the metho --
14 methodologies. In other words, I'm looking forward now
15 and saying, Okay, we reviewed the methodologies, 2005, we
16 changed it.

17 That change in methodology could occur in
18 the future?

19 MR. JIM CHRISTIE: Yes. There's a slight
20 nuance here. What was changed was the process for
21 establishing case reserves, the value that was attached
22 by an individual claim adjuster to an individual claim.
23 That was changed in 2005 to be a tabular look-up from a -
24 - from a best-judgment process.

25 The methodologies that we use are what

1 I'll call the traditional actuarial methods of incurred
2 development, paid development, Bornhuetter-Ferguson paid
3 development, and Bornhuetter-Ferguson incurred
4 development. Those four (4) techniques are being used.

5 What we are doing and what we did in 2005
6 is shift the weight that was being used in those four (4)
7 approaches to relying only on the last five (5) diagonals
8 or the year since the case reserving method had changed.
9 I'm not sure if I've made myself sufficiently clear here,
10 but there is always the possibility that any organization
11 will change its case reserving process.

12 What you try to do with -- with actuarial
13 methodologies is reflect that change. Now, in the case
14 of MPI, that was relatively easy to estimate what the
15 impact was because they had a before and after. What you
16 can't readily measure is whether some -- some creep going
17 on in -- in the way cha -- individual case estimates are
18 being done simply because individual case adjusters read
19 the newspaper and they see a particular event happening.

20 And -- and like most people, when you --
21 whatever you -- you recently read you think is more
22 likely to happen to you than stuff you've read before or
23 that you haven't read about. So those kinds of things
24 could happen.

25 At this point, I wouldn't expect to see a

1 significant change in the case tabular reserving that MPI
2 is using simply because it seems to be working.

3 MR. REGIS GOSSELIN: The creep, I guess,
4 is the -- I mean, on the one (1) -- on the one (1) hand,
5 we're saying okay, let's be conservative here, let's make
6 sure that we have enough reserves to address any
7 potential adverse consequences, so I can understand that.

8 So, you know, I -- I'm -- I kind of see
9 that as being a -- sort of a typical insurer's position,
10 to be conservative rather than aggressive.

11 But I guess the -- on the -- on the other
12 hand, you talked about a creep, related to a number of --
13 of factors, such as court decisions, regulatory change.
14 And I guess what I'm wondering is is the -- the fact that
15 you're dealing with a creep -- you know, a creep in
16 coverage, how material -- I mean, how material is that
17 generally speaking, in terms of your perspective?

18 In other words, what I'm saying is that,
19 you compensate for -- you compensate for creep and you
20 add a measure of in -- in -- of comfort I guess, in the -
21 - in the reserve system, to -- to cover you off.

22 I mean are we talking one (1) and the same
23 here?

24 MR. JIM CHRISTIE: No. Most of the --
25 the creep, if we can call it that, is inherently included

1 in the datasets we get. Because we -- we get data from a
2 number of accident years, and if there's been creep, it's
3 been happening if you will, along a diagonal, because the
4 diagonal is the current year of e -- of events.

5 So, if for instance -- a good example is
6 the -- a new safety feature has been added to vehicles --
7 an airbag. That may very well be reducing injury claims,
8 but it's probably significantly increasing collision
9 claims because the airbags deploy and then have to be
10 replaced.

11 So, over time, more and more of the auto
12 fleet that's being insured is going to have airbags and
13 so we're going to see the costs of collision claims
14 creeping upward. You still have to repair the fender and
15 you still have to repair everything else, but now you've
16 got to put -- now in some cars there's sixteen (16)
17 airbags. Not all of them are going to deploy in an
18 accident but more are. So you're going to see that
19 creeping into the costs.

20 On the other hand, you're going to see
21 probably less claims happening on the injury side, simply
22 because the airbags did deploy. So we'll see that
23 gradually happening in the -- we won't know exactly why.
24 We can rationalize why it's happening, but we won't know
25 exactly what the -- is, because we're dealing with

1 aggregate data. I mean, you can drill down and try to
2 find how many airbag claims there were this year compared
3 to last year, if you've got some idea what it is.

4 But in broad terms, you -- you've --
5 typically wouldn't be doing that kind of detailed
6 analysis, unless you were in a rate making environment,
7 where you were trying to say, Okay, I'm going to give a
8 credit for cars with air bags on the injury side, but I'm
9 going to put a surcharge on for the physical damage,
10 because it costs more to repair them.

11

12 CONTINUED BY MS. KATHY KALINOWSKY:

13 MS. KATHY KALINOWSKY: Just only have a
14 few more questions to proceed with and then I can close
15 your direct examination, Mr. Christie, but I want to ask,
16 have you reviewed the three (3) pre-asked questions that
17 were filed by the Consumers Association of Canada, and
18 the cross-examination of Mr. Palmer on those three (3)
19 asked questions?

20 MR. JIM CHRISTIE: I have reviewed both
21 the questions and the examination.

22 MS. KATHY KALINOWSKY: The line of
23 questioning seems to suggest whether there should be a
24 mechanical or an arithmetic calculation to determine
25 unpaid claims liabilities. Would you like to comment on

1 this line of questioning?

2 MR. JIM CHRISTIE: Well, I have a bias
3 that I think you should be using a professional actuary.
4 But anyone who is simply turning a crank on a mechanical
5 process runs a significant risk of missing something
6 that's inherent in the data. This is typically not,
7 simply throw it into a hopper, follow the recipe, and out
8 comes the answer.

9 A significant part of what I do as the
10 actuary for the Corporation is review the results of the
11 mechanical calculations and look for aberrations or
12 abnormalities or un -- unusual circumstances and suggest
13 where we might want to spend more time looking.

14 MS. KATHY KALINOWSKY: Thank you for
15 that. Another aspect of the line of questioning from the
16 Consumers' Association of Canada dealt with collision
17 claims rather than bodily injury.

18 Would you like to comment on that line of
19 questioning?

20 MR. JIM CHRISTIE: Well, sure. All lines
21 -- all lines of business are important. But in the grand
22 scheme of the liabilities on the balance sheet, not the
23 liabilities for rate making purposes, but in the balance
24 sheet, the big ticket item are the bodily injury, wage
25 replacement, their medical and rehabilitation claims.

1 In broad terms there's roughly \$1.2
2 billion of claim liabilities on the balance sheet, and
3 roughly 1 billion of those are arising out of wage
4 replacement, medical rehabilitation or bodily injury.
5 And a very small amount is relating the physical damage
6 claims.

7 And that's largely a function that
8 physical damage claims close very quickly. That --
9 typically it doesn't take more than a few weeks to get a
10 car repaired, so there's nothing on the balance sheet,
11 but there is in the income statement because you've paid
12 the dollars out.

13 MS. KATHY KALINOWSKY: Just to follow up
14 a little bit on Mr. Gosselin's question with respect to
15 MPI. It's a Crown corporation, of course.

16 Compared to a privately held insurer, is
17 there anything different in the review of claims
18 liabilities?

19 MR. JIM CHRISTIE: No. The standards of
20 practice -- the Canadian Institute of Actuaries do not
21 differentiate between the ownership of an organization.
22 If there were an entity with the same sorts of
23 liabilities that MPI had that was privately held, in my
24 opinion, the liabilities would be essentially the same.
25 The difference between the two (2) would largely be the

1 judgment of the two (2) actuaries, unless it was the same
2 actuary with exactly the same data.

3 MS. KATHY KALINOWSKY: So at the end of
4 the day then, you would agree that your opinion is
5 slightly conservative. And you specifically prepared
6 your opinion to include those elements of conservatism.

7 Can you possibly summarize what are the
8 benefits then of incorporating that conservatism into
9 your report?

10 MR. JIM CHRISTIE: Well, the first one is
11 -- as I've alluded to earlier, there will occasionally be
12 a bad year. The conservatism in and of itself won't
13 cover that directly, but it does allow for the fact that
14 when the bad year happens you've already incorporated
15 that into your analysis and future projections and you
16 don't need to bump up -- in addition to having a bad
17 year, you don't have to bump up your reserves on the
18 balance sheet and therefore have an additional increase
19 flowing through the income statement.

20 I'd say the -- this is not a direct
21 consideration in my analysis, but for a corporation like
22 MPI there's a decided public relations advantage to
23 paying out a dividend than asking for a rate increase.

24 MS. KATHY KALINOWSKY: And finally, Mr.
25 Christie, is your review the best estimate of the unpaid

1 claims liabilities?

2 MR. JIM CHRISTIE: Well, "best estimate"
3 is a -- a very nebulous term. I would say it is my best
4 estimate of the liabilities of Manitoba Public Insurance
5 as at February 2011.

6 It doesn't necessarily mean it is the best
7 estimate in a statistical sense, which would be a
8 straight aver -- numeric average with no anal - or
9 analysis. I think it is the best estimate for the
10 purposes of financial reporting for this organization.

11

12 (BRIEF PAUSE)

13

14 MS. KATHY KALINOWSKY: With that, I'm
15 finished my direct examination. And I see Board member
16 Gosselin is interested in asking a further question, Mr.
17 Christie.

18 MR. REGIS GOSSELIN: You've been involved
19 in IFRS, I guess, at the international level?

20 MR. JIM CHRISTIE: I have.

21 MR. REGIS GOSSELIN: And I'm trying to
22 look forward here. What potentially could happen in the
23 near term on IFRS with -- with respect to MPI?

24 MR. JIM CHRISTIE: I have in fact
25 appeared before the International Actuarial Standards

1 Board to describe how accounting standards and actuarial
2 standards in Canada interrelate because they were quite
3 interested. And we have a fairly well respected in -
4 interaction between the two (2) professions.

5 In terms -- in short-term, IFRS has been
6 adopted in Canada, it already applies to MPI as to any
7 other large organization. Unfortunately, IFRS as adopted
8 in Canada doesn't include a standard for insurance.
9 There is a standard there but, effectively, that standard
10 says, Do whatever you were doing before. So for Canada
11 that means the old Canadian GAAP prior to the
12 introduction of IFRS.

13 When -- the Board was supposed to release
14 a final standard several times delayed in June of this
15 year. It's now not expected until at least June of next
16 year and possibly later. Given the past history of
17 delays, I am on the conservative side of saying it won't
18 happen in June of 2012.

19 Because they are now talking about a new
20 release of a new draft as opposed to a final version
21 there are possibilities that the -- the -- a strong
22 possibility that the new standard that is released is
23 different from the one we have seen. So my answer is,
24 only around the one I've seen, and -- which is about a
25 year and a half old, and listening to what Board member -

1 - ISB Board members say at the various hearings they've
2 had since.

3 And this -- so the short answer for MPI is
4 that not a lot will change because the model for claims
5 liabilities that is being proposed is essentially the
6 Canadian model. It's not quite the Canadian model, but
7 it talks about, first of all, a best estimate of the
8 cashflows, which we do, then the present value of them,
9 which we do, and then to add a margin for -- well, they
10 call it a risk margin, we call it a provision for average
11 deviation, which we do.

12 The difference will be if the current
13 draft comes to -- is the final version is that the
14 requirement for the risk margin will be more formalized
15 in the accounting literature than -- or in the accounting
16 standard than is the -- the case right now.

17 Right now, the risk margin in Canada is
18 based entirely on what the actuarial standards say. And
19 those actuarial standards are -- well, I helped write
20 them in the early 1990s. The science has progressed
21 since then, so there's some likelihood that the risk
22 margins may change to some extent. You'll still
23 recognize the financial statements.

24 MR. REGIS GOSSELIN: I guess the long and
25 short of it, from what I'm -- from what I'm hearing, I

1 think from my interpretation of your comments is that
2 it's not likely to have a material impact on MPI's
3 results?

4 MR. JIM CHRISTIE: It's -- the caveat in
5 that is if the rules around margins for average deviation
6 change significantly. The likelihood is that they will -
7 - the standards will re -- the accounting standards will
8 require them to be expressed as -- as some sort of
9 confidence level, a likelihood of being adequate, which
10 is not inherent in the current margins for average
11 deviation.

12 So when the -- when and if that happens
13 actuaries will be forced to build models to compute the
14 likelihood of -- of being sufficient, and then state
15 those. And then the margins may turn out to be somewhat
16 different than the ones that are currently being done,
17 which are largely driven by here's the maximum, here's
18 the minimum.

19 I would characterize the Canadian practice
20 right now is here's the max, here's the minimum, here are
21 examples of high margins situations, here are mar --
22 examples of low margin situations. Look at your
23 organization and decide where on that spectrum they lie,
24 and then pick a margin that is reflective of where in the
25 spectrum they lie.

1 THE CHAIRPERSON: All right. Thank you
2 very much for that. And I think we're turning now to
3 you, Ms. Grammond.

4 MS. CANDACE GRAMMOND: Yes. Thank you,
5 Madam Chair.

6 MR. BYRON WILLIAMS: Madam Chair -- and I
7 apologize for interrupting, Ms. Grammond. There's just
8 one (1) reference in the direct that I -- I would
9 appreciate some clarification from MPI on if I -- if I
10 might?

11 THE CHAIRPERSON: Sure.

12 MR. BYRON WILLIAMS: I -- there was
13 reference to a -- I believe it was a KPMG document by --
14 by Mr. Lam, and I'm presuming they're referring to the --
15 the external audit and a review of the appointed
16 actuary's reports.

17 And I'm just wondering whether that -- I
18 just want to make sure that that document is currently on
19 the record.

20

21 (BRIEF PAUSE)

22

23 MS. KATHY KALINOWSKY: I'm advised that
24 it's at PUB-1-28.

25 MR. BYRON WILLIAMS: Thank you for that.

1 THE CHAIRPERSON: Okay. I think we can
2 proceed.

3 MS. CANDACE GRAMMOND: Thank you, Madam
4 Chair.

5
6 CROSS-EXAMINATION BY MS. CANDACE GRAMMOND:

7 MS. CANDACE GRAMMOND: On that note,
8 coincidentally, regarding PUB/MPI-1-28, I actually am
9 going to ask that we go there and it is at the Board's
10 book of documents at Tab 18. So, Tab 18, book of
11 documents, PUB/MPI-1-28.

12 And for the record, the document that Mr.
13 Williams just referenced, prepared by Mr. Lam, is found
14 at (d). That's not where I'm going right now, but for
15 the purposes of the record, that's where Mr. Lam's report
16 is found.

17 So, Tab 18, PUB/MPI-1-28 at (b), Mr.
18 Christie, we had a -- a question and answer with respect
19 to -- in addition to some -- some other individuals, your
20 role and responsibilities. And if we look at the answer,
21 we see at page 2, so I'm at PUB/MPI-1-28, page 2. We see
22 the answer to (b). So I'm -- Tab 18 of the book of
23 documents.

24 We have there a description of the roles
25 and responsibilities of the internal actuarial department

1 at MPI, of Ernst and Young as external actuary, and then
2 as the -- the external auditors, KPMG. So I'd like you,
3 Mr. Christie, to focus on the second section relating to
4 external actuary.

5 We see a list of bulleted points that
6 reflect the -- the roles and responsibilities. Can you
7 take a moment to review those and tell me if you accept
8 that description as your role for MPI?

9 MR. JIM CHRISTIE: That's a reasonable
10 description. The only thing I would add is that I take -
11 - we personally write the twenty (20) or thirty (30) page
12 summary that goes at the front of the report. That's not
13 written by the -- MPI, although there is a clear amount
14 of dialogue between the two (2) organizations. We're not
15 trying to -- particularly trying to get the -- the typing
16 of that sort of stuff done by MPI to reduce costs. I --
17 I review -- I -- I take responsibility for writing that
18 text.

19 MS. CANDACE GRAMMOND: Okay. Thank you.

20 Thank you. Mr. Christie, I think another
21 thing you had mentioned in your direct evidence that's
22 not specifically on this list, but that you do, or did,
23 is meetings with the audit committee of MPI?

24 MR. JIM CHRISTIE: That is correct.
25 Every year I do meet with the audit committee, typically

1 to provide them with assurance that what I've done is
2 appropriate and -- and answer any questions they may
3 have.

4 MS. CANDACE GRAMMOND: Thank you. Now,
5 we typically describe you, Mr. Christie, as the
6 Corporation's appointed actuary.

7 MR. JIM CHRISTIE: Yes.

8 MS. CANDACE GRAMMOND: And there's a
9 specific definition of that term from the standards of
10 practice of the CIA, which I'll read in and you can tell
11 me if it sounds correct. That -- that the definition of
12 the term is, "The appointed actuary" -- or, sorry --
13 that:

14 "The appointed actuary of an entity is
15 an actuary formally appointed, pursuant
16 to legislation, by the entity, to
17 monitor the financial condition of that
18 entity."

19 Does that sound like the right definition?

20 MR. JIM CHRISTIE: That is the definition
21 in the CIA standards of practice.

22 MS. CANDACE GRAMMOND: And would you say
23 that that definition applies to your role within the
24 Corporation specifically?

25 MR. JIM CHRISTIE: Not quite. Because I

1 am not appointed under any legislative mandate. I am
2 appointed by the board of directors, hence the
3 terminology "appointed." But my responsibilities are
4 largely those of what was historically termed evaluation
5 actuary, to attest to the liabilities of the -- the
6 policy liabilities of the organization as of their fiscal
7 year end.

8 MS. CANDACE GRAMMOND: I think you had
9 testified earlier that MPI is actually not required to
10 have an appointed actuary, but it does.

11 MR. JIM CHRISTIE: It does.

12 MS. CANDACE GRAMMOND: So your
13 appointment, as you've indicated, is not pursuant to
14 legislation, but rather by the board of directors of the
15 Company.

16 MR. JIM CHRISTIE: That is correct.

17 MS. CANDACE GRAMMOND: Okay. I'm going
18 to ask you then to go and, yeah, I think it would
19 probably be best if you go there, to your opinion from
20 October of 2010, and that's found in our filing at AI-
21 13(a).

22 MR. JIM CHRISTIE: AI-13(a).

23 MS. CANDACE GRAMMOND: So that's the fat
24 volume -- or, the fat part of Volume III, which contains
25 the AI filings. And we have AI-13(a) and AI-13(b), which

1 are the two (2) reports at the two (2) different points
2 in time.

3 MR. JIM CHRISTIE: Yes. I have the
4 report in front of me.

5 MS. CANDACE GRAMMOND: Thank you.

6 THE CHAIRPERSON: We need help to find
7 it.

8 MS. CANDACE GRAMMOND: Okay. So it's --
9 it's Volume III --

10 THE CHAIRPERSON: Volume --

11 MS. CANDACE GRAMMOND: -- the fat binder.
12 They're -- Volume III has two (2) parts. Part 1, which
13 is the thin one, and Part 2, which is the fat one. So
14 we're in the fat one.

15 THE CHAIRPERSON: Volume III, Part 2.

16 MS. CANDACE GRAMMOND: And then we're at
17 -- behind Tab 13.

18 THE CHAIRPERSON: Okay. Oh, okay.
19 Thank you.

20 MS. CANDACE GRAMMOND: So we're in (a),
21 which is the first part of what we find in that binder.
22 And I'm -- specifically we'll go to page 3.

23

24

(BRIEF PAUSE)

25

1 CONTINUED BY MS. CANDACE GRAMMOND:

2 MS. CANDACE GRAMMOND: So, Mr. Christie,
3 you've indicated in -- Mr. Christie, you've indicated
4 here, this is as at October, 2010, that you have valued
5 the policy liabilities of MPI in accordance with accepted
6 actuarial practice including selection of appropriate
7 assumptions and methods.

8 Is that right?

9 MR. JIM CHRISTIE: That is correct.

10 MS. CANDACE GRAMMOND: Can you tell us in
11 what respect, if any, does that accepted actuarial
12 practice, as it applies to MPI, vary from accepted
13 actuarial practice as it applies to your work in the
14 private sector? For example, for a federally regulated
15 Canadian P&C insurance company -- or, property and
16 casualty insurance company.

17 MR. JIM CHRISTIE: To the best of my
18 knowledge there's no difference in the evaluation of the
19 policy liabilities.

20 MS. CANDACE GRAMMOND: You've also stated
21 in AI-13(a), the October 2010 report that we're looking
22 at, that the amount of the policy liabilities for MPI
23 makes appropriate provision for all policyholder's
24 obligations.

25 When you refer to the phrase, "appropriate

1 for -- pro -- provision," what do you mean by that?

2 MR. JIM CHRISTIE: That is the wording
3 suggested by the Canadian Institute of Actuaries. I take
4 it to be the dictionary definition of appropriate,
5 meaning not unreasonable.

6 MS. CANDACE GRAMMOND: Now at AI-13 we
7 have behind Tab B -- and you -- you can certainly go
8 there if you wish. We have a similar report for a
9 different point in time, whereas Tab A is October of
10 2010. We have at Tab B report as of February of 2011.
11 And we don't see similar language in the February report
12 that we just discussed, that is -- that there is
13 appropriate provision for all policyholder's obligations.

14

15 Should we attach any significance to that
16 difference?

17 MR. JIM CHRISTIE: No, you should not.
18 This is an internal report to MPI describing the mapping
19 from October to February. In the formal published
20 financial statements of the organization you -- which we
21 spoke about earlier today, I think on page 47 I issue and
22 sign an unqualified opinion and it includes the wording
23 that it is a -- the policy liabilities are appropriate.

24 MS. CANDACE GRAMMOND: Thank you. And I
25 recall that Ms. Kalinowsky took you to the annual report

1 for the Corporation in your direct evidence.

2 There's also an -- an annual report that's
3 filed with this Board that's -- just relates to Basic,
4 that's also found in the -- the filing at AI-7 where we
5 have the annual report. And you're -- you're welcome to
6 go there if you -- if you wish to do so. You don't
7 necessarily have to, but if you wish to.

8 So I'm now looking at Volume III, the
9 skinny volume, AI-7 --

10 MR. JIM CHRISTIE: Yes.

11 MS. CANDACE GRAMMOND: -- where we find
12 the -- the coloured bound annual report that we looked at
13 earlier today. Immediately before that there's a black
14 and white report that just relates to the universal
15 compulsory program or Basic.

16 MR. JIM CHRISTIE: Yes, I have that
17 opinion in front of me.

18

19 (BRIEF PAUSE)

20

21 MS. CANDACE GRAMMOND: Now, we see at
22 that document and on the sixth page -- now that's not
23 page 6, but if we count from the front, about six (6)
24 pages in we see a document, Mr. Christie, on your
25 letterhead from Ernst & Young, and it's dated May 2nd,

1 2011?

2 MR. JIM CHRISTIE: Yes.

3

4 (BRIEF PAUSE)

5

6 MS. CANDACE GRAMMOND: Okay. So we see
7 there, Mr. Christie, just above your signature, your
8 opinion as set out, that the amount of the policy
9 liabilities makes appropriate provision for all
10 policyholder obligations and the financial statements
11 fairly present the results of the valuation.

12 Should -- should any significance be
13 attached to the fact that this opinion wording differs
14 from the October 2010 report wording?

15 MR. JIM CHRISTIE: There should be no
16 significance attached. They're intended to be standard
17 opinions. The short wording that you see here is the
18 formal report of the actuary. It is deliberately
19 designed to be short, concise, to contain no numbers, and
20 to simply signify to a reader that it is the same wording
21 that they see in any other report.

22 The report you saw at October is -- it's a
23 summary report consistent with how I report to the
24 regulators wherein they have asked that the -- the
25 numbers be specifically included even though the numbers

1 are not included in the standard of practice of the
2 Canadian Institute of Actuaries.

3 So where a regulator asks, we do that. I
4 simply followed that practice. In the February letter
5 that went out, the financial statements haven't been
6 prepared yet so I can't make the statement that they fair
7 -- the financial statements fairly present the results.
8 This is getting out there in a hurry or as quickly as we
9 can, "hurry" is not the right word, as quickly as we can
10 so that they can prepare the financial statements.

11 And then later in the process I actually
12 issue this short form letter once I have actually seen
13 the fina -- drafts of the financial statements.

14

15 (BRIEF PAUSE)

16

17 MS. CANDACE GRAMMOND: So the absence of
18 the language with respect to fair presentation in the
19 October document is reflective of the fact that the
20 financial statements are not available to you?

21 MR. JIM CHRISTIE: In the October
22 document? I just have to get that in front of me.

23 MS. CANDACE GRAMMOND: Sure. That's back
24 at AI-13.

25 MR. JIM CHRISTIE: Oh, yes. AI-13.

1 (BRIEF PAUSE)

2

3 MR. JIM CHRISTIE: The reason this -- the
4 reason the wording is as it is is I'm issuing this report
5 in February for as of October. The Corporation is
6 issuing financial -- monthly financial statements and
7 prepare -- and releasing some of them on a quarterly
8 basis.

9 I cannot -- they wouldn't know what my
10 numbers were going to be in February when they released
11 their October report, so I can't -- I can't make the
12 statement that the financial statements fairly present
13 the results of my report because it wasn't done then.

14 What I can say is that the numbers that
15 are in here fairly present the results of my analysis,
16 which presumably then a -- MPI management incorporates in
17 their reports once they get them.

18 Now, they would have had this number
19 basically done in late December or early January. I'm --
20 it depends on the year, the precise timing of that. So I
21 would presume they would be reflected in the December
22 financial statements that are used internally.

23 MS. CANDACE GRAMMOND: Mr. Christie, in
24 the context in which you speak and -- and make the
25 statements in the document that the financial statements

1 do fairly present the results of the -- the valuation.

2 What do you mean by that?

3 MR. JIM CHRISTIE: What I mean by that
4 is, that I have done an analysis, produced estimates, and
5 that the numbers in the financial statements as they
6 relate to my -- the -- the items in the financial
7 statements on which I have opined, are similar to the
8 numbers I've estimated. In fact, in this case, they are
9 identical to. But the opinion would allow similar to.

10 MS. CANDACE GRAMMOND: Okay. Mr.
11 Christie, you -- you said earlier this morning that
12 there's an internal policy within Ernst and Young, that
13 work is reviewed -- one (1) actuary's work is reviewed by
14 another actuary within the office.

15 Do I have that right?

16 MR. JIM CHRISTIE: Yes, you did -- do.

17 MS. CANDACE GRAMMOND: And is that
18 something that is followed with respect to the work that
19 you do for the Corporation? So your work is then
20 reviewed by a colleague within your office?

21 MR. JIM CHRISTIE: Yes, it is.

22 MS. CANDACE GRAMMOND: And that would be
23 -- that colleague would be an -- another actuary.

24 MR. JIM CHRISTIE: That is correct. In
25 fact, the actuary who reviewed this year's is in the back

1 row here today.

2 MS. CANDACE GRAMMOND: And that -- that's
3 Mr. McFarlane?

4 MR. JIM CHRISTIE: That is correct.

5 MS. CANDACE GRAMMOND: Okay. Mr.
6 Christie, we've spoken a little bit about the documents
7 at AI-13(a) and (b), those are the two (2) valuation
8 reports. First, October of 2010 and then February of
9 2011.

10 Can you tell us about any interaction that
11 you may have had with the Corporation's auditors,
12 external auditors, KPMG, with respect to the valuations
13 that are contained in those two (2) reports?

14 MR. JIM CHRISTIE: Sure. Because the
15 October analysis is the prime driver of the numbers that
16 go on to the financial statements and February is
17 basically just an update to that, KPMG actuaries
18 requested of me the datasets that were -- would be used
19 in the financials in preparing the October analysis.
20 Those were provided and the -- and basically the triangle
21 that you see in these exhibits -- were provided to KPMG,
22 along with our selections. I presume then KPMG did
23 something with that data to reach the conclusion that's
24 indicated later on, that my estimates are reasonable.

25 They also asked us for other material.

1 For instance, the policy liabilities questionnaire we
2 send to each of our clients each year to -- to formally
3 identify any changes in practice that might have taken
4 place. We do that on a regular basis. And the
5 Corporation would typically be telling me these things,
6 but we try to get it down in writing that these are the
7 changes that have happened, or -- or internal memos that
8 have -- might have been sent about a particular change
9 in claim reserving practice, or something like that.

10 Changes in senior management team, that's
11 always an issue. Not that it created a problem, but
12 simply when -- when management changes there's always the
13 possibility that there -- there may be implicit claims
14 reserving practices being changed because one manager has
15 a different focus than another one.

16 THE CHAIRPERSON: Ms. Grammond, I'm
17 noticing the clock. And I'm wondering when it might be
18 appropriate for us to break. I don't want to interrupt
19 this line of questioning if you're doing a few more
20 questions on it. But what -- what are your thoughts?

21 MS. CANDACE GRAMMOND: Madam Chair, I
22 have a -- a few more questions for Mr. Christie.
23 Ballpark maybe ten (10), fifteen (15) minutes of
24 questions.

25 Now, I know we do have the two (2)

1 gentlemen from KPMG here and they are to testify this
2 afternoon. And we do want to get them through today,
3 hopefully, as well. I know one (1) of them has come in
4 from out of town. So I -- I think my inclination would
5 be to keep going with Mr. Christie, and I -- I don't know
6 how much the Intervenors may have, but I -- I would at
7 least like to complete my cross of Mr. Christie before
8 lunch.

9 THE CHAIRPERSON: Okay.

10 MS. CANDACE GRAMMOND: If that's
11 agreeable with the panel's indulgence.

12 THE CHAIRPERSON: Yes. You go ahead
13 then. And perhaps we'll take a look at the clock when
14 you finish. Thanks.

15 MS. CANDACE GRAMMOND: Thank you.

16

17 CONTINUED BY MS. CANDACE GRAMMOND:

18 MS. CANDACE GRAMMOND: Mr. Christie, just
19 following up on the -- the question I -- I posed about
20 KPMG, can you tell the Board what, if anything, you look
21 to KPMG for in their capacity as auditors for MPI for
22 comfort in the evaluations that you're doing?

23 MR. JIM CHRISTIE: In fact, our standards
24 of practice between accountants and actuaries require us
25 to exchange letters of -- exchange letters indicating

1 that we will be doing work and what we will be asking the
2 other professional to do.

3 From my perspective I look at the -- the
4 datasets that are there and look to see if there appears
5 to be any aberrations in the data. I check that the data
6 adds up to the financial control records. I ask KPMG to
7 review the -- the raw data, or the -- the material
8 flowing into that to assure themselves, or to -- to pro -
9 - to give me some assurance that the process of -- of
10 going from individual case files to the aggregations is
11 appropriate.

12 I ask them to sample that individual claim
13 files do exist, that individual premium files do exist,
14 that these are not phantom claims or phantom policies. I
15 ask them to ensure that any reinsurance treaties are
16 signed. And to -- just generally provide me with any
17 commentary they may have with some -- anything they
18 notice.

19 They do not provide an opinion, as such,
20 to me. Their opinion -- they are engaged by MPI to
21 provide an opinion on the financial statements. What
22 they do is provide me with a summary of -- of their
23 findings and allow me to form my opinion. Similarly, I
24 send them letters describing what I have done in my work,
25 which helps them assess whether the -- the -- those

1 particular items on the financial statements are
2 appropriate.

3 MS. CANDACE GRAMMOND: Thank you. Mr.
4 Christie, turning to your interaction with the actuarial
5 staff at MPI, can you describe for the Board the extent
6 and nature of -- of your interactions with the MPI
7 actuarial people, again, with respect to the evaluations
8 AI-13(a) and (b).

9 MR. JIM CHRISTIE: Sure. The collation
10 of data is done by MPI staff. The initial selection of -
11 - of factors lea -- in the methods is equally done by MPI
12 and then I -- and roughly a month after the data closes
13 I'm provided with a preliminary analysis. I and my staff
14 then review that analysis, first of all to make sure the
15 -- the data sets tie, and secondly we select our own
16 factors that may be different from the ones that MPI have
17 -- staff have selected. And we may select different
18 weights for the various methodologies.

19 Having done that, we then have a series of
20 conference calls with the MPI actuarial staff to review
21 the differences and say, This is what we would expect to
22 be putting in there, tell us why you picked something
23 different, let me understand what's there. Also, to get
24 an understanding of any changes that might have taken
25 place within the data sets themselves. Are -- is there -

1 - as was alluded to earlier, a mistake in -- in the -- in
2 the computer systems. We're not aware of any of those at
3 either February or October.

4 There was a change in the -- in their
5 underlying data system that's called FINEOS -- or, I'm
6 not sure how it's pronounced, which meant that certain
7 expense estimates were now in the data sets and had not
8 been there in the past. So we had to modify the data to
9 make it consistent over time.

10 So those kind -- I mean, we'd ask the
11 question, What's changed in the data? In that particular
12 instance the -- the numbers were on the margin of whether
13 they -- we would no -- have noticed them without having
14 been told. They looked a little higher, but not
15 unreasonably higher.

16 MS. CANDACE GRAMMOND: Okay. Thank you.
17 For the October 2010 evaluation in particular, can you
18 tell us who initiated the decision to change the basis of
19 selection evaluation results from the various
20 methodologies applied?

21 MR. JIM CHRISTIE: My recollection is it
22 was myself, but I'm not positive of that. Certainly, the
23 individual analysis was -- of the methods was originally
24 done by MPI, but typically the weighting is done later on
25 in an exhibit format. And my recollection of the first

1 run was that the same methods as been used in the past
2 were -- were done, but I'm not -- I -- I can't recall
3 exactly.

4 MS. CANDACE GRAMMOND: Thank you. Mr.
5 Christie, in -- in current years, and -- and even in --
6 in recent prior years, MPI has used the expression before
7 this Board "prudent best estimate" as well as the phrase
8 "prudently conservative" to describe the basis for the
9 Basic insurance valuations before consideration for Pfad,
10 or the provisions for adverse deviation.

11 Would you agree with those
12 characterizations?

13 MR. JIM CHRISTIE: To the best of my
14 knowledge, "prudently conservative" is a phrase coined in
15 Manitoba for MPI. I'm not aware of exactly what that
16 means. I can only let MPI management express what they
17 mean by that.

18 MS. CANDACE GRAMMOND: What about
19 "prudent best estimate"?

20 MR. JIM CHRISTIE: I can infer what it
21 means, but I would presume it's some sort of conservative
22 estimate, but it's not a term that I would personally
23 use. I'm not aware of the term being used -- or defined
24 in the actuarial literature.

25 MS. CANDACE GRAMMOND: So how would you

1 then characterize the basis for the valuations?

2 MR. JIM CHRISTIE: I would characterize
3 the basis as being slightly conservative, and don't read
4 into -- anything that -- more than what's in the
5 dictionary for the word "slightly."

6

7 (BRIEF PAUSE)

8

9 MS. CANDACE GRAMMOND: Again, with
10 respect to the two (2) valuations at AI-13, the October
11 10 -- of 2010 and February, 2011, valuations. You had
12 indicated that these reflected best estimates, this is --
13 I'm now referring to your direct evidence today, and that
14 you have no expectation of significantly -- or
15 significant favourable or adverse runoff in the future.

16 Is -- is that a fair statement?

17 MR. JIM CHRISTIE: Yes, I think that's a
18 fair characterization of what I had intended to say, so
19 it seems like you got what I said.

20 MS. CANDACE GRAMMOND: Okay. Good. Can
21 you tell us whether you would have offered the same view
22 three (3) or even five (5) years ago?

23 MR. JIM CHRISTIE: Yeah, I think I would
24 have. It's hard to separate current knowledge from where
25 I sat at that point in time, but there was no intent ever

1 to deliberately overstate these liabilities. The intent
2 was to put a best estimate with the information we had at
3 the time.

4 And so if you had asked me that question
5 five (5) years, do I expect favourable development, I
6 would have -- not any -- to any significant amount, and
7 it would have been obviously wrong.

8 MS. CANDACE GRAMMOND: Do you agree that
9 the -- the Pfad or the provision for adverse deviation,
10 as -- as used by the Corporation, is another source of
11 conservatism?

12 MR. JIM CHRISTIE: Yes.

13 MS. CANDACE GRAMMOND: And can you
14 explain then to the Board why the Corporation would make
15 a conservatism provision in the analysis before the
16 application of Pfad?

17 MR. JIM CHRISTIE: Well, I tried to
18 explain it in my testimony this morning. The likelihood
19 is that there will be more adverse experience showing up
20 in the future, more severe adverse than there is severe
21 favourable. If that's a term -- can use that adjective
22 in front of favourable.

23 Provision for average deviation, on the
24 other hand, is intended to allow for the random
25 fluctuation within a model. It's not that the -- or that

1 the model is wrong. The best that you can do in an
2 actuarial analysis is create a model that resembles
3 reality. Nobody purports that it is the exactly the same
4 as reality. It's obviously some sort of simplification.
5 So there's always risk that the model is wrong. In fact,
6 there's significant risks for that.

7 And that's part of what margins for
8 average deviation are -- are designed to reflect the fact
9 that the model may not be the -- first, the model may not
10 be the right model and, second, you may have
11 parameterized the model incorrectly.

12 MS. CANDACE GRAMMOND: Okay. Thank you,
13 Mr. Christie. I just have a few more questions. The
14 first is specifically with respect to the -- the large
15 releases that were seen in the last fiscal year and that
16 flowed from the October, 2010, valuation.

17 Can you tell us when you first became
18 aware of the -- the significant reserve releases at that
19 time?

20 MR. JIM CHRISTIE: Sometime in November.
21 I think towards the latter part of November, an email
22 from MPI staff indicating that there was a -- significant
23 reductions indicated.

24 MS. CANDACE GRAMMOND: I believe the
25 email was from Mr. Phoa does that sound about right?

1 MR. JIM CHRISTIE: Yes they were from --
2 yes, that's correct.

3 MS. CANDACE GRAMMOND: Okay. Ms.
4 Kalinowsky asked you to look at PUB/MPI-1-26, that was
5 the question that you had provided an answer for. So I
6 just want to ask you a -- a couple of questions about the
7 -- the information that you provided.

8 Looking at the -- the second page of your
9 document, which is the attachment in -- in particular the
10 second-last paragraph. You've made the statement, with
11 respect to the October, 2010, development, you say:

12 "These observations have shown relative
13 consistency in the periodic claims
14 development patterns since the
15 introduction of the new process in
16 2005. And hence, we felt that the new
17 process was credible."

18 Given that view, as expressed there, and
19 in the context of the February, 2011, evaluation that
20 followed, what reasons might there be for selecting loss
21 development assumptions generally above recent observed
22 historical levels?

23 MR. JIM CHRISTIE: The biggest reason for
24 that is that we only have five (5) observations under the
25 new reserving practice. Five (5) observations under any

1 system, doesn't produce a robust answer. The risk is
2 that the next observation may be significantly higher or
3 lower. Unlikely to be much lower, simply the nature of
4 these claims. But there could be a higher one.

5 And if that happens and we're using an
6 average, then we're going to increase -- and we would
7 typically use an average of the observations. We might
8 discount that one (1) observation to some extent, but it
9 would typically go up.

10 You then have a double impact. You have
11 the -- the -- the raw data producing extra claims
12 payments or a case incurred in the year, following
13 through the income statement, and a change to the -- the
14 factor, in -- which is then applied to all accident
15 years, which increases the liabilities on the balance
16 sheet and, therefore, increases the incurred claims in
17 the year.

18 We don't want estimates that are wildly
19 fluctuating. We pre -- prefer to have the estimates as
20 best we can, consistent from one (1) year to the next.
21 In a perfect world, there would be no development. Now,
22 that's not going to happen, but... And that's the reason
23 why I'm -- I'm generally picking a number slightly above
24 the -- the numbers that are indicated from the last five
25 (5) observations.

1 MS. CANDACE GRAMMOND: Mr. Christie,
2 there was some evidence given on your direct about the
3 issue of certain claimants with MPI that are receiving
4 benefits and the fact that their caregivers are growing
5 more elderly and -- and may need to be replaced with
6 professionals at some point in the future.

7 Would you agree that that's an issue in
8 the context of the valuations that really goes more to
9 the tail factor than the -- the history?

10 MR. JIM CHRISTIE: Oh, absolutely. I
11 mean, there might be one (1) or two (2) or even a hundred
12 claim -- such claimants in the data we've seen so far.
13 But the -- the likelihood is that these are going to be
14 happening twenty (20) to thirty (30) years after the
15 claim, when the -- when the caregivers age.

16 There will be -- I mean at -- at some
17 point in time there -- there might have been a claimant
18 with a sixty (60) year old caregiver, you know, at the
19 date of the accident, that is now seventy-five (75).

20 But the ra -- most likely incidence is
21 that those people are -- those caregivers were in their
22 thirties to fifties and -- and still have -- we still
23 haven't seen that.

24 Now, I don't want to make a big issue out
25 of this, because those caregivers are entitled to -- to

1 payments, and many of them do accept those payments.
2 But, some don't, which will increase at -- to some ext --
3 but you have to remember that it's only for those
4 claimants that are still collecting when their -- I'll
5 call them parents -- that -- they may not be parents --
6 when their parents are too old.

7 Most -- a lot of people will get -- will
8 be off the system because they will have recovered and
9 gone. So it doesn't matter that you break your leg and
10 your parents are sixty (60), you go back to work in a
11 years time.

12 So there won't be a lot of those. And --
13 and -- but there will be some. I should -- and it was
14 really put out as a -- a spec -- I tried to put this in a
15 specific context that there are -- there are things that
16 can go wrong that we can -- can visualize, but we don't
17 have data to substantiate what that would be at this
18 point in time.

19 MS. CANDACE GRAMMOND: Mr. Christie, when
20 we speak about what some of these -- these family members
21 are paid now and what the increase in costs might be, at
22 some point when a professional needs to -- to step in, is
23 that information in terms of a range that you have or --

24 MR. JIM CHRISTIE: I do not.

25 MS. CANDACE GRAMMOND: Okay. So that --

1 that's a question then better posed to -- to MPI, that's
2 fine. I think I just have one (1) additional question
3 for you Mr. Christie, and that relates to the -- the
4 February, 2011, evaluation that we've been speaking
5 about.

6 We've looked at a minute from the audit
7 committee -- one (1) of the audit committee meetings of
8 MPI and there was discussion about a possible additional
9 \$100 million provision for claims-related costs
10 associated with IFRS implementation.

11 Can you tell me if you were privy to that
12 discussion?

13 MR. JIM CHRISTIE: I don't recall it.
14 And I'm not sure whether it was a -- intended to be an
15 increase in claim liabilities or whether it was intended
16 to be an increase in the operating costs to produce the
17 claim liabilities, I can only speculate.

18 One (1) of the issues that IFRS was
19 potentially contemplating was a requirement that claim
20 liabilities be required to be discounted at a risk-free
21 rate. That is not the case right now, but it was
22 certainly one (1) of the considerations. If that were to
23 be the case then MPI discounts its claim liabilities
24 basically at the rate related to the assets that they
25 currently hold that match these liabilities, which is

1 somewhat higher, not significantly, but somewhat higher
2 than the risk-free rate.

3 MS. CANDACE GRAMMOND: Thank you. Madam,
4 I -- I have no further questions, but I think Board
5 member Gosselin does.

6 MR. REGIS GOSSELIN: Is Mr. Christie
7 going to be here after lunch?

8 MS. CANDACE GRAMMOND: Well, I -- I note
9 that neither Mr. Williams nor Mr. Oakes are in the
10 hearing room at the moment. I suspect -- I -- I think
11 Mr. Oakes told me last week that he probably wasn't going
12 to have questions for Mr. Christie. But Mr. Will --
13 Williams may well have questions. So I think we have to
14 ask Mr. Christie to come back.

15 MR. JIM CHRISTIE: I will be here after
16 lunch.

17 MS. CANDACE GRAMMOND: Okay. Sorry. One
18 (1) -- one (1) moment. I may have spoken to soon --
19 about that I was finished.

20

21 (BRIEF PAUSE)

22

23 CONTINUED BY MS. CANDACE GRAMMOND:

24 MS. CANDACE GRAMMOND: Sorry. I -- I
25 unintentionally misspoke. I do have a couple more

1 questions for you, Mr. Christie, but on a topic that we
2 haven't talked about yet.

3 You -- you said in your direct evidence
4 that in the past you had prepared DCAT reports for the
5 Corporation and then that was later taken in-house.

6 MR. JIM CHRISTIE: Yes.

7 MS. CANDACE GRAMMOND: Have you seen the
8 most recent DCAT report that the Corporation filed in the
9 --

10 MR. JIM CHRISTIE: I have not seen the
11 one that was spoken about in evidence this morning. The
12 last one I saw was roughly a year old.

13 MS. CANDACE GRAMMOND: Okay. How would
14 you interpret a recommendation contained within a DCAT
15 report that the minimum RSR target point for the
16 Corporation be increased from 185 million to 210 million?

17 MR. JIM CHRISTIE: It's my personal
18 opinion. I think it's low, it should be higher. I've
19 said this to MPI the -- you know, If you guys were a
20 private company running under a regulated regime in
21 another province the regulators would shut you down, you
22 don't have enough surplus.

23 Now you have to bear in mind that MPI has
24 -- at least in theory, the ability to increase premiums
25 and the policyholders have nowhere to go. The practical

1 reality of that is there's a limit on how much you can
2 increase rates.

3 MS. CANDACE GRAMMOND: So if I understand
4 you correctly you're -- you're saying the increase from
5 \$185 million target point to a \$210 million target point
6 is a step in the right direction, but you think not
7 enough?

8 MR. JIM CHRISTIE: Yes. I have -- I have
9 not read that report, but that would be my initial bias.

10 MS. CANDACE GRAMMOND: And I appreciate
11 that you haven't read the report, so I'm trying to keep
12 the -- the questions more general in -- in scope.

13 Can you tell us whether, in your view, the
14 risk profile of MPI has changed since -- within the last
15 year or since a year ago?

16 MR. JIM CHRISTIE: It probably has, first
17 of all for the reason that Mr. Palmer gave earlier, that
18 they have additional equities on their balance sheet --
19 or in their asset portfolio. Equities have a much more
20 risky nature to them.

21 The other reason why I would say the risk
22 profile has increased in the last year is the fact that
23 we've reduced liabilities. When -- whenever you have a
24 significant change in liabilities it clearly indicates
25 that there's some potential for the -- the claim

1 liabilities to swing.

2 I don't anticipate it would, but if you
3 look at any corporation where a particular item on their
4 balance sheet swings dramatically, that prob -- and
5 hadn't in the past, that probably suggests that their
6 risk profile has changed.

7

8 (BRIEF PAUSE)

9

10 MS. CANDACE GRAMMOND: Thank you, Madam
11 Chair.

12 THE CHAIRPERSON: I think now we can take
13 a lunch break, and we'll reconvene at 1:30.

14

15 --- Upon recessing at 12:21 p.m.

16 --- Upon resuming at 1:32 p.m.

17

18 THE CHAIRPERSON: We're just exploring
19 the humming sound. There's a -- but I don't know what it
20 is.

21 Well, in the interest of time, we'll just
22 have to ignore the humming sound but proceed. And I
23 think we're now at the point where Mr. Williams -- is
24 that right? Mr. Williams, would you like to cross-
25 examine this witness?

1 MR. BYRON WILLIAMS: Yes. Good
2 afternoon, Madam Chair and members of the Board.
3 Probably be about half an hour in terms of this witness.

4

5 CROSS-EXAMINATION BY MR. BYRON WILLIAMS:

6 MR. BYRON WILLIAMS: And I should have
7 notified him earlier, but also to the Board, I wonder if
8 you can grab for yourself, first from Information Request
9 CA -- response of MPI to CAC-1-1?

10 And also, okay, so it's First Round 1-1,
11 and also the CAC Exhibit number 8, which should be the --
12 the long sheet excerpted from the -- the actuary's report
13 as at October 31st, 2005.

14 And, Mr. Christie, I probably have a --
15 one (1) page of that here for you if you require it.

16

17 (BRIEF PAUSE)

18

19 THE CHAIRPERSON: Go ahead.

20 MR. BYRON WILLIAMS: Madam Chair, I just
21 see some papers still shuffling, so I'll -- I'll -- I'll
22 wait for a couple of seconds and -- if -- with your
23 permission.

24

25 (BRIEF PAUSE)

1 THE CHAIRPERSON: I think what we're
2 struggling to find is the second thing that you requested
3 us find.

4 MR. BYRON WILLIAMS: And that would have
5 been distributed on Thursday, and it is a long --

6 THE CHAIRPERSON: Oh, yes.

7 MR. BYRON WILLIAMS: -- a long sheet, and
8 there should be -- you might have two (2) in your bundle
9 of papers. One (1) is number 6, which is from 2011, and
10 one (1) is number 8, which is from 2005. And it's the
11 2005 long sheet that I'm referring to.

12 THE CHAIRPERSON: Okay. We'll have to
13 share this one. Go ahead.

14

15 CONTINUED BY MR. BYRON WILLIAMS:

16 MR. BYRON WILLIAMS: The -- the record
17 will show that the Board is cuddling.

18 Mr. Christie, I was kind of rude, and I
19 forgot to say good afternoon, so good afternoon, Sir.

20 MR. JIM CHRISTIE: Good afternoon.

21 MR. BYRON WILLIAMS: And, Madam Chair,
22 are we -- are we okay to proceed or...?

23 THE CHAIRPERSON: Yes. Yeah, we have it
24 right in front of me. And if the rest don't get closer
25 they won't see it. Okay.

1 MR. BYRON WILLIAMS: We really should get
2 a photograph.

3

4 CONTINUED BY MR. BYRON WILLIAMS:

5 MR. BYRON WILLIAMS: Mis -- Mr. Christie,
6 just for of all, in terms of CAC Exhibit 8, would I be
7 correct -- and -- and you'll agree with me, first of all,
8 that this is reproduced from your report as at October
9 31st, 2005, with regard to the Basic line of Manitoba
10 Public Insurance.

11 Would that be fair, Sir?

12 MR. JIM CHRISTIE: It appears to be. I
13 do not memorize all the numbers in my report.

14 MR. BYRON WILLIAMS: Will you accept it,
15 Mr. Christie, subject to -- to review?

16 MR. JIM CHRISTIE: Yes, although I do
17 have the report here. I can get the original.

18 MR. BYRON WILLIAMS: If that makes you
19 feel better, Mr. Christie, lead on.

20

21 (BRIEF PAUSE)

22

23 MR. JIM CHRISTIE: I can't find it at the
24 present time, so I'll take this as -- as reasonable.

25 MR. BYRON WILLIAMS: Well -- well, I'm --

1 I'm going to ask you actually to -- to...

2

3 (BRIEF PAUSE)

4

5 MR. JIM CHRISTIE: I have the original
6 document here.

7 MR. BYRON WILLIAMS: And, Mr. Christie,
8 if you have any concerns that the exhibit doesn't portray
9 the original document you'll check that out and -- and
10 bring that back to the Board's attention?

11 MR. JIM CHRISTIE: I will.

12 MR. BYRON WILLIAMS: Okay. thank you.

13 THE CHAIRPERSON: Sorry. Are we ready or
14 did I miss something?

15 MR. BYRON WILLIAMS: No, we're -- I think
16 we're all set up.

17 THE CHAIRPERSON: Okay.

18 MR. BYRON WILLIAMS: And I just wanted to
19 make sure the Board was -- was with us. Okay, thank you,
20 Madam Chair. I appreciate your patience.

21

22 CONTINUED BY MR. BYRON WILLIAMS:

23 MR. BYRON WILLIAMS: Mr. Christie, when -
24 - when I look at this -- this document would I be correct
25 in characterizing this ta -- the table in Appendix E,

1 page 23, as presenting the adverse development in the
2 tabular reserve process which led to the 6 percent
3 loading for the one hundred and twenty-two (122) ultimate
4 tail?

5 Would that be fair, Sir?

6 MR. JIM CHRISTIE: Yes, that's a correct
7 characterization of this exhibit.

8 MR. BYRON WILLIAMS: And, Mr. Christie,
9 so if you can keep this exhibit at hand. And I also
10 would ask if you would pull up, which you should have
11 before you, the response to CAC/MPI-1-1.

12 Do you have that, sir?

13 MR. JIM CHRISTIE: I do. I do.

14 MR. BYRON WILLIAMS: And before we get to
15 the Information Response, Mr. Christie, just in the --
16 the loss triangle section of the Appendix E, page 23, so
17 that's the long sheet in front of the Board, Mr.
18 Christie, that's from your 2005 report, page 23, mi --
19 you --

20 MR. JIM CHRISTIE: Yes.

21 MR. BYRON WILLIAMS: Yes. I just want to
22 draw your attention to a figure in the insurance year
23 '93/'94 at one hundred and thirty-two (132) months of
24 development.

25 Do you see that figure, sir, being

1 nineteen million sixty-three thousand seven hundred and
2 thirty-one (19,063,731)?

3 MR. JIM CHRISTIE: I do.

4 MR. BYRON WILLIAMS: Thank you. Now, Mr.
5 Christie, turning now to CAC First Round Information
6 Request 1-1. If you flip to the second page of -- of
7 that Information Request you'll see the question under
8 (j). And I'm going to paraphrase, Mr. Christie, and --
9 but essentially I'll suggest to you that the question was
10 asking -- it's looking at Appendix E and seeing this
11 figure of nineteen (19) -- 19 million, and then saying --
12 but in the appointed actuary's report as at October 31st,
13 2004, the '93/'94 ultimate is at fourteen seven seven
14 seven (14,777), which is presumably a hundred and thirty-
15 two (132) months of development.

16 And so it was -- in -- in broad strokes
17 I'll suggest to you that it was asking for a
18 reconciliation between those figures.

19 Is that your understanding, sir, at
20 reviewing that question as well?

21 MR. JIM CHRISTIE: Yes.

22 MR. BYRON WILLIAMS: And I just want to
23 refer you now to page 3 of that Information Request,
24 which is at the bottom sub -- (j), is the response to
25 that question, I'll suggest to you.

1 And I'll -- I'll ask you to con -- confirm
2 that -- that essentially the Corporation responded that
3 the 19 million was -- is the ultimate as at February
4 28th, 2005, adjusted to current 2005 benefit levels,
5 whereas the fourteen seven seven seven (14,777) --
6 fourteen million seven hundred and seventy-seven thousand
7 (14,777,000) is the adjusted ultimate as at October 31st,
8 2004.

9 Is that your understanding as well, sir?

10 We'll get through the adjustment in just
11 one (1) second, sir.

12 MR. JIM CHRISTIE: According the text of
13 Exhibit J, it says the fourteen seven seven seven
14 (14,777) is the unadjusted estimate. You asked me
15 whether it was adjusted.

16 MR. BYRON WILLIAMS: I may -- so, sir,
17 then essentially I'll suggest to you that the thrust of
18 the Corporation's answer -- and I'll restate the question
19 more properly then, is that the 19 million was the
20 ultimate at February 28th, 2005, adjusted to current 2005
21 benefit levels. Whereas the fourteen seven seven seven
22 (14,777) was the unadjusted ultimate at October 31st,
23 2004, correct, sir?

24 MR. JIM CHRISTIE: Yeah, the fourteen
25 seven seven seven (14,777) would have been the unadjusted

1 number as of that point in time, not the ultimate number.

2 MR. BYRON WILLIAMS: Thank you for that.
3 And if we go to the next page you'll see we're continuing
4 in the response to -- to this Information Request,
5 specifically 1(1)(j).

6 And essentially, I'll suggest to you, Mr.
7 Christie, that to -- to perform this adjustment you took,
8 first of all, actual paid as at February 28th, 2005, and
9 then adjusted them to current 2005 benefit levels.

10 MR. JIM CHRISTIE: That's -- yes, that's
11 the basic concept here. The historical data is at prior
12 benefit levels -- in order to project the expected costs
13 into the future we use current benefit levels which
14 requires a restatement of prior data to the current
15 benefit level.

16 MR. BYRON WILLIAMS: And you did that as
17 well, sir, I'll suggest to you, with the unpaid tabular
18 reserves as at February 28th, 2005. And again, adjusting
19 them to the current 2005 benefit level, correct, sir?
20 That's -- that's lines 3 and 4, sir.

21 MR. JIM CHRISTIE: Yes, that is correct.

22 MR. BYRON WILLIAMS: And so on line 5 of
23 that response we see the ultimate as at February 28th,
24 2005, prior to the adjustment to current 2005 benefit
25 levels, correct?

1 MR. JIM CHRISTIE: That means that --

2 MR. BYRON WILLIAMS: Being fourteen
3 million seven hundred and ninety-three thousand
4 (14,793,000)?

5 MR. JIM CHRISTIE: Yes, that appears to
6 be correct.

7 MR. BYRON WILLIAMS: And at line 6, sir,
8 we see the ultimate as at February 28th, 2005, adjusted
9 to current 2005 benefit levels, being the, roughly, 19
10 million figure --

11 MR. JIM CHRISTIE: Yes.

12 MR. BYRON WILLIAMS: -- correct?

13 In terms of the loss triangle shown at the
14 top of Appendix E, Page 23, of the 2005 report as at
15 October 31st, would it be accurate to say that the
16 ultimates were taken from prior year valuations and
17 brought up to 2005 benefit levels, sir?

18 MR. JIM CHRISTIE: No, the values as at
19 that point in time were brought up to current benefit
20 levels. The whole point of this exhibit is to get
21 historic data and then estimate the ultimate after the
22 fact.

23 MR. BYRON WILLIAMS: Okay. Let me
24 restate the question then, sir.

25 Would it be accurate to say that the

1 values shown in the loss triangle, on Appendix E, Page 23
2 of the 2005 report were taken from prior year valuations --
3 valuations and brought up to 2005 benefit levels?

4 MR. JIM CHRISTIE: Yes. In broad terms
5 this exhibit is designed to show what the historical data
6 would have been had the 2005 benefit levels been in place
7 from 1984 through 19 -- 2005.

8 MR. BYRON WILLIAMS: Thank you for that.
9 And would it be accurate to say that from these values
10 brought up to 2005 benefit levels in the -- in the loss
11 triangle at the top, would it be accurate to say that the
12 development factors in the middle of the page were
13 calculated?

14 MR. JIM CHRISTIE: The middle of the page
15 is essentially just an arithmetic calculation of dividing
16 one (1) column by another column.

17 MR. BYRON WILLIAMS: Mr. Christie, I
18 didn't -- I didn't hear -- hear that response. So, just
19 if you'll repeat it please?

20 MR. JIM CHRISTIE: I'm not sure I
21 understood the question so I tried to give you the right
22 answer, to what I thought your question was. So if you
23 would repeat the question?

24 MR. BYRON WILLIAMS: Absolutely. We --
25 we shall.

1 The observed development factors are the
2 arithmetic result of the calculations related to the
3 values brought up to 2005 benefit levels, sir?

4 MR. JIM CHRISTIE: Yes.

5 MR. BYRON WILLIAMS: And flowing from
6 this analysis, the -- the -- I'll suggest to you -- the --
7 - and taking into account -- let me back up.

8 Flowing from this analysis, the selected
9 factors were chosen, sir, is that right?

10 MR. JIM CHRISTIE: Yes, that is correct.

11 MR. BYRON WILLIAMS: Now, sir, directing
12 your attention again to Appendix E, page 23, which is the
13 long sheet, would it be accurate to say that in 2005, the
14 last development period with more than two (2) years
15 history on which to base factor selections was two
16 hundred and twenty-eight (228) months?

17 MR. JIM CHRISTIE: With a proviso. That
18 is two (2) years of observations under a system that
19 predated PIPP. So you have to make the assumption that
20 development under a PIPP system would be identical to
21 that under the pre-PIPP system. A reasonable but not
22 verifiable assumption.

23 MR. BYRON WILLIAMS: With that proviso,
24 sir, would it be accurate to say that the last
25 development period presented on this table, with more

1 than two (2) years history on which to base factor
2 selection, was two twenty-eight (228) months?

3 MR. JIM CHRISTIE: Yes.

4 MR. BYRON WILLIAMS: And when I look at
5 the selected factor two forty (240) to ultimate, it would
6 be correct to say that that was based upon judgement,
7 sir?

8 MR. JIM CHRISTIE: Yes.

9 MR. BYRON WILLIAMS: And namely, that
10 judgement, sir, was the assumption that there would be a
11 further two (2) years of development at one point zero
12 zero three (1.003), followed by eight (8) years at one
13 point zero zero two (1.002)? Correct?

14 MR. JIM CHRISTIE: That is correct.

15 MR. BYRON WILLIAMS: Thank you. And it
16 would be accurate to say that the selected tail factor of
17 one point zero two two two (1.0222) flows from this
18 judgmental selection, sir?

19 MR. JIM CHRISTIE: That's correct.

20 MR. BYRON WILLIAMS: And would it be
21 accurate, sir, to suggest that this selection adds 2.2
22 percent to the ultimate for every accident year in this
23 analysis?

24 MR. JIM CHRISTIE: No. I'm sorry. Yes,
25 for every accident year in this analysis.

1 MR. BYRON WILLIAMS: Thank you for that.
2 That's helpful in understanding what you've -- you've
3 done, sir.

4 Mr. Christie, I -- I have a few questions
5 flowing from your discussion with My Friend, Ms.
6 Kalinowsky, this morning. And I'm fearful of making the
7 Board shuffle around and look for more papers. But --
8 but they may want to -- they may want to have at hand the
9 big fat volume, which is Volume III. And a -- AI-13(a).

10

11 (BRIEF PAUSE)

12

13 MR. BYRON WILLIAMS: And the -- the Board
14 might also want to have at hand the PUB book of
15 documents, which is PUB Exhibit number 9. Thank you.
16 Mr. Christie, I don't think you need to turn there, but
17 you'll recall this morning you discussed with My Friend,
18 Ms. Kalinowsky, the actu -- actuarial review performed by
19 Mr. Lam on behalf of the extro - external auditor KPMG
20 with regard to your reports for Manitoba Public
21 Insurance.

22 Do you recall that, sir?

23 MR. JIM CHRISTIE: Yes.

24 MR. BYRON WILLIAMS: And -- and you'll
25 recall as well your discussion with My Friend, Ms.

1 Kalinowsky, from this morning in -- in terms -- in terms
2 of the fact that while Mr. Lam considered some of your
3 estimates slightly conservative, there was a suggestion
4 that they remained within his range of reasonableness.

5 Do you recall that?

6 MR. JIM CHRISTIE: That was not a
7 suggestion. That was a statement of fact.

8 MR. BYRON WILLIAMS: Okay. And
9 certainly, sir, I appreciate your precision. You'll
10 recall the conclusion he reached, that they were within
11 his range of reasonableness?

12 MR. JIM CHRISTIE: Yes.

13 MR. BYRON WILLIAMS: And, sir, from your
14 conversation with My -- My Friend, Ms. Kalinowsky, this -
15 - this morning, I took it that -- that disagreements
16 between actuaries on -- on where a particular estimate
17 might lie within a range of reasonableness are really
18 part of the normal deliberations between the
19 practitioners of the actuarial art.

20 Would that be fair?

21 MR. JIM CHRISTIE: Yes, I would -- and if
22 one (1) actuary makes an estimate he can only regard
23 other act -- actuaries' estimates as reasonable relative
24 to his own. So each of Mr. Lam and myself have our own
25 observation of what we think the answer is.

1 And we -- and in the case of Mr. Lam's
2 letter, he is concluding that my estimate is reasonably
3 the same as his estimate.

4 MR. BYRON WILLIAMS: And indeed, in the
5 course of other reviews you've done of other actuaries'
6 work you have drawn that same type of conclusion, that
7 while the -- the numbers might be a little different,
8 it's within a range of reasonableness, correct?

9 MR. JIM CHRISTIE: That is correct.

10 MR. BYRON WILLIAMS: And, sir, If I had
11 your evidence right from this morning, I think you may
12 have performed -- you suggested that you've performed in
13 the range of two hundred and fifty (250) peer reviews of
14 other actuaries' work.

15 Would that be fair?

16 MR. JIM CHRISTIE: I have -- my statement
17 was that I had performed over two hundred and fifty (250)
18 reviews either internal, from my firm, or external, for
19 other firms, which would have been the type of question
20 we're talking about here with Mr. Lam. That would have
21 been an external review.

22 MR. BYRON WILLIAMS: So in the course of
23 those two hundred and fifty (250) reviews, whether
24 internal or external, have you ever expressed the view
25 that another actuaries' estimates were beyond your range

1 of reasonableness?

2 MR. JIM CHRISTIE: Yes, I have.

3 MR. BYRON WILLIAMS: And how frequent
4 would that be, sir? And I'm not looking for a count, but
5 I want to know is it a frequent occurrence or a
6 relatively rare occurrence, sir?

7 MR. JIM CHRISTIE: It's a relatively rare
8 occurrence when the letter is issued. It is a fairly
9 common occurrence when we start to do the analysis. And
10 then we would typ -- when -- if I was doing it, or my
11 staff, we would typically talk to the other actuary to
12 understand why we have a difference.

13 In many cases, it is because the opining
14 actuary is aware of information which we, as the
15 reviewing actuaries, are not. And when that is explained
16 that often resolves the difference, but not always.

17

18 (BRIEF PAUSE)

19

20 MR. BYRON WILLIAMS: And just so I
21 understand your evidence, and I thank you for the
22 thoroughness, I -- I believe your evidence was that it
23 would be relatively rare where a reviewing actuary would
24 suggest in the form of a letter that someone else's
25 estimates were beyond the range of reasonableness.

1 Would that be fair?

2 MR. JIM CHRISTIE: In terms of the formal
3 letter? Yes, because typically that dialogue would have
4 taken place long before that, first of all, to resolve
5 differences in -- in knowledge. And, secondly, if we
6 continue to have a difference this is going to create --
7 at least in my firm is going to create an issue around
8 the audit, and so we have to resolve that difference
9 before I send my letter to the audit partner.

10 I mean, it's possible it not -- might not
11 get resolved, but this is not a position anybody wants to
12 be in.

13 MR. BYRON WILLIAMS: And writing that the
14 estimates or the selected claims liabilities with respect
15 to a certain line of business are above the range of
16 reasonableness -- putting that in writing is not
17 something that you or any other actuary would do lightly,
18 fair enough?

19 MR. JIM CHRISTIE: Be careful. We often
20 have a disagreement about a line of business being
21 materially different or un -- unreason -- like not within
22 our range of reasonableness. We are opining in the audit
23 firm on the overall num -- single number on the balance
24 sheet, not on individual line of business.

25 And so if there are two (2) offsetting

1 errors the aggregate amount might very well be reasonable
2 even though two (2) -- two (2) lines of business within
3 fifteen (15) or sixteen (16) individually were not within
4 our range or reasonableness. But we are opining on the
5 number on the balance sheet, not on how the number on the
6 balance sheet was calculated.

7 MR. BYRON WILLIAMS: And I appreciate
8 that distinction. That's helpful. Let's back up then
9 just for a second, sir. In terms of moving away from the
10 balance sheet --

11 MR. JIM CHRISTIE: Yes?

12 MR. BYRON WILLIAMS: -- to whether the
13 suggestion that an es -- a certain line -- estimate of
14 liabilities was above our range -- or above a range of
15 reasonableness or beyond a range of reasonableness, is it
16 your evidence that that is a fairly common occurrence?

17 MR. JIM CHRISTIE: An individual line?
18 Yes. And, in fact, it is our practice in our -- in Ernst
19 & Young that if the individual differences offset each
20 other we're not going to make this a per -- an issue in
21 the audit because the audit is opining only on the
22 aggregate number, not on the individual component parts.

23 If there are separate reports issued for
24 auto physical damage and auto liability and there are
25 audit opinions on the separate reports we would worry

1 about that. But when you're only opining on universal
2 comprehensive insurance, the only issue is is the number
3 on the balance sheet reasonable.

4 MR. BYRON WILLIAMS: And in terms of the
5 type of letter that one might write to an auditor if you
6 were per -- performing that peer review task, would it be
7 incumbent upon you to identify differences in terms of
8 selected claims liabilities beyond a range of
9 reasonableness, sir?

10 MR. JIM CHRISTIE: That's a issue for
11 individual accounting firms or audit firms to determine.
12 My personal practice in writing to the audit partner
13 would be to -- to describe the differences by line,
14 indicate verbally or in text what the differences were,
15 explain why the -- why -- why it seemed to have caused
16 the difference or speculate what caused the difference.
17 Wouldn't always know because we might not have talked to
18 the other actuary.

19 And then -- but heading off the thing and
20 -- and the conclusion would be the results are reasonable
21 or the results are not. And even when the results are
22 unreasonable, if I could use that word, typically there
23 would be a lot of dialogue before that letter was
24 actually written.

25 In the most recent circumstances I can

1 recall where we've had unreasonable differences has been
2 because there hasn't been support for a statement and we
3 have, as the audit firm, demanded additional support,
4 which was sometimes slow in coming. And they were
5 holding over the company's head was we're going -- the
6 actuary won't sign an -- that the results are
7 unreasonable without evidence to support this assertion.

8 MR. BYRON WILLIAMS: And, sir, just -- I
9 want to make sure I understand your -- your final point.
10 You're pronouncing an opinion on the -- the balance
11 sheets as -- as a whole?

12 MR. JIM CHRISTIE: Not the balance sheet
13 as a whole, the unpaid claim liabilities which are a
14 single item on the balance sheet.

15 MR. BYRON WILLIAMS: Yeah. And my
16 question was imprecise, so I thank you for that. In
17 terms of those claims liabilities, to the extent that
18 there were two (2) estimates beyond a range of
19 reasonableness, from your perspective, but they were
20 offsetting, that would not -- you wouldn't feel necessary
21 to opine upon that in a -- in a -- in a opinion letter.

22 MR. JIM CHRISTIE: Specifically not.
23 Because the opinion is on the number on the balance
24 sheet. To be extreme about it, if the company was using
25 a Ouija board but they got an answer that was reasonable,

1 that's what our opinion would be, it was reasonable.
2 That's not what we're -- typically is done, but the
3 opinion is on the reasonableness of the final result, not
4 on the reasonableness of the approach to get there.

5 MR. BYRON WILLIAMS: And -- and I would
6 assume that the Ouija board methodology is relatively
7 rare, sir?

8 MR. JIM CHRISTIE: I've never seen it in
9 practice.

10 MR. BYRON WILLIAMS: That's reassuring.
11 In terms of -- I don't think you need to turn there, sir,
12 but if -- if you -- if you wish to, in terms of your
13 February, 2011, report, the appointed actuary's report is
14 at October 31st, 2010, which is AI --

15 MR. JIM CHRISTIE: Yes, I have it.

16 MR. BYRON WILLIAMS: You have it? Your
17 AI-13(a). Page -- it's specifically at page 12 of your -
18 - your evidence, or your -- your report. I want to
19 direct your attention to the -- the top paragraph, sir.
20 So that's AI-13(a), page 12 of your actuary's report.

21 MR. JIM CHRISTIE: I have it in front of
22 me.

23 MR. BYRON WILLIAMS: And we'll just --
24 and we'll just give people a -- a moment to turn there,
25 Mr. Christie.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

(BRIEF PAUSE)

MR. BYRON WILLIAMS: Now, Mr. Christie, in -- in your report on this page, you -- you -- and I'm -- I'm -- I'm drawing your attention to the top paragraph on the left, and -- oops, sorry.

THE CHAIRPERSON: We're not sure where you are.

MR. BYRON WILLIAMS: Okay. I apologize for that, Madam Chair. It's the big, fat volume, AI-13(a), page 12. So it's Volume III, and I think it's Part 2, AI-13(a).

We -- we may have set a record for references to big, fat volume on the -- on the record. Page 12, Madam Chair.

(BRIEF PAUSE)

THE CHAIRPERSON: We're all there now.

CONTINUED BY MR. BYRON WILLIAMS:

MR. BYRON WILLIAMS: Mr. Christie, just directing your attention to the first paragraph, and -- and you adverted to this in your evidence this morning.

1 But you're essentially stating, starting at the third
2 line, that when the new reserving method was implemented,
3 the case reserves for accident benefit WI and accident
4 benefit other indexed, decreased in aggregate by
5 approximately 250 million. But that since this new
6 reserving method was based on theoretical models, that
7 you were reluctant to reduce claims liabilities by such a
8 large amount, and instead conservative loss development
9 factors were initially se -- selected to offset the drop
10 in case estimates by increases in IBNR.

11 Is that a fair representation of that
12 statement, sir?

13 MR. JIM CHRISTIE: Yes.

14 MR. BYRON WILLIAMS: And, Mr. Christie,
15 you can correct me if I'm incorrect in this, but if I
16 went back to the -- your October 31st, 2005, report,
17 would I find that reference to the \$250 million there,
18 sir?

19 MR. JIM CHRISTIE: I can't recall whether
20 it was in there or not.

21 MR. BYRON WILLIAMS: Mr. Christie, we
22 could probably do this by way of undertaking which might
23 be more efficient, sir. And My Learned Friend can -- can
24 follow with me be -- because, Mr. Christie, I -- what I'd
25 like you to do is examine your -- your reports from -- as

1 at October 31st, 2005, through October 31st, 2009. And
2 if there are references to that \$250 million I -- I would
3 appreciate you undertaking to identify those to our --
4 for our clients.

5 MR. JIM CHRISTIE: I'm certainly willing
6 to do that.

7

8 (BRIEF PAUSE)

9

10 MR. BYRON WILLIAMS: And just for the
11 purposes of the court reporter, Mr. Christie, you're
12 confirming that you will undertake to review your reports
13 with regard to Basic in term -- flowing from October --
14 as at October 31st, 2005, through October 31st, 2009, for
15 the purposes of identifying references to the 250 million
16 in the same context as where it may be referenced in this
17 report?

18 MR. JIM CHRISTIE: I will either provide
19 you with the references or an indication that there was
20 no reference.

21

22 --- UNDERTAKING NO. 19: Mr. Christie to review his
23 reports with regard to Basic
24 as at October 31st, 2005,
25 through October 31st, 2009,

1 for the purposes of
2 identifying references to the
3 250 million
4

5 CONTINUED BY MR. BYRON WILLIAMS:

6 MR. BYRON WILLIAMS: And just from the po
7 -- the -- the -- from the -- in terms of actuarial
8 standards, sir, would it be -- it's certainly -- if you
9 chose, it certainly would not have been inappropriate to
10 put in a reference such as you put in this report in any
11 of those prior reports.

12 That would not be inappropriate?

13 MR. JIM CHRISTIE: Typically, they re --
14 it would not be inappropriate. Typically, we would
15 describe what changes we -- we were aware of in the
16 underlying datasets. The amount of disclosure in
17 actuarial reports has increased over the years, not so
18 much because the standards have changed, but because
19 practices evolved to include more disclosure of what is
20 in there.

21 MR. BYRON WILLIAMS: So if -- if I
22 understand your answer, sir, if you were faced with a
23 similar circumstance today you would be likely to -- to
24 disclose a figure of that magnitude?

25 MR. JIM CHRISTIE: Oh, certainly of that

1 magnitude. We -- we -- all my of clients, every year we
2 ask the -- the question, What kinds of changes have been
3 made in your case-reserving practices. Sometimes
4 companies are able to describe that in -- in detail, as
5 was the case in MPI, with a particular change in -- in
6 practice.

7 Other times, it is much more difficult.
8 It's only description that we've -- we've increased the
9 number of claims examiners, we've changed the senior
10 manager on the account, or whatever. But we do take that
11 into account, and we -- to the extent we can in perusing
12 the data, we look for changes and ask the companies to
13 rationalize why this change might have taken place.

14 If we can identify some rationale for a
15 change we would try to amend the data to reflect that, as
16 in your earlier questions of why we had changed the
17 accident benefits weekly indemnity triangle. We brought
18 it to the current inco -- benefit levels because we knew
19 that had happened, so it was an attempt to adjust the
20 data.

21 So generally we would try to adjust data,
22 or if we can't adjust the data use methods that rely less
23 heavily on whatever the change was.

24 MR. BYRON WILLIAMS: Thank you, Mr.
25 Christie. In terms of the Public Utility Board book of

1 documents, Tab 17 now I'm referring you to, sir, and you
2 may have gone there with My Friend, Ms. Grammond, but I'm
3 -- I'm referring you to the fourth-last page, which would
4 be a -- what appears to be an email from a Mr. Luke
5 Johnston to yourself dated, November 2, 2010, yeah.

6 So it's about four (4) pages from the
7 back. And -- and we're just assisting the Board, Mr.
8 Christie.

9 MR. JIM CHRISTIE: Yeah.

10 MR. BYRON WILLIAMS: And it should be
11 from Luke Johnston to -- to yourself dated, November 2nd,
12 2010.

13 Mr. Christie, first of all, is -- is this
14 an email that you re -- that you're familiar with or that
15 you recall receiving?

16 MR. JIM CHRISTIE: I recall receiving
17 this email, yes.

18 MR. BYRON WILLIAMS: And you will recall
19 within the email communication from MPI - we're directing
20 you to the second -- or the first paragraph, suggesting:

21 "It's been very hard to defend our PIPP
22 forecast as best estimate assumptions,
23 when the prior year's development is
24 consistently coming in fifty (50) to
25 seventy (70) cent -- seventy (70) -- 50

1 percent to 70 percent below our
2 forecast."

3 Do you recall that, sir?

4 MR. JIM CHRISTIE: Yes.

5 MR. BYRON WILLIAMS: To the -- to the
6 best of your recollection, do you recall inquiring of Mr.
7 Johnston, who the Corporation was having trouble
8 defending its estimates with? Was it the board of
9 directors, or the PUB, or do you recall exploring that
10 conversation, sir?

11 MR. JIM CHRISTIE: My recollection of --
12 of a number of conversations was that this was really
13 with respect to the PUB, in terms of their rate
14 applications and -- and the fact that they were showing
15 favourable development for several years.

16 From my perspective, that -- I didn't --
17 didn't affect me one (1) way or the other because I -- my
18 work -- well, the -- the MPI may rely on it for the PUB
19 hearings, my work stops and ends at getting the financial
20 statements correct at February 28th each year.

21 MR. BYRON WILLIAMS: Sir, and -- and if
22 you can't answer this I'll -- I'll understand perfectly,
23 but to the best of your recollection, can you indicate
24 where -- at what point in time you formed the opinion
25 that a revision of the estimates of this magnitude was

1 required?

2 MR. JIM CHRISTIE: Early November, 2010.

3 MR. BYRON WILLIAMS: Madam Chair, subject
4 to the undertaking, which I -- I thank Mr. Christie for
5 agreeing to, my clients have no further questions.

6 THE CHAIRPERSON: Thank you very much.

7 I should turn to Mr. Oakes and see if he
8 has some questions.

9 MR. RAYMOND OAKES: Madam Chairperson, I
10 do have several questions. I'll be relatively brief,
11 especially now that the issue of the Ouija board has been
12 fully examined. I can delete my questions relative to
13 that methodology.

14

15 CROSS-EXAMINATION BY MR. RAYMOND OAKES:

16 MR. RAYMOND OAKES: Mr. Christie, you
17 spoke prior to the lunch break, in an exchange with Board
18 counsel, and you talked about actuaries building a model
19 that resembles reality. Do you recall that conversation,
20 sir?

21 MR. JIM CHRISTIE: I do recall that
22 statement, yes.

23 MR. RAYMOND OAKES: And you accompanied
24 that statement with a further statement that in building
25 that model, you're always at significant risk for being

1 wrong. Do you recall that?

2 MR. JIM CHRISTIE: I don't recall that
3 statement, but that would be a true -- true
4 characterization of any model.

5 MR. RAYMOND OAKES: Okay. And really,
6 what actuaries are trying to do is, in this context,
7 bring some predictability to the unpredictable world of
8 auto insurance.

9 Is that correct?

10 MR. JIM CHRISTIE: Yes. In two (2)
11 facets with the model. One (1) is trying to get a model
12 that is reasonably reflective of reality. It will
13 obviously have to be a simplification. That's the first
14 thing we're trying to do with a model.

15 What we can't do with a model is reflect
16 the random -- even if you have the model exactly right,
17 there will still be random fluctuations with any -- any
18 real life situation, so we can't predict that with the
19 model. We can try to estimate what the -- the range
20 might be, but we can't avo -- we can't avoid the -- the
21 stat -- random statistical fluctuation that may come
22 about, even if you have the model right.

23 MR. RAYMOND OAKES: And my further
24 question would be, no matter what math or science or art
25 you bring to this application, you're likely to be wrong

1 in the final event.

2 Isn't that correct?

3 MR. JIM CHRISTIE: Yes. I -- to give you
4 a really simple example, we -- I think we can all look at
5 -- remember the concept of a dice. The numbers one (1)
6 to six (6) on the -- on the dice. The average roll is
7 three and a half ($3 \frac{1}{2}$). The actuary will predict that
8 you will roll three and a half ($3 \frac{1}{2}$) and, in fact, you
9 will be wrong every single time, because you will never
10 roll three and a half ($3 \frac{1}{2}$). But yet, three and a half
11 ($3 \frac{1}{2}$) is the average roll of the dice.

12 MR. RAYMOND OAKES: I appreciate that
13 example. It's a very visual one (1). And your
14 inaccuracy is going to range from slightly inaccurate to
15 the present circumstance, where we have some runoff of
16 some \$284 million, to being grossly inaccurate.

17 Is that correct?

18 MR. JIM CHRISTIE: I would quarrel with
19 the adjective you've used but the -- the estimate can
20 certainly be different for any number of reasons. The
21 models get refined. Even if the models aren't refined,
22 there is still the potential for statistical fluctuation
23 within the models.

24 MR. RAYMOND OAKES: And I think the
25 adjective you used in your exchange with Ms. Grammond was

1 that it was obviously wrong in this case.

2 MR. JIM CHRISTIE: Yes.

3 MR. RAYMOND OAKES: The transcript at
4 page 7,573 of these hearings talks about the case
5 reserves, and I appreciate you weren't here for that part
6 of the hearing. But does it accord with your
7 understanding of MPI that the total amount of case
8 reserves MPI would have would be in the range of \$864
9 million?

10 MR. JIM CHRISTIE: That's about the right
11 order of magnitude, but I can confirm.

12 MR. RAYMOND OAKES: That's fine. If
13 you'd just accept that for the pur -- purpose of the
14 example. And the favourable runoff was some \$284
15 million?

16 MR. JIM CHRISTIE: It was.

17 MR. RAYMOND OAKES: And you -- you
18 mentioned the State Farm example. Would you agree with
19 me that that's a gross anomaly in the experience of the
20 insurance forecasting?

21 MR. JIM CHRISTIE: It's an anomaly.
22 Whether it's gross or not, I'm not sure.

23 MR. RAYMOND OAKES: You're not trying to
24 tell the Board that being a billion dollars out on a
25 forecast would be acceptable forecasting standards?

1 MR. JIM CHRISTIE: I have no knowledge of
2 how they established the estimate, or -- or why they
3 changed it. I'm only dealing with the published facts.
4 I know that they published a result that showed a million
5 dollar loss.

6 I can say that in the case of MPI, in two
7 (2) thou -- knowing now, if we had known that in 2005, I
8 would not have put up the liability that I did. That's
9 why it was obviously wrong. But was it -- it wasn't
10 necessarily wrong -- in fact it wasn't wrong, in my
11 opinion, when we made it in 2005, because we didn't have
12 the information we have today.

13 And I just go back to the dice example.
14 After you roll the dice it's pretty obvious what the
15 answer is. But before you roll it, there's no way of
16 knowing what it's going to be.

17 MR. RAYMOND OAKES: Well, in 2005, sir,
18 you did have a material difference between the two (2)
19 results produced by the two (2) methodologies.

20 MR. JIM CHRISTIE: No. The first was a
21 case estimate process, it was not a methodology. It was
22 a change in the way case estimates were established.

23 The case estimates were changed by an
24 amount of roughly \$250 million by applying a tabular
25 reserve. The meth -- actuarial methods that were used

1 were the same for 2004, 2005, and 2006. The standard
2 actuarial techniques of incurred development, paid
3 development, Bornhuetter-Ferguson development, and paid
4 Bornhuetter-Ferguson development.

5 The technique -- the meth -- the methods
6 were unchanged. What we had was a significant change in
7 the underlying data. The fact that you dropped a quarter
8 of a billion dollars out of the case liabilities was
9 clearly going to impact the results of any of the
10 methodologies.

11 And, in fact, no reasonable actuary would
12 use a technique where the factors were based on historic
13 data when he -- when he or she knew that the -- the
14 current data was at a significantly different level of --
15 of sufficiency.

16 The fact that we knew that -- that the
17 Company had changed its reserving practices and had
18 dropped out of the case reserves two hundred and fifty
19 mill -- roughly \$250 million. You had to take that into
20 account when you apply the methodologies. Failing to do
21 that would be very poor actuarial practice.

22 MR. RAYMOND OAKES: Would you agree with
23 me, that the result of assigning zero credibility is the
24 same as ignoring that data?

25 MR. JIM CHRISTIE: Arithmetically, yes,

1 they are. But the fact remains we didn't ignore it. We
2 knew very much about it and we adjusted for that change.
3 And the adjustments were broadly speaking, to -- to
4 effectively ignore -- to replace the existing numbers at
5 October, 2005, with what they -- what would probably have
6 happened if that change in reserving prac -- case-
7 reserving practice had not taken place.

8 MR. RAYMOND OAKES: Did you issue a
9 qualified report that warned of the consequences in the
10 event that there was significant credibility to be
11 applied to that data?

12 MR. JIM CHRISTIE: No.

13 MR. RAYMOND OAKES: And why not, sir?

14 MR. JIM CHRISTIE: Because, in my
15 opinion, it didn't need to be qualified. We'd made our
16 best estimate. And, in fact, what we're engaged to do is
17 establish a best estimate. My best estimate at the time
18 included making an allowance to offset the changing case-
19 reserving approach.

20 MR. RAYMOND OAKES: Well, if you didn't
21 point up a warning of the alternative consequences how
22 could Mr. Lam then provide any meaningful acceptance of
23 the report that you produced?

24 MR. JIM CHRISTIE: I'm not sure how Mr.
25 Lam could -- or could not have done his work. And, in

1 fact, I don't know who did the review in 2005. I'm
2 typically not privy to those letters. Those are internal
3 documents for the audit firm. I would only be apprised
4 if they had concerns.

5 And certainly we would have been
6 describing to the audit firm in some context what we had
7 done. So it wouldn't have been just a, Here's a number,
8 take it or leave it. There would have been some
9 description of what was going on and our explanation of
10 the rationale.

11 It was no secret within MPI that this
12 change in practice had taken place. It took a se --
13 series -- a significant amount of time to get the process
14 in place. It was carefully monitored when it was put in
15 place. That's why we collect -- the Corporation was able
16 to collectively estimate the impact of about -- at about
17 \$250 million because they had monitored the estimates on
18 the fi -- case files before the application of the new
19 case-reserving methodology and the value on the case file
20 after the application of the new methodology.

21 MR. RAYMOND OAKES: My Learned Friend
22 talked about the email from Mr. Luke Johnston of November
23 2nd, and we examined that, where he -- and I'll repeat
24 what Mr. Williams has read into the -- the record:

25 "It has been very hard to defend our

1 PIPP forecasts as best estimate
2 assumptions when the prior year's
3 actual development is consistently
4 coming in 50 percent to 70 percent
5 below our forecast."

6 My question to you, sir, is, especially in
7 -- in recognition of your distinguished work in the
8 actuarial field for some decades, why does it take a
9 junior relative to your own experience and achievements,
10 a junior actuary, to bring this to your attention or to -
11 - to make that statement, that he can't defend the PIPP
12 forecast as best estimates with those numbers?

13 MR. JIM CHRISTIE: My presumption was he
14 was referring to the PIPP forecasts that were brought to
15 the PUB for rate-filing purposes. I am not part of the
16 rate-filing process.

17 I have appeared here -- this is I --
18 either my second or third time in fifteen (15) years to
19 address specific issues relating to my appointed
20 actuary's report, which I understand is an input into the
21 rate-filing process, but it in no way or matter does my
22 report attempt to forecast what two (2) -- next year's
23 claims are going to be for which next year's premiums
24 have to be set.

25 My report is an analysis of the

1 liabilities of the Corporation as of a particular date
2 for the claims that have occurred up to that date.

3 MR. RAYMOND OAKES: Were you not annually
4 reviewing the MPI PIPP runoff?

5 MR. JIM CHRISTIE: I was reviewing the
6 PIPP runoff, but that is not -- well, at least not my
7 understanding of what the first paragraph of Mr.
8 Johnston's letter referred to.

9 MR. RAYMOND OAKES: Well, let me make the
10 question simpler. How did you not know that the prior
11 year's actual development is consistently coming in 50
12 percent to 70 percent below the forecast?

13 MR. JIM CHRISTIE: In my opi - first of
14 all, it wasn't coming in 50 to 70 percent lower. That
15 was the forecast that MPI was bringing to the -- the PUB.
16 What we always look at every year is the cha -- is the
17 development triangles. We were aware of those. We saw
18 that there was a change.

19 As I've alluded to in my filed testimony,
20 we saw that the -- the new case-reserving approach seemed
21 to be accurate in -- from third year onward in that the
22 development fa -- factors that we saw in the first year
23 subsequent to the implementation of the change were close
24 to unity, implying that the factors were roughly
25 accurate.

1 But we had only one (1) observation. I
2 chose for two (2) years to assign zero credibility to
3 that because it was a theoretical method, at that point
4 still unproven.

5 In the third year, where we saw still
6 relatively consistent, close to unity, factors, we
7 started to apply -- allow credibility -- put more
8 credible -- credibility to the -- the new data. I had --
9 we had done that to a greater extent the next year, but
10 it was only in 2010, when we had five (5) years of
11 observations, that all showed the same thing, that we
12 decided it was -- that I decided that it was time to
13 release that.

14 Because our standards of practice require,
15 when we have a true change in the estimate, that I'm
16 convinced the new number is better, to go to it. Not to
17 smooth it over a period of time, but to release it then.

18 MR. RAYMOND OAKES: So did you decide to
19 change prior to his memo or after his memo? His email.

20 MR. JIM CHRISTIE: It would have been
21 after his memo, because until we get the data, we don't -
22 - we don't do an analysis. So I was -- we were starting
23 the analysis in November. It's October data, so we
24 wouldn't typically get it until mid-November.

25 MR. RAYMOND OAKES: You -- in your cross-

1 examination by Board counsel, you were asked of any
2 benefit of your use of conservatism in the MPI review.
3 And your answer was that it assists with public relations
4 if you're so conservative as to result in dividends.

5 You're not suggesting that you have any
6 role to play in this process with helping MPI and
7 government with public relations or being so conservative
8 as to result in dividends, are you sir?

9 MR. JIM CHRISTIE: Absolutely not. I'm
10 not suggesting that in any way.

11 MR. RAYMOND OAKES: Those are my
12 questions, Madam Chairperson.

13 THE CHAIRPERSON: Thank you very much.
14 Now, I'm -- oh, go ahead.

15 MR. REGIS GOSSELIN: I have a follow-up
16 question. This is -- I'm not looking for anything in the
17 closet, I just want to find out if, for example, the
18 opposite had occurred. You know, if you had adverse --
19 your forecasts were too low relative to the experience.
20 I guess the question is, would you have pulled the
21 trigger a lot sooner?

22 Like, I mean --

23 MR. JIM CHRISTIE: It's a hypothetical
24 question, but I'd have to say that I probably would have
25 been more inclined to pull the trigger sooner with -- if

1 it was the adverse than if it was favourable. That's my
2 personal inclination and that's -- I don't think there's
3 a -- I -- I think you're supposed to be unbiased, but the
4 reality of my personal inclinations is that I would be
5 much more biased to get bad news out than to get good
6 news out.

7 MR. REGIS GOSSELIN: And I would do the
8 same, I think.

9 THE CHAIRPERSON: I'm looking now to CAC.
10 Do you want to -- CCA, sorry. CCA. Do you want to ask
11 any questions?

12 MS. LIZ PETERS: No, we have no
13 questions.

14 THE CHAIRPERSON: Okay. Thank you. I
15 think then we're ready for -- is it new witnesses? We
16 maybe should be taking a break and -- for them to be able
17 to...

18 MS. CANDACE GRAMMOND: We should probably
19 take a break before KPMG goes --

20 THE CHAIRPERSON: Yes.

21 MS. CANDACE GRAMMOND: -- but we just
22 should ask if Ms. Kalinowsky has any redirect?

23 THE CHAIRPERSON: Oh, right.

24 MS. KATHY KALINOWSKY: No, I have no
25 redirect questions of Mr. Christie.

1 THE CHAIRPERSON: Okay.

2 MS. CANDACE GRAMMOND: Yeah. I would --
3 I would say then, Madam Chair, Mr. Christie can be
4 excused. We should take a short break.

5 THE CHAIRPERSON: I want to thank you,
6 Mr. Christie, for giving us your time. And it was very
7 informative. I found it very interesting. Up until the
8 time you got to the loss triangles. I find them a little
9 challenging but -- but it's been a very interesting day.

10 MR. JIM CHRISTIE: I'll take that as a
11 personal compliment that I made an actuarial presentation
12 interesting, because I don't often get that.

13 THE CHAIRPERSON: Well, and
14 understandable. You made it understandable and that's
15 not easy.

16
17 (PANEL STANDS DOWN)

18
19 THE CHAIRPERSON: All right. We're going
20 to take a break and we'll be back at about quarter to
21 3:00.

22
23 --- Upon recessing at 2:31 p.m.

24 --- Upon resuming at 2:45 p.m.

25

1 THE CHAIRPERSON: well, Ms. Kalinowsky,
2 you're ready to begin with the witnesses?

3 MS. KATHY KALINOWSKY: Yes, I am. I'm
4 very pleased to have with me as witnesses, they have to
5 be sworn, but it's Mr. Neil Parkinson to my immediate
6 right, and to his right is Mr. Rob Kowalchuk.

7

8 (BRIEF PAUSE)

9

10 MPI PANEL 3:

11 ROBERT KOWALCHUK, Sworn

12 NEIL PARKINSON, Sworn

13

14 THE CHAIRPERSON: Go ahead.

15

16 EXAMINATION-IN-CHIEF BY MS. KATHY KALINOWSKY (QUAL.):

17 MS. KATHY KALINOWSKY: Thank you. I'd
18 like to proceed in the same manner and framework that I
19 did with -- earlier this -- today with Mr. Christie. So
20 I'll talk a bit generally and guide the witnesses through
21 some questions for the direct with respect to their
22 qualifications first.

23 But, Mr. Kowalchuk, can you please explain
24 what your present position is at KPMG and can you
25 describe your work?

1 MR. ROBERT KOWALCHUK: Yes. I'm
2 currently a partner in the audit practice of KPMG here in
3 Winnipeg, over twenty (20) years of experience. I'm
4 responsible for several financial statement audits both
5 in the private and public sectors, including those in the
6 insurance industry.

7 MS. KATHY KALINOWSKY: And, Mr.
8 Parkinson, same question.

9 MR. NEIL PARKINSON: I'm the national
10 director of KPMG's insurance sector practice. I'm based
11 in Toronto. I have over thirty (30) years of experience
12 in dealing with insurance enterprises, both public,
13 private mutuals, stock companies, workers' compensation
14 boards, and similar organizations. I'm a chartered
15 accountant in Ontario since 1978 and FCA Ontario, 2008.

16 MS. KATHY KALINOWSKY: And Mr. Kowalchuk,
17 what are your qualifications to be the auditors of MPI?

18 MR. ROBERT KOWALCHUK: I'm a chartered
19 accountant in good standing, as I mentioned, with twenty
20 (20) years of practice, almost exclusively in the audit
21 side. I have experience auditing Crown corporations,
22 government entities, as well, as I mentioned, companies
23 in the insurance industry.

24 MS. KATHY KALINOWSKY: And same question
25 for you, Mr. Parkinson.

1 MR. NEIL PARKINSON: Well, I mentioned my
2 -- my year -- years of experience. In addition to that I
3 should mention the -- some of the industry and technical
4 involvements. I'm the chair of the Auditors Advisory
5 Committee for Insurance to the Federal Superintendent of
6 Financial Institutions. I'm a member of the Canadian
7 Accounting Standards Boards, Insurance Accounting Task
8 Force, let's see, KPMG Global Technical Committee on
9 Insurance, and also the advisory committee to OSFI, the
10 federal regulator with respect to IFRS matters. All
11 three (3) of those bodies relate really to the
12 development of IFRS now and going forward.

13 Also was the chair of the CICA working
14 group that produced the guidance on how auditors use the
15 work of actuaries that resulted in Audit Guideline 43.
16 And the joint task force of the CICA and the CIA which
17 updated those standards for the interpretation of the new
18 Canadian audit standards that were effective at the end
19 of 2010.

20 Accounting advisor to the Canadian
21 Institute of Actuaries on reinsurance matters, and co-
22 chair of the CICA/CIA task force on communications with
23 actuaries. And as previously mentioned, also national
24 director of our insurance practice.

25 MS. KATHY KALINOWSKY: Thank you for

1 that, Mr. Parkinson.

2 Mr. Kowalchuk, for how many years has KPMG
3 prepared the MPI audit?

4 MR. ROBERT KOWALCHUK: We've been the
5 external auditors from 2003 till present day. I believe
6 we were also auditors in the mid 1990s.

7 MS. KATHY KALINOWSKY: And who was the
8 team that performed the 2010/'11 audit of MPI from KPMG?

9 MR. ROBERT KOWALCHUK: I was the lead
10 audit engagement partner. Another partner in our
11 Winnipeg office, Scott Sissons assisted me on the
12 engagement. Mr. Parkinson was the engagement quality
13 control review partner on last year's audit. The senior
14 manager in our office, Scott MacLennan, from information
15 risk management was involved in the audit. Mr. Edward
16 Lam was our audit support actuary from our Toronto
17 office. And as well, there were several other CAs and CA
18 articling students on the engagement team.

19 MS. KATHY KALINOWSKY: And, Mr.
20 Parkinson, you performed what is known as the second
21 partner review of the audit.

22 Can you just explain that function?

23 MR. NEIL PARKINSON: Yes. I've been
24 carrying out that role since 2003, in my case. What the
25 EQCR does -- that's the acronym for what you described,

1 is be involved in and concur in all the key decisions
2 related to the planning, execution, gathering, and
3 interpretation of evidence and, ultimately, forming our
4 opinion on the financial statements.

5 MS. KATHY KALINOWSKY: And it's common to
6 have a second partner review?

7 MR. NEIL PARKINSON: Based on our own
8 internal standards we would always have a second partner
9 review in an engagement of this type that is a
10 significant financial institution.

11 MS. KATHY KALINOWSKY: And all of your
12 responses and answers today will be from your point of
13 review as an engagement as an auditor of MPI.

14 Is that correct?

15 MR. NEIL PARKINSON: Yes, that's correct.
16 It really relates to our issuing an opinion on the
17 financial statements of MPIC.

18 MS. KATHY KALINOWSKY: At this point, I'd
19 like to have both gentlemen -- both witnesses qualified
20 as experts in the audit function, and also for Mr.
21 Parkinson the audit of insurers.

22 MS. CANDACE GRAMMOND: I have no comments
23 or objections to that, Madam Chair.

24 THE CHAIRPERSON: Okay. I'll just turn
25 to our Intervenors. Mr. Williams...?

1 MR. BYRON WILLIAMS: We accept the
2 qualifications of the witnesses as presented.

3 THE CHAIRPERSON: And Mr. Oakes...?

4 MR. RAYMOND OAKES: As do we.

5 THE CHAIRPERSON: Right. And I should
6 have the names in front of me here, but...

7 MS. LIZ PETERS: Ms. Peters.

8 THE CHAIRPERSON: Pardon me?

9 MS. LIZ PETERS: It's Ms. Peters. Yeah,
10 we have --

11 THE CHAIRPERSON: Ms. Peters. Sorry. Do
12 you accept these witnesses?

13 MS. LIZ PETERS: We do.

14 THE CHAIRPERSON: Okay. Thank you.

15 MR. REGIS GOSSELIN: Can I ask a
16 question? We referred to a document earlier today that
17 talks to the roles of the external auditor. Can you --
18 can you bring us back to that document?

19 MS. CANDACE GRAMMOND: Sure.

20 MR. REGIS GOSSELIN: Do you remember
21 where that is?

22 MS. CANDACE GRAMMOND: It's -- it's at 1-
23 28. It's at Tab 18 of the book of documents, page 2.
24 And that -- that relates on page 3 to the -- there's a
25 blurb there about the KPMG auditors. This does relate

1 though to the actuarial role component. But is this what
2 you were referring to?

3 MR. REGIS GOSSELIN: Yes, that is. Thank
4 you.

5 MS. CANDACE GRAMMOND: Okay.

6

7 RULING (QUAL.):

8 THE CHAIRPERSON: Okay. Hearing no
9 objections, I think we're prepared to accept your
10 witnesses.

11

12 EXAMINATION-IN-CHIEF BY MS. KATHY KALINOWSKY:

13 MS. KATHY KALINOWSKY: Thank you very
14 much for that.

15 Mr. Parkinson, can you just explain the
16 purpose of an audit? I know Mr. Gosselin, of course,
17 will be very familiar with this.

18 MR. NEIL PARKINSON: Okay. It's for an
19 independent firm of public accountants to express an
20 opinion on the financial statements of the organization
21 as to whether they fairly present the financial position,
22 results of operations, and cashflows within a prescribed
23 accounting framework.

24 At the time, this was Canadian generally
25 accepted accounting principles, although going forward it

1 will be under IFRS as the accounting framework.

2 MS. KATHY KALINOWSKY: And, Mr.
3 Kowalchuk, perhaps you could explain to the Board members
4 as to who would be interested in or rely upon the audited
5 financial statements of Manitoba Public Insurance?

6 MR. ROBERT KOWALCHUK: Sure. Well, there
7 would be several stakeholders. Certainly, management of
8 MPI who's responsible for the preparation of the
9 financial statements, the audit committee of the board of
10 directors of MPI who recommends to the board that the
11 statements be approved, the chair of the board of
12 directors of MPI who would deliver the report to the
13 minister.

14 Of course the minister responsible for MPI
15 would be a stakeholder, government since MPI's financial
16 statements form part of the consoli - consolidated
17 financial statements of the province. The auditor
18 general of the province of Manitoba would be an
19 interested party, as would the Crown corporation's
20 counsel in their oversight role of all the Crown
21 corporations, the various provincial political parties as
22 they review and are required to pass the annual report in
23 the standing committee of the legislature, the Public
24 Utilities Board in their role as the regulator and, in
25 general, the public, those who have insurance, driver's

1 licence, or vehicles registered with MPI would have a
2 general interest in the financial state of the Crown
3 corporation.

4 MS. KATHY KALINOWSKY: Thank you. And,
5 Mr. Kowalchuk, I'll proceed with asking you the following
6 questions. But the audit is done by working with the
7 office of the auditor general.

8 Do you just want to explain to the Board
9 what actually occurs in that regard?

10 MR. ROBERT KOWALCHUK: Certainly. We do
11 work with the office of the auditor general on the audit
12 engagement. The OAG receives a copy of our planning
13 information. They receive copies of our draft audit
14 opinion, financial statements, any recommendations in
15 draft as well as in final form.

16 We understand and acknowledge that the OAG
17 will be using the KPMG audit work for the purposes of
18 consolidation in the public accounts. We also see the
19 OAG present at every audit committee meeting of the MPI
20 board of directors, where monthly and quarterly and
21 annual financial statements are presented and policies
22 and procedures are discussed.

23 MS. KATHY KALINOWSKY: And, Mr.
24 Parkinson, I can also see that KPMG coordinates and uses
25 the work of the external actuary, who has been Jim

1 Christie, from Ernst & Young, who testified earlier
2 today?

3 MR. NEIL PARKINSON: That's correct. And
4 the relevant professional standards for these purposes,
5 and -- and I'm using the new references, Canadian audit
6 standards are under Section 500, audit evidence, and also
7 Section 620, use of the work of an auditor's expert.

8 And these really supplant but were
9 consistent with the previous Audit Guideline 43 which
10 testified on last year in describing what we do in
11 coordinating work with the actuaries, and was updated
12 with the updated CICA guidance that I referred to as
13 having been issued last January.

14 What we do in this -- in these
15 circumstances, because the work of the external actuary
16 is, you know, obviously one (1) of the largest amounts
17 shown on the financial statements and certainly the most
18 judgmental and susceptible to differences arising, is,
19 you know, take a fairly structured and disciplined
20 approach to how it's done.

21 We have to insure that the data used by
22 the appointed actuary is appropriate, ties into the
23 records that the -- so we do provide, you know, some
24 assurance as to the data used by the actuary in terms of
25 how it's sorted out by duration, year, by type of loss

1 and things of that nature that are relevant to the
2 actuarial analysis.

3 We look at the methodologies, the
4 assumptions and the judgements reached by the appointed
5 actuary, and we also do recomputation testing of the work
6 of the -- the appointed actuary. All -- all directed at
7 coming to a conclusion on whether the valuation that the
8 appointed actuary has come to is within a reasonable
9 range of actuarial estimates, based on what -- what would
10 be -- I think we would say generally accepted actuarial
11 standards.

12 MS. KATHY KALINOWSKY: And, Mr.
13 Kowalchuk, can you provide an estimate to the Public
14 Utilities Board of how much time is spent on the MPI
15 audit by KPMG?

16 MR. ROBERT KOWALCHUK: Yes, we would
17 spend in excess of eight hundred (800) hours in total by
18 the total team.

19 MS. KATHY KALINOWSKY: And that's
20 annually?

21 MR. ROBERT KOWALCHUK: That's annually,
22 yes.

23 MS. KATHY KALINOWSKY: And Mr. Kowalchuk,
24 KPMG provides two (2) -- or audits two (2) financial
25 statements of MPI. The Basic and the overall corporate.

1 Can you outline the different types of audit procedures
2 performed on the Basic as opposed to the overall
3 corporate?

4 MR. ROBERT KOWALCHUK: Yes. The audit
5 procedures are very similar, with the exception for the
6 Basic line of business. We need to perform audit
7 procedures over the allocations in order to provide a
8 clean audit opinion on the Basic line of business as a
9 stand-alone set of financial statements.

10 So even though we don't specifically
11 refer, in our auditor's opinion, to the fairness and
12 reasonableness of the allocations, if in our opinion they
13 weren't fair and reasonable we would have to qualify our
14 audit opinion on the Basic line of financial statements.

15 MS. KATHY KALINOWSKY: And, ultimately,
16 when you talk about your opinion, your opinion is found
17 in the annual report. One (1) for Basic and one (1) for
18 the overall corporate.

19 Is that correct?

20 MR. ROBERT KOWALCHUK: That's correct.

21 MS. KATHY KALINOWSKY: And would the
22 Board members like to turn towards the annual report? It
23 should be on page 46. Actually on -- it's on page 47 of
24 the annual report. But would you like to quickly outline
25 each item of the opinion, why it is there and what it

1 tells us?

2 MR. ROBERT KOWALCHUK: Certainly. So the
3 -- the first paragraph of the independent auditor's
4 report -- first I got -- I've got to step back. It's
5 addressed to the board of directors of MPIC.

6 The first paragraph sort of outlines the
7 scope of our audit engagement, the various statements
8 that are subject to audit, including all of the notes to
9 the financial statements, which collectively form the
10 financial statements.

11 The next paragraph outlines management's
12 responsibility for the financial statements, and they are
13 responsible for the preparation and a fair presentation
14 of the financial statements. If -- in this example, in
15 accordance with Canadian generally accepted accounting
16 principles. As well, they are responsible for internal
17 control.

18 The next three (3) paragraphs outline the
19 auditor's responsibility. So the first paragraph under
20 that heading talks about that it is the auditor's
21 responsibility to express an opinion on these financial
22 statements, and that we have conducted our audit in
23 accordance with Canadian generally accepted auditing
24 standards.

25 The next paragraph talks about what is

1 involved in the audit, introduces the concept of
2 performing testing to gain sufficient appropriate audit
3 evidence. It also highlights to the reader that we are
4 not expressing an opinion on the effectiveness of the
5 entity's internal control.

6 The final paragraph, under auditor's
7 responsibility, confirms whether or not we've obtained
8 sufficient and appropriate audit evidence in order to
9 form an opinion on the financial statements.

10 And, finally, the last paragraph is our
11 opinion, which would state that the financial statements
12 present fairly in all material respects, the financial
13 position of the Corporation, its results of operations
14 and its cash flows for the year ended February 28th,
15 2011, in accordance with Canadian generally accepted
16 accounting principles.

17 MS. KATHY KALINOWSKY: And in fact,
18 you've prepared two (2) such opinions. One (1) is for
19 the overall corporate and the other is for the Basic, and
20 both are virtually identical other than the name for
21 which the financial statements are? Correct?

22 MR. ROBERT KOWALCHUK: That is correct.

23 MS. KATHY KALINOWSKY: And this is what's
24 known as a "clean audit"?

25 MR. ROBERT KOWALCHUK: That is correct.

1 This is a -- a clean audit opinion, or an unmodified
2 audit opinion is another terminology.

3 MS. KATHY KALINOWSKY: And for each year
4 that KPMG has audited MPI, has KPMG issued a clean audit
5 opinion?

6 MR. ROBERT KOWALCHUK: Yes, we have.

7 MS. KATHY KALINOWSKY: Mr. Kowalchuk,
8 you've been involved with the MPI audit since 2003. Has
9 KPMG ever identified any fraud or noncompliance with laws
10 or regulation? Any material misstatements, material
11 weakness in internal controls, significant difficulties
12 encountered during the audit, going concern issues,
13 reporting issues?

14 MR. ROBERT KOWALCHUK: No, we have not.
15 Any matters that we have identified during the audit that
16 have been brought to the attention of management has been
17 satisfactorily dealt with by management of MPI.

18 MS. KATHY KALINOWSKY: And further, Mr.
19 Kowalchuk, KPMG's audit of MPI is also reviewed by the
20 Office of the Auditor General, is that correct?

21 MR. ROBERT KOWALCHUK: That is correct.

22 MS. KATHY KALINOWSKY: And has the Office
23 of the Auditor General raised any issues with KPMG?

24 MR. ROBERT KOWALCHUK: No, they have not.

25 MS. KATHY KALINOWSKY: So the Office of

1 the Auditor General has not expressed any concerns with
2 the audit or the financial estimates -- or sorry,
3 financial statements of MPI?

4 MR. ROBERT KOWALCHUK: That is correct.

5 MS. KATHY KALINOWSKY: Has the Office of
6 the Auditor General identified any areas for improvement
7 to KPMG with regard to the KPMG audit or to MPI's
8 financial statements?

9 MR. ROBERT KOWALCHUK: No, they have not.

10 MS. KATHY KALINOWSKY: And has the Office
11 of the Auditor General made any recommendations to KPMG
12 with regard to the audit or to the financial statements
13 of MPI?

14 MR. ROBERT KOWALCHUK: No, they have not.

15

16 (BRIEF PAUSE)

17

18 DR. LEN EVANS: Okay, the two (2) audits,
19 but which audit covers DVL?

20 MR. ROBERT KOWALCHUK: DVL would be
21 included in the overall corporate financial statements.

22 DR. LEN EVANS: I'm sorry, I didn't hear
23 you.

24 MR. ROBERT KOWALCHUK: DVL would be
25 included in the overall corporate financial statements,

1 not the Basic financial statements.

2 THE CHAIRPERSON: But, I understood you
3 to say there were two (2) audits. One (1) on the Basic.
4 The other one was on the other aspects of MPI? Is that
5 true?

6 MR. ROBERT KOWALCHUK: There is one (1)
7 on Basic, correct.

8 THE CHAIRPERSON: Yes.

9 MR. ROBERT KOWALCHUK: And then the other
10 one is the total corporate, including Basic.

11 THE CHAIRPERSON: Okay. So that's where
12 DVL would be found, in the total corporate?

13 MR. ROBERT KOWALCHUK: That's correct.

14 THE CHAIRPERSON: Okay. Thank you.

15

16 CONTINUED BY MS. KATHY KALINOWSKY:

17 MS. KATHY KALINOWSKY: And just to
18 clarify that then, Mr. Kowalchuk, for the Board members.
19 DVL would be found within the extension line of business
20 which is in -- within the overall corporate?

21 MR. ROBERT KOWALCHUK: Yes, that is
22 correct.

23 MS. KATHY KALINOWSKY: And the overall
24 corporate would also contain SRE or special risk
25 extension?

1 MR. ROBERT KOWALCHUK: Yes, that is
2 correct.

3 MS. KATHY KALINOWSKY: In addition to
4 Basic?

5 MR. ROBERT KOWALCHUK: In addition to
6 Basic, yes.

7 MS. KATHY KALINOWSKY: Moving -- moving
8 forward now, we're going to talk a little bit about IT
9 optimization. And no, it's not Mr. Geffen making a -- an
10 appearance. That will be tomorrow. But we're going to
11 talk about the accounting treatment of IT optimization
12 that was brought forward in questions in cross-
13 examination from Board counsel.

14 But, Mr. Kowalchuk, you're aware of the
15 accounting treatment of the IT optimization reserve?

16 MR. ROBERT KOWALCHUK: Yes, I am aware of
17 that. The -- we feel that the reserve is appropriately
18 accounted for and disclosed in the financial statements
19 of the Corporation, in accordance with Canadian GAAP, or
20 generally accepted accounting principles. The accounting
21 treatment is also acceptable under IFRS.

22 MS. KATHY KALINOWSKY: Can you give us an
23 example of any other reserves in other situations? Are
24 you familiar with the treatment or reserves in other
25 situation -- treatment of reserves in other situations?

1 MR. ROBERT KOWALCHUK: Yes, I've seen
2 that treatment before in other sets of financial
3 statements. One (1) example might be an appropriation of
4 retained earnings set aside for a capital project, such
5 as a construction of a building or a plant.

6 MS. KATHY KALINOWSKY: And KPMG has
7 discussed the matters of the accounting treatment of IT
8 optimization reserve with both senior management at MPI,
9 and also the audit committee of the board of directors?

10 MR. ROBERT KOWALCHUK: That is correct.
11 And it is normal course of action for management to bring
12 such accounting matters to the attention of the auditors
13 prior to recording any such transactions. So we did have
14 several conversations with -- with senior management.

15 As well, it was discussed at -- at one (1)
16 of the -- at least one (1) of the audit committee
17 meetings that we were in attendance at, specifically, the
18 January 27th, 2011, audit committee meeting, where
19 management discussed the creation of the IT optimization
20 reserve with the committee members. And we also obtained
21 evidence that the reserve was approved by the MPI board
22 of directors on February 24th of 2011.

23 MS. KATHY KALINOWSKY: And you have no
24 concerns with the IT optimization reserve as the
25 accounting treatment?

1 MR. ROBERT KOWALCHUK: No concerns, no.

2 MS. KATHY KALINOWSKY: Moving towards
3 IFRS 4, Mr. Kowalchuk, you're aware of a potential \$100
4 million that was earmarked from retained earnings for
5 IFRS 4 that was discussed at the audit committee meeting
6 on January 27th, 2011?

7 MR. ROBERT KOWALCHUK: Yes, I was in
8 attendance at that meeting.

9 MS. KATHY KALINOWSKY: And you're
10 ultimately aware that this hundred million dollar earmark
11 was -- for IFRS 4 was not proceeded with?

12 MR. ROBERT KOWALCHUK: That's correct.
13 You know, the standard is still not close to being
14 finalized. A number of decisions still need to be made
15 which would impact ultimately how the claims liabilities
16 will be measured under IFRS on a go-forward basis.
17 Therefore, there really is too much uncertainty at this
18 time to come up with an estimated impact.

19 MS. KATHY KALINOWSKY: And, mis -- Mr.
20 Parkinson, you were present earlier on today when Mr.
21 Christie testified about IFRS 4. Would you agree on an
22 overall basis with his testimony?

23 MR. NEIL PARKINSON: Yes, I would. I
24 think that the impact of measurement under the -- first
25 of all, under the existing IFRS standards was really a

1 non-event from the standpoint of measuring claims
2 liabilities for -- and going forward, it is unlikely we
3 will see new of -- new IFRS standards effective prior to
4 2015. And those standards will not be known for -- even
5 in their basic shape we won't have any great certainty on
6 it for a few months as they're -- they're still in a
7 state of transition for the next while.

8 MS. KATHY KALINOWSKY: Thank you for
9 that. I'd like to move into some other questions with
10 respect to the allocation methodology reviews. And I
11 know that Mr. Gosselin has asked some questions in the
12 past, so.

13 MR. REGIS GOSSELIN: Before you go there,
14 I wonder if I could ask a question in relation to a
15 response from Mr. Kowalchuk, I believe. You talked about
16 eight hundred (800) hours allocated to -- or at least
17 spent on the audit.

18 What portion of that would have related to
19 the examination of the insurance reserve that we just
20 spoke about earlier today?

21 MR. ROBERT KOWALCHUK: The insurance --
22 the 250 million reserve? Is that...?

23 MR. REGIS GOSSELIN: That's right, yeah.

24 MR. ROBERT KOWALCHUK: Right. You know,
25 I don't think that that time was tracked specifically,

1 but certainly, you know, it was an issue identified in
2 the audit planning process, and we ensured that an
3 appropriate amount of time was spent examining it. I
4 couldn't give you an exact hour figure.

5 MR. REGIS GOSSELIN: Okay. And in
6 relation to -- given the fact that this was an issue
7 identified in the pre-planning, you would have increased
8 the number of hours, I guess, to address that issue
9 specifically, relative to what you would have done in
10 other years?

11 MR. ROBERT KOWALCHUK: Yes, that is
12 correct.

13 THE CHAIRPERSON: Proceed.
14

15 CONTINUED BY MS. KATHY KALINOWSKY:

16 MS. KATHY KALINOWSKY: Thank you for
17 that. With respect to the allocation methodology
18 reviews, Mr. Kowalchuk, MPI implements an allocation
19 methodology to allocate costs between Basic and the other
20 lines of business.

21 How does this come into play when you're
22 preparing two (2) different audit opinions?

23 MR. ROBERT KOWALCHUK: So, as I mentioned
24 previously, we do perform additional procedures on the
25 allocation methodologies. Each year management performs

1 its own internal review of the allocation methodologies
2 and that KPMG was satisfied that in the course of our
3 financial statement audits that the allocations were fair
4 and reasonable.

5 In terms of procedures, we review what is
6 new in terms of the methodologies, any updates from a
7 prior year, assess those changes for reasonableness. We
8 use what we call information risk specialists on the
9 audit team to ensure that the formulas are coded properly
10 and -- and producing the proper results.

11 And after assessing the reasonableness of
12 the allocation methodologies we do take a look at the
13 numbers to ensure that they're being allocated into the
14 correct line of business. We also perform an overall
15 analytical review of the Basic allocations as compared to
16 the Corporation as a whole which includes the -- the
17 Basic line of business, and we would investigate any
18 anomalies from that analysis.

19 MS. KATHY KALINOWSKY: And, Mr.
20 Kowalchuk, has KPMG reviewed the cost allocation
21 methodologies that have been prepared by Deloitte at the
22 request of MPI?

23 MR. ROBERT KOWALCHUK: Yes, we did
24 perform a review of the allocation method --
25 methodologies last year.

1 MS. KATHY KALINOWSKY: And, Mr.
2 Kowalchuk, what was the conclusion reached?

3 MR. ROBERT KOWALCHUK: The conclusion
4 reached in our report indicated that we found that the
5 proposed allocating methodologies are reasonable and
6 result in a fair allocation of costs and assets and
7 liabilities among the relevant lines of business at MPI.

8 MS. KATHY KALINOWSKY: And over to you,
9 Mr. Parkinson. In your professional experience, is
10 allocation methodology the usual way to attribute costs
11 between lines of business within a corporation?

12 MR. NEIL PARKINSON: Yes, and
13 specifically for insurance organizations. There are
14 very, very few indeed insurance organizations that would
15 only have, perhaps, one (1) very narrowly defined line of
16 business or product. And so it -- there's really no
17 other way to measure profitability on a, you know, fair
18 and reasonable basis without allocating common costs.

19 And there are quite a number of costs that
20 are not necessarily specifically attributable to any one
21 (1) product line or activity, that you have to take into
22 account in assessing overall profitability in a line of
23 business. Things like finance, management, HR. IT
24 functions quite often have a lot of costs that you cannot
25 specifically attribute to any one (1) line of business or

1 product.

2 And so my experience is that, really, all
3 insurance organizations in particular, have some form of
4 allocation methodology to arrive at a fair allocation of
5 costs across those lines in order to ensure that they're
6 not fooling themselves as to what the profitability is of
7 a particular activity or line. And also, in some
8 instances, whether regulated or not, to ensure there's no
9 cross-subsidization of products so it -- one (1) product
10 doesn't look like it's better than it is and -- and
11 another worse.

12 So it's really -- pretty much the only way
13 to go about allocating costs to get to a, you know, an
14 assessment of profitability in any given line of
15 business.

16 MS. KATHY KALINOWSKY: Thank you for
17 that.

18 Mr. Kowalchuk, in summary then, you've
19 audited the Basic financial statements for the year
20 ending February 28th, 2011?

21 MR. ROBERT KOWALCHUK: Yes, that's
22 correct.

23 MS. KATHY KALINOWSKY: And based upon
24 your audit the financial statements accurately reflect
25 the Basic financial status of MPI on its 2010/2011 fiscal

1 year end?

2 MR. ROBERT KOWALCHUK: Yes.

3 MS. KATHY KALINOWSKY: And after the
4 allocation of expenses there is no material cross-
5 subsidization between MPI's line of business and -- MPI,
6 sorry, Basic line of business and other lines of
7 business?

8 MR. ROBERT KOWALCHUK: That is correct.

9 MS. KATHY KALINOWSKY: Is there anything
10 in the financial statements that indicates that the
11 extension and SRE lines of business and the DVL, which is
12 included in extension, have any material financial impact
13 upon the Basic line of business?

14 MR. ROBERT KOWALCHUK: There is nothing
15 to suggest that. Again, as I mention, KPMG did examine
16 the process and methodologies and allocations, and have
17 not identified any audit differences with respect to any
18 cross-subsidization.

19 MS. KATHY KALINOWSKY: Thank you for
20 that, Mr. Kowalchuk. I'll be concentrating most of the
21 questions now on Mr. Parkinson as I move into the realm
22 of audit support and the actuarial specialist now.

23 Mr. Parkinson, last year in the general
24 rate application the PUB specifically wanted to hear from
25 KPMG on the audit support with respect to the actuarial

1 evaluation of Basic claims liabilities including the
2 findings of -- and reporting on what was then Auditing
3 Guideline 43, which is now CAS 620, for the actuarial
4 specialist for this latest and recent prior fiscal year
5 ends?

6 MR. NEIL PARKINSON: That's correct.

7 MS. KATHY KALINOWSKY: And, Mr. -- Mr.
8 Parkinson, why are you particularly well suited to
9 testify on audit support and specifically the actuarial
10 specialist function?

11 MR. NEIL PARKINSON: Well, in -- in part
12 because really virtually all of my clients are insurance
13 enterprises where we use actuary a lot of support and
14 work with valuation actuaries on the other side of the
15 table in producing the numbers that are audited.

16 But in addition to that, I've been at the
17 sort of leadership positions in developing the
18 professional guidance on how you go about that as
19 auditors.

20 I mentioned before, I chaired the CICA
21 task force that produced the Audit Guideline 43, that
22 deals with how auditors should carry out audits of
23 actuarially determined amounts for insurance enterprises.
24 And then, last year, developed guidance that would be
25 suitable under the new Canadian Audit Standards for the

1 same thing, broadened into not just insurance
2 enterprises, but also pension and benefit plans.

3 So I've been very much involved at the
4 standards setting level and I'm now also dealing with
5 that at a sort of a training level at a global level for
6 our firm, as well.

7 And as mentioned, my practice is pretty
8 much devoted organizations where we have to deal with
9 these or -- problems on a day to day basis.

10 MS. KATHY KALINOWSKY: And, Mr.
11 Parkinson, perhaps you could explain to the -- the Board
12 that, as auditors conducting an audit of an insurance
13 company, an actuarial specialist is indeed required now?

14 MR. NEIL PARKINSON: Yes. Both under the
15 former audit guideline 43 and under the -- the new
16 guideline that's titled, rather ponderously, The CICA-CIA
17 Guide to Audits of Financial Statements That Contain
18 Amounts That Have Been Determined Using Actuarial
19 Liability Calculations. You'll be forgiven for still
20 staying Audit Guideline 43, I still do.

21 The -- one (1) of the fundamental aspects
22 of this is it's a very complex and subjective area of
23 estimates. And accountants are not actuaries and require
24 professional expertise of actuaries to verify actuarial
25 calculations.

1 I've been operating and serving insurance
2 enterprises for over thirty (30) years, have built
3 actuarial projection models myself and, you know, had a
4 mathematics background, but I would not dream of going
5 to, you know, the coal face on this without an actuary at
6 my side myself. So you really do need that and that's
7 one (1) of the fundamental principles of what you do in
8 carrying out an audit of an insurance company.

9 As mentioned, the new guidance is
10 substantially the same as the old Audit Guideline 43.
11 Then in some measure that was because we built Audit
12 Guideline 43 on the same chassis as the new international
13 audit standards were.

14 The actuarial specialist, as touched on
15 briefly before, is involved in doing the things -- and
16 understanding and interpreting what the valuation actuary
17 is doing, understanding the methodologies, the
18 assumptions and judgments, concluding whether they are
19 being done within appropriate actuarial professional
20 standards, but importantly, you know, testing the co --
21 the application of those -- those standards and
22 principles and judgments and doing recomputation testing
23 of how they, you know -- basically how they did their
24 sums and what the end result was, and then forming a view
25 about whether the result was within a reasonable range of

1 estimates. And that's really the critical judgment you
2 get to at the end.

3 The actuary is just that. It's a -- I
4 haven't run into any actuary who is also an accountant or
5 vice versa, but the -- these are, for MPIC, always KPMG
6 employed actuaries.

7 Historically, up until this past year, it
8 was a quite seasoned fellow by the name of Blair
9 Manktelow who was only maybe seven (7) or eight (8) years
10 less experienced than Jim Christie.

11 Last year it was Edward Lam, who is
12 another fully qualified and accredited actuary, who had
13 been assisting Blair before he left our firm to -- to
14 take on a senior actuarial role with another major
15 insurance company.

16 MS. KATHY KALINOWSKY: Thank you for
17 that.

18 And, Mr. Parkinson, I'll ask you to
19 explain, in step by steps, the process for incorporating
20 the review of basic policy liabilities into the audit.

21 MR. NEIL PARKINSON: Okay. And I'll
22 maybe touch on maybe a couple of specifics as it applies
23 to MPIC.

24 Somewhat differently than -- than is the
25 case with some organizations where this is a once a year

1 event, in this case as mentioned there was an October
2 31st take on the actuarial liabilities, which is where a
3 lot of the, you know, the change in experience and -- and
4 the heavy lifting from an analysis standpoint is done.
5 So we're very much engaged in reviewing the actuarial
6 valuation at that point, as well as doing a roll forward
7 at the end of the year.

8 So we involve the -- or our actuary at
9 that point. We exchange correspondence to confirm the
10 mutual use of each other's work with the appointed
11 actuary, in this case Mr. Christie in the past. We
12 obtained the -- you know, the - the same reports that the
13 external actuary is working with. And we reconcile and
14 test that data back to the corporate records to ensure
15 that the external actuary is dealing with appropriate and
16 accurate data.

17 We then, as -- also as mentioned, have a
18 look at what is done from a, you know, pro -- from a
19 process methodology and judgment standpoint. Quite
20 often, that is done while the -- the actuarial work is
21 still a little bit in progress to try to identify issues
22 early. And in, I -- I guess the -- as Mr. Christie
23 mentioned, where there are issues or differences that are
24 apparent or questions that we have, they tend to be
25 surfaced earlier on in the process with a view to

1 reconciling or bridging any of those differences,
2 undertaking further analysis, asking questions about
3 what's going on in order to deal with those issues.

4 And, typically, the -- that -- that
5 addresses most issues well before we issue, you know, a
6 final internal memorandum indicating what our findings
7 are. It would be unusual for our memo to come out in
8 finished form, and that would be -- and that be a
9 surprise to anyone that we had an issue. Ordinarily,
10 that's been dealt with interactively with management and
11 the external actuary earlier on in the process.

12 Ordinarily, any differences we find are
13 resolved, as I mentioned, by, you know, further analysis
14 and understanding of the data, in some instances by
15 changes made by the external actuary. And at the end of
16 the day, we get a memo as has been provided. In this
17 case, this year's memorandum was provided as part of the
18 pre-filing, I believe, that summarizes the work done,
19 some -- does certain other things that are required under
20 the professional standards, and we'll come to that
21 memorandum in detail in a few moments.

22 The -- we then, in the overall audit team,
23 take that overall opinion and that becomes part of our
24 work papers as part of our assessment of whether there
25 are any audit differences.

1 If we have a finding that the appointed
2 actuary's evaluation is within a reasonable range of
3 estimates the view is that we do not have an audit
4 difference or audit error to -- to contend with, and so
5 we -- we don't have anything out of the ordinary to
6 report to anyone.

7 And if -- you know, if there were any
8 differences that couldn't be resolved, and in my
9 experience as they virtually always are, we might have an
10 audit difference that would go on our report to
11 management and the audit committee indicating that we had
12 an audit difference that was immaterial, or if it was a
13 material difference that we couldn't resolve then -- and
14 unless that could be resolved, it could result in a
15 qualification of an audit report, but that is very rare
16 as you might imagine.

17 MS. KATHY KALINOWSKY: Thank you for
18 that. Mr. Parkinson, what is the responsibility of KPMG
19 in the valuation process?

20 MR. NEIL PARKINSON: Well, we -- we
21 explicitly don't have a responsibility for the valuation.
22 We're auditing it, and we have some -- some input from
23 the standpoint that we are basically validating or
24 providing assurance on it.

25 And the -- that -- that provides assurance

1 to the audit committee and management as to whether
2 there's, you know, a sort of a second view on whether the
3 financial statements properly portray the actuarial
4 evaluation.

5 MS. KATHY KALINOWSKY: And, Mr.
6 Kowalchuk, has the actuarial specialist ever provided a
7 report to the audit committee of the MPI Board of
8 Directors that you are aware of?

9 MR. ROBERT KOWALCHUK: No, not that I'm
10 aware of.

11 MS. KATHY KALINOWSKY: And what about
12 you, Mr. Parkinson? Would you know whether it's common
13 for the actuarial specialist to provide a report directly
14 to an audit committee of any board of directors of an
15 insurer?

16 MR. NEIL PARKINSON: No, the result of
17 the -- the actuarial review is a significant part of the
18 audit and would be included in our main audit filings
19 report that would summarize the work we did and our
20 findings in all major areas of the audit, but typically
21 there would not be a separate report to the audit
22 committee.

23 MS. KATHY KALINOWSKY: So typically there
24 would not be a separate report. Well, under what
25 circumstances could you perhaps think of that a actuarial

1 specialist would provide that report to the audit
2 committee?

3 MR. NEIL PARKINSON: Well, on request,
4 par -- it is possible, and it happened on occasions when
5 the -- an audit committee of an organization has asked
6 for more granularity of reporting, particular where
7 there's been substantial growth or changes in an
8 organization.

9 In some cases, the auditor's actuary also
10 carries out a peer review report on a periodic basis, and
11 that peer review report might go to the audit committee.

12 And lastly, as mentioned, if there was an
13 unresolved audit difference of any size then there would
14 likely be some additional reporting to the audit
15 committee with respect to those actuarial matters,
16 whether it was a separate report or otherwise.

17 MS. KATHY KALINOWSKY: And, Mr.
18 Kowalchuk, for each year that KPMG has audited MPI, there
19 have been no significant issues or concerns been raised
20 by the actuarial specialist to qual -- to cause a
21 qualified opinion to be issued?

22 MR. ROBERT KOWALCHUK: That is correct.

23 MS. KATHY KALINOWSKY: Has the actuarial
24 specialist ever raised an issue that has caused the MPI
25 appointed actuary to alter his basic review of policy

1 liabilities?

2 MR. ROBERT KOWALCHUK: No, they have not.

3 MS. KATHY KALINOWSKY: Did KPMG provide
4 specific permission for MPI to file with the PUB the
5 internal KPMG model -- memo from the actuarial specialist
6 to the accounting auditors?

7 MR. ROBERT KOWALCHUK: Yes, we did.

8 MS. KATHY KALINOWSKY: Had this internal
9 memo ever been disclosed to MPI prior to the request last
10 year of the Public Utilities Board?

11 MR. ROBERT KOWALCHUK: No, not prior to
12 last year. And, you know, no previous memos had ever
13 been disclosed. It would -- it's very unusual for
14 detailed audit documentation to be disclosed to the
15 entity that's subject to audit. You know, we try to --
16 we need to make the audit process unpredictable for
17 management, and also because we're not providing audit
18 opinions on separate parts of the financial statements,
19 but rather as on the financial taken as a whole.

20 MS. KATHY KALINOWSKY: Mr. Parkinson, the
21 Public Utilities Board last year and this year
22 specifically requested this internal memo from the
23 actuarial spec -- specialists. You've provided
24 accounting and audit services to numerous insurers
25 throughout Canada for in excess of thirty (30) years.

1 For any of these insurers that you have
2 provided these services to, are you aware as to whether
3 its rate setting board has requested a copy of this
4 internal memo from the actuarial specialist on the audit?

5 MR. NEIL PARKINSON: No, I'm not.

6 MS. KATHY KALINOWSKY: Has KPMG ever been
7 asked to disclose this internal memo from the actuarial
8 specialist to an insurance rate setting body?

9 MR. NEIL PARKINSON: No, not previously
10 to my knowledge.

11 MS. KATHY KALINOWSKY: Mr. Parkinson, as
12 somebody who is very much at the forefront of insurance
13 accounting and auditing matters, are you aware of any
14 other circumstances in which the copy of the internal
15 memo from the actuarial specialist has been requested by
16 an insurance rate setting board?

17 MR. NEIL PARKINSON: Not to my knowledge.

18 MS. KATHY KALINOWSKY: Mr. Parkinson, as
19 the Chair of the CICA Auditing Guideline 43, audit of
20 actuarial liabilities of insurance enterprises, and also
21 the subsequent CICA-CIA task force, can you provide some
22 circumstances as to when an external body might request a
23 copy of this actuarial memo?

24 MR. NEIL PARKINSON: Well, events of this
25 sort aren't really provided for in any standards or

1 guidance on this. So the only circumstances that I can
2 think of where this sort of thing might happen is in the
3 event of some catastrophic circumstances, you know,
4 bankruptcy or financial failure of an organization where
5 the auditor's working papers as a whole might be the
6 subject of review by third parties due to litigation or
7 other -- other reasons.

8 But other than that, in Canada, I would
9 say, no.

10 MS. KATHY KALINOWSKY: And the memo that
11 Mr. Lam prepared, that's a fairly standard memo?

12 MR. NEIL PARKINSON: Yes, aside from the
13 specifics pertaining to MPIC, it's of the same format and
14 content as we see in our other audit support memos for
15 our other insurance audit files.

16 MS. KATHY KALINOWSKY: And were there any
17 concerns regarding noncompliance with actuarial standards
18 and auditing standards?

19 MR. NEIL PARKINSON: No, the -- this
20 provides complete coverage of the issues that we need to
21 address from the standpoint of auditing standards and the
22 memorandum also refers to the work of the external
23 actuary as having been conducted, you know, within the
24 standards of practice of the actuarial profession.

25 MS. KATHY KALINOWSKY: Moving into a

1 slightly different area here, Mr. Parkinson, but in your
2 experience across Canada, is a program like PIPP
3 difficult to forecast the ultimate losses? PIPP, of
4 course, was legislated in 1994 and many of these costs
5 for PIPP might be very long-term.

6 MR. NEIL PARKINSON: Well, I -- I think
7 that, as was mentioned this morning, there -- while there
8 are some broadly similar automobile insurance schemes,
9 Ontario and Saskatchewan were mentioned this morning,
10 they're of, you know, similar vintage to this, so they
11 don't give a longer term clue on the performance of the
12 program than what you have yourselves.

13 It's a fairly long duration product, a lot
14 of exposure to changes in the costs of care, the types of
15 care, and -- and how injuries can evolve; so it's
16 certainly unpredictable. I would say that auto insurance
17 generally, not just this particular program, has tended
18 to be somewhat unpredictable, somewhat resistant to
19 analysis no matter what its terms over the past couple of
20 decades.

21 And it is fundamentally something where,
22 you know, significant changes that are unanticipated can
23 happen and do happen and have -- have occurred with all
24 kinds of insurance organizations, whether they're stock
25 companies, workers comp boards, you name it.

1 MS. KATHY KALINOWSKY: And for this PIPP
2 product at this stage of its life you would expect to
3 have deviations or adjustments on unpaid claims reserves
4 every year?

5 MR. NEIL PARKINSON: Well, you would
6 expect some level of differences to run through due to
7 re-estimation every year. You would probably not expect
8 them to be of the sort of magnitude as was the case last
9 year, but certainly you're going to have differences due
10 to changes in estimate every year.

11 MS. KATHY KALINOWSKY: And getting more
12 into the accounting issues, Mr. Parkinson, but could you
13 explain the relationship between a change in the review
14 of unpaid liabilities and the impact that has on the
15 income statement?

16 MR. NEIL PARKINSON: Well, quite simply,
17 if you make a change in the estimation of the liabilities
18 the -- 100 percent of that change in estimate goes
19 through the income statement in the year in which you
20 make that change in estimate. So something that might
21 not even we'll call that large in the context of an
22 overall balance sheet can nevertheless have a fairly
23 significant impact on income.

24 For instance, in this case, about a 1
25 percent change in liabilities is -- amounts to about \$15

1 million in net income, so it's not hard to see that, you
2 know, you can have significant impacts on income, even
3 with something that a fairly small percentage change.

4 I think most actuaries would be grateful
5 if they could get their estimates within two (2) or three
6 (3) percentage points of ultimate. And so it's -- it's
7 very easy to see such significant differences arising in
8 unusual years and normally not insignificant differences
9 in any year.

10 MS. KATHY KALINOWSKY: Thank you. I want
11 to move towards the opinion as at October 31st, 2010. In
12 particular, Mr. Parkinson, in reviewing the As At October
13 31st, 2010 Report on Unpaid Claims Liabilities, what was
14 the conclusion of the KPMG actuary?

15 And perhaps to answer that question for
16 the Board and provide for their education you might want
17 to walk through PUB-1-28, which is found, the Board's
18 book of documents, at Tab 18.

19

20 (BRIEF PAUSE)

21

22 MS. KATHY KALINOWSKY: It should be the
23 fourth page in. It's the KPMG confidential memo.

24

25 (BRIEF PAUSE)

1 MR. NEIL PARKINSON: Just wanted to do
2 just a check to see whether everyone's got hold of the
3 memo. Okay.

4 THE CHAIRPERSON: The Board has.

5 MR. NEIL PARKINSON: Okay. No. So this
6 memo is titled at the top, "To Rob Kowalchuk from Edward
7 Lam," who was the audit support actuary, and it's dated,
8 April 12th. Specifically, this memo deals with the Basic
9 coverage, and there are a number of sort of introductory
10 pieces to this that lay out the purpose of the
11 memorandum, distribution and use.

12 At the bottom of the first page it talks
13 about the appointed actuary and just provides a summary
14 comment, as is required in these memos, that the:

15 "We have eval -- evaluated the
16 qualifications and experience of the
17 valuation actuary whose work we're
18 checking."

19 And then there's some discussion on scope
20 of actuarial support, and you'll see it talks about the
21 types of liabilities, but also there's a reference in
22 there to data and the materiality used.

23 We -- at the bottom of that second page
24 there's a specific comment on what Mr. Christie used as
25 his materiality level for the purposes of his review, and

1 we always conform the materiality levels we and the
2 actuary are working at so they're both working from the
3 same sort of tolerances.

4 There is on the third page some discussion
5 about the changes from prior year -- year analysis
6 referred to here, and so I don't have anything in detail
7 to say about that.

8 But at the top of page 4 you'll see that
9 there is just a summary comment that the -- for some of
10 the lines of business reviewed we considered the
11 estimates to be slightly conservative while remaining
12 within our range of reasonableness. And this was also
13 true in the overall sense. That was the conclusion that
14 was reached by the audit support actuary, that there were
15 some individual lines that might have been slightly
16 conservative but still within range, and, overall, it was
17 certainly within range.

18 Then there are a couple of pages talking
19 about the actuarial analysis, conducted the nature of the
20 audit support done, the actuar -- actuarial details. And
21 you can see there's a certain level of detail, for
22 instance, at the bottom of page 4 for Basic Autopac
23 coverage, the -- the level we were drilling down to.

24 And carrying on to the top of page 5 with
25 the same sort of thing, referencing back to the October

1 2010 analysis which was done probably in a little greater
2 level of detail by both the appointed actuary and
3 ourselves.

4 The last couple of sections of the memo
5 deal with -- you know, just saying that we did some
6 computation testing on unpaid claims, looking at LAE, or
7 loss adjustment expenses, because you have to include in
8 claims liabilities the cost of adjusting and
9 administering claims as well.

10 Discussion on the -- how present valuing
11 or time value of money was applied at the top of page,
12 and indicating the discounting calculations are
13 reasonable. And the -- there is a reference at the
14 bottom of the memo under, "Other," saying that the -- the
15 audit support actuary had relied on the audit team to
16 confirm certain amounts regarding inter-company
17 recoveries and so on.

18 And I can tell you that, in fact, the
19 audit team did do that, so that's just closing the loop
20 to make sure that we had all done our thing there. Okay.

21 MS. KATHY KALINOWSKY: Just so that the
22 Board understand this, Mr. -- this is a opinion
23 specifically on Basic.

24 Is that correct?

25 MR. NEIL PARKINSON: Yes, that's correct.

1 MS. KATHY KALINOWSKY: And Mr. Lam also
2 produced another opinion, which is not contained here,
3 but on other lia -- other say overall corporate?

4 MR. NEIL PARKINSON: That's correct.
5 There was a separate memo for the total corporate.

6 MS. KATHY KALINOWSKY: So, for instance,
7 on page 4, when Mr. Lam is referring to for some of the
8 lines of business reviewed, he's not referring in the --
9 to SRE or Extension, he's referring to lines within
10 Basic?

11 MR. NEIL PARKINSON: That's correct. He
12 was referring only to the lines included in the Basic
13 coverage.

14 MS. KATHY KALINOWSKY: Thank you. And
15 when you read, as an auditor, what -- what is your
16 reaction when you read,

17 "The estimates are slightly
18 conservative while remaining within our
19 range of reasonableness"?

20 MR. NEIL PARKINSON: This would be
21 interpreted to mean that actuarial review did not detect
22 an error. We would only conclude that there was an error
23 to the extent that we felt that the -- the actuary's
24 number was outside of reasonable range of estimates.

25 MS. KATHY KALINOWSKY: And based upon

1 this actuarial review, as auditors at KPMG, you were
2 prepared to issue an unqualified opinion on the financial
3 statements, subject, of course, to the other audit work
4 that had to be done?

5 MR. NEIL PARKINSON: That's correct.
6 There is nothing in this to indicate that there would
7 have been a material error in the financial statements,
8 and so nothing that would have affected our opinion
9 adversely.

10 MS. KATHY KALINOWSKY: I'd like you to
11 take a moment for you to look at PUB-1-25. And I'll -- I
12 think it'd be helpful for the Board members to take a
13 look at that.

14

15 (BRIEF PAUSE)

16

17 MS. KATHY KALINOWSKY: And this is a very
18 similar question to what was also asked. I believe it's
19 the next question, 1-26, and that was addressed to the
20 Corporation's external actuary which Mr. Christie
21 discussed this morning?

22 Tha -- is that correct?

23 MR. NEIL PARKINSON: That's correct.

24 MS. KATHY KALINOWSKY: I'd just let the
25 Board members review this question briefly. But there's

1 also another follow-up question which you don't have to
2 pull out right now. But CAC-2-14. 2-114.

3 Can you just res -- give an overall
4 summary as to your response to both of those questions?

5 MR. NEIL PARKINSON: I think the gist of
6 the questions was whether the large release of -- from
7 actuarial liabilities that was made was indicative of
8 anything that needed to be changed in the prior financial
9 statements. In fact, whether those statements should
10 have been amended and -- and -- and reissued.

11 And our response in both of these -- both
12 the documents that counsel was referring to, indicate
13 that we were satisfied that the adjustment to claims
14 liabilities that flowed through the 2010/'11 fiscal year,
15 represented a change in estimates based on the best
16 available information at the time, and that they were not
17 indicative of an error in the -- the financial statements
18 in previous years which also reflected estimates that
19 were the, you know, appropriate actuarial judgments and
20 estimates made at the time.

21 It is -- and we, in the second document,
22 went on to recite some of the professional standards
23 backup for that and describing in -- in what
24 circumstances financial statements would be amended and
25 which ones they were.

1 And in summary, I would say that we were
2 con -- we were content that the changes in estimates did
3 not represent an error and, accordingly, our previous
4 opinions did not require revision, nor did the previous
5 financial statements they pertained to.

6 MS. KATHY KALINOWSKY: At KPMG's
7 insurance practice, are you often asked a question
8 similar to this?

9 MR. NEIL PARKINSON: It is not uncommon
10 to have discussions about when there is a change in
11 estimate of any significance, whether it represented an
12 error or not. But I would say that it is commonly
13 understood amongst actuaries and financial accountants
14 that the -- the changes in estimates are not indicative
15 of errors and don't require revisions of prior
16 statements.

17 MS. KATHY KALINOWSKY: So, if I could
18 summarize then. Could you conclude that the financial
19 statements from 2005 to 2010, still fairly present the
20 Corporation's financial position?

21 MR. NEIL PARKINSON: Yes. I think that
22 the -- to say again, that the reserve release made was --
23 represented a change in estimate as -- as we -- we see it
24 and very clearly, the GAP literature and for that matter
25 the new IFRS literature, require -- don't just permit,

1 but require that changes in estimates be reflected in
2 income in the current period. And not be amended in
3 prior years' financial statements.

4 And there is a distinction to be made
5 between what's an error and what's a difference in
6 judgment. The -- the -- there's a large difference and
7 our conclusion was these did not represent mistakes or
8 errors in actuarial assessments in prior years.

9 MS. KATHY KALINOWSKY: Mr. Parkinson,
10 upon reviewing the report in the Ernst & Young actuarial
11 memo, were you concerned with the actuarial report on
12 unpaid claims liabilities as at October 31st, 2010?

13 MR. NEIL PARKINSON: Oh, we're very
14 interested in understanding the -- the -- the scale of
15 the difference, but we were not concerned with the -- the
16 report, either our report or Mr. Christie's report.

17 MS. KATHY KALINOWSKY: And just getting
18 towards the end of my direct examination. But KPMG
19 ultimately issued an unqualified opinion for the year
20 ending February 28th, 2011?

21 MR. NEIL PARKINSON: That's correct.

22 MS. KATHY KALINOWSKY: And I note that
23 the KPMG's actuarial review with -- by Mr. Edward Lam
24 concluded that Mr. Christie's report is slightly
25 conservative.

1 Is that a more desirable conclusion than
2 being slightly aggressive?

3 MR. NEIL PARKINSON: Well, first -- first
4 of all from an auditor's perspective, we're not meant to
5 care whether you're slightly -- slightly high or slightly
6 low - a difference is a difference. But the -- we would
7 be concerned if an organization went from slightly
8 conservative to slightly -- to somewhat aggressive from
9 time to time, because that's a mechanism for, you know,
10 jockeying numbers around. And so we look for consistency
11 in approach and we -- we think we've seen consistency in
12 approach here.

13 I think that the other comments that were
14 discussed this morning really come down to, I would say,
15 more of a man-in-the-street view of what is a more
16 troublesome problem? If you are somewhat low, and you
17 prove to be low, it puts more pressure on costs having to
18 be paid for out of future premiums and maybe future
19 premium rates.

20 Having said that, it's not my -- my
21 mandate or role figure out -- to -- to tell you how to
22 set premiums, but I -- I think it -- not -- it may be
23 that being too high is logically no better than being too
24 low, but it can sometimes be more painful to deliver
25 people unhappy surprises in the form of higher premium

1 rates.

2 MS. KATHY KALINOWSKY: Thank you. And
3 what would -- I think you've already touched on this a
4 bit, but what would be the consequences of being slightly
5 aggressive in the report on unpaid claims liabilities?

6 MR. NEIL PARKINSON: Well, simply, if it
7 proves out -- if your estimates are -- are relatively low
8 and the -- the facts, the final costs, turned out to be --
9 -- be true and you end up having to pay more than you --
10 you had allowed for, some -- somehow it's going to have
11 to be paid for presumably out of other -- out of future
12 premiums, and that does put more pressure on future
13 premium costs.

14 MS. KATHY KALINOWSKY: As the head of the
15 insurance practice at KPMG, you've seen -- and -- and
16 involved -- being involved in so many different
17 professional committees and task forces, are you aware of
18 internal actuarial memos that conclude of a slightly
19 aggressive reserving practices?

20 MR. NEIL PARKINSON: Yeah, that -- that
21 is not infrequent. And -- and I would say that's not
22 just for public sector organizations or mutual companies.
23 It also applies to stock companies. That many
24 organizations dislike unhappy surprises, so a lot of
25 public companies are reluctant to be on the aggressive

1 side of the ball on -- on claims liabilities because the
2 analyst community really hates it. They really punish
3 companies who have adverse development emerging from
4 their -- their claims liabilities.

5 And so I would say, generally, a lot of
6 organizations tend to the conservative. But there's --
7 there's certainly the case that there are any number of
8 organizations out there where we will see memos
9 indicating that there may be somewhat below the -- the
10 line numbers on -- while still being within a reasonable
11 range.

12 MS. KATHY KALINOWSKY: And fin -- one (1)
13 final question, Mr. Parkinson, but how do other insurance
14 companies provide for an accounting treatment of
15 favourable actuarial releases?

16 MR. NEIL PARKINSON: Well, in the same
17 way any changes in estimates are -- go through and come
18 in the current period.

19

20 (BRIEF PAUSE)

21

22 MS. KATHY KALINOWSKY: At this point, I
23 have no further questions in my direct examination, so
24 both Mr. Parkinson and Mr. Kowalchuk, of course, are
25 willing and able to stay for cross-examination questions,

1 and questions from the Board too.

2 THE CHAIRPERSON: Any questions?

3 MR. REGIS GOSSELIN: I do. In respect of
4 the -- the phrase that suggests that Mr. Christie's
5 estimates are slightly conservative, can you point me to
6 the variables that would cause you to come to that
7 conclusion?

8 What variables are -- are at play here
9 when we -- when you say the estimates are slightly
10 conservative? There must be some variables that are on
11 the high side for you to come to that conclusion. I'd
12 like to know what those are.

13 MR. NEIL PARKINSON: Well, while there
14 are a number of items here, I think you were taken
15 through the concept of a claim's triangle before. And
16 basically all the actuaries are trying to do is fill in
17 the numbers on the blank side of the -- the rectangle.

18 To do that, they set loss development
19 factors that are meant to say, Well, if claims went up by
20 a certain percentage over a duration thirty-six (36)
21 months to forty-eight (48) months, the last couple times
22 it'll probably go up by about that much this time.

23 Actuaries don't always make the same
24 statistical judgment about what that development factor
25 ought to be. So, ordinarily, it's about the selection of

1 those things. It can be about the selection of interest
2 rates used in discounting. And there is a certain amount
3 of judgment around the provisions for adverse deviation
4 for a range of factors because they're inherently
5 somewhat judgmental under Canadian standards of practice
6 on the actuarial side.

7 So it can be any number of things. But I
8 would put a little bit of a box around it in a way. When
9 we say "slightly conservative," it -- I couldn't quote
10 you the individual lines and they're not referenced in
11 the memo, but, you know, it could be 2, 3 percent, maybe
12 up to five -- anywhere up to 5 percent plus or minus as a
13 typical range of reasonableness for most property
14 casualty companies.

15 MR. REGIS GOSSELIN: Now, your roles as
16 an auditor is not to look at that -- those factors and
17 say, That one's out of line, or -- or am I wrong here?

18 MR. NEIL PARKINSON: That's why I get an
19 actuary to do it. I -- well, I -- as I say, I have done
20 the math and have done -- I actually did build, not
21 having a life, the actuarial projection model some years
22 ago for -- for a simple 'p' and 'c' operation I -- that's
23 what we have actuaries of our own to do the detailed
24 computations on that.

25 So I wouldn't expect -- you -- I could

1 probably do it better than 99 percent of the insurance
2 auditors in the company because of my experience, but I
3 wouldn't dream of trying.

4 MR. REGIS GOSSELIN: I guess what I'm
5 trying to get at is, you know, I -- I can understand the
6 part where you say the calculations are correct. You
7 know, the calculations that derived from that variable of
8 correct.

9 But at what point do you say that variable
10 is too high, or too low or...?

11 MR. NEIL PARKINSON: Well, for -- for
12 some things, for instance, the selection of provisions
13 for adverse deviation and so on, there is guidance that
14 is published periodically by the Canadian Institute of
15 Actuaries for some things that help put some sanity range
16 around where an actuary's judgment might go, right. So
17 that helps to try to provide some black and white
18 guidance to actuaries.

19 And I think that a lot of it then goes to
20 the actuarial judgment. I'm not talking about Mr.
21 Christie's judgment. In our case it's our own actuarial
22 staff's judgment based on what they're seeing with other
23 auto insurers. And we do a lot of auto insurance work
24 both on a -- on an audit and also on the rate making
25 side, so we've got a lot of experience in the -- in the

1 space.

2 MR. REGIS GOSSELIN: I guess what the --
3 what -- what I'm struggling with is the fact that the
4 sudden result seems to have happened suddenly. You know,
5 this -- it was a sudden result. I mean, in other words
6 the data was under the radar and all of a sudden it burst
7 into bloom and we have a \$250 million surplus reserve
8 situation.

9 And I guess I'm wondering what could be
10 done differently to avoid that happening in the future
11 because it sounds like it could happen again. I mean, we
12 -- we have inde -- we have actuaries internally working
13 for MPI, we have the external appointed actuary, we have
14 KPMG's actuary looking at it.

15 So all of these -- all of these salaries
16 are being paid by people who subscribe to MPI insurance.
17 And we're sort of sitting here and wondering, Why
18 couldn't this have been picked up a lot earlier? I mean,
19 why couldn't there have been some flag go up and say,
20 There's too much money here. Let's get it back in the
21 pockets of the people who are paying for insurance. I
22 guess that's really what I'm struggling with.

23 MR. NEIL PARKINSON: Well, I think Mr.
24 Christie answered some of that better, perhaps, than --
25 than I will. So I'll try to answer it maybe a little bit

1 differently.

2 I think, for instance, he indicated that,
3 okay, he had so many years of indications and then,
4 finally, got to a point where he couldn't ignore the
5 data. But I guess in looking at that with hindsight, he
6 -- he was not in a position to say two (2) years ago or
7 three (3) years ago, I think, in his view, that the next
8 couple of years were going to turn out the way they --
9 they did.

10 And when I -- when I say "with hindsight"
11 someone might say, Well, that -- that turned out to be
12 too conservative, maybe you should have got money back to
13 people sooner.

14 But nevertheless, I think from our
15 standpoint our -- it was a defensible judgment. It may
16 have been rooted in conservatism, but the -- the other
17 part of your question though, was you -- what -- to say,
18 Why -- why couldn't it happen again?

19 And the exposure you have to these kinds
20 of events is based on changes in products or systems.
21 And it is far less likely you're going to see these kinds
22 of wild swings, I would say, in the future on the basis
23 that you're getting more information all the time. And
24 you -- if you were to come up with a whole new way of
25 delivering auto insurance benefits in the province, you

1 would, just as been the case in other provinces, notably
2 Ontario, have periods of significant uncertainty around
3 whether the product is going go work out and cost the way
4 you think.

5 And really what you're coping with here is
6 that perhaps very substantial, perhaps even extreme ver -
7 - result of having a certain amount of uncertainty about
8 how the costs of delivering these benefits was going to
9 play out. I think you have a lot less exposure to it
10 going forward just because of the continuing maturity of
11 the data and analysis around it.

12 MR. REGIS GOSSELIN: I guess the -- the
13 other question I have is in relation to the -- to the
14 statements themselves.

15 I realize that they're addressed to the
16 Board of Directors, but you know, Mr. Kowalchuk indicated
17 a long list of -- of readers of those financial
18 statements who come to rely on their statements.

19 I guess I'm wondering, would -- would that
20 cause you to -- the fact that it's read by and relied
21 upon by so many people, would that cause you to be -- to
22 err on the side of transparency as opposed to -- to
23 providing less information?

24 What I'm getting at is: Are you prodding
25 the MPI people to provide additional information for the

1 greater audience that's out there looking at these
2 statements?

3 MR. ROBERT KOWALCHUK: I would say that,
4 certainly we recognize the long list of stakeholders that
5 I read out, place some reliance on the financial
6 statements. But at the end of the day, what we're trying
7 to do is gain sufficient appropriate audit evidence on
8 those financial statements taken as whole.

9 Certainly, we recognize all of the users
10 of the financial statements, but there wouldn't be, you
11 know, any extra -- or procedures in excess of what we
12 considered necessary, you know, for MPI compared to an
13 organization with -- with maybe less stakeholders.

14 You know, we perform enough audit
15 procedures and gather enough audit evidence in order for
16 us to form our opinion, no matter how many readers or
17 stakeholders.

18 MR. REGIS GOSSELIN: Now, in relation to
19 -- to the discussion about similar organizations. You
20 mentioned Ontario and Saskatchewan and so on. I realize
21 that when you're doing a review of -- when you're doing
22 audited financial statements you're probably looking at
23 bench marking -- some bench marking to evaluate the
24 reasonableness of data that you're getting from -- from
25 MPI.

1 What benchmark are you using if you're --
2 if you're doing those kinds of assessments?

3 MR. NEIL PARKINSON: Well, I think the --
4 the similarity with Ontario is -- is not an easy one (1)
5 because it's of course, still private sector insurance.
6 So you've got a couple of hundred different property
7 casualty insurers delivering a product which is
8 conceptually somewhat similar, but not identical in the
9 way the -- the benefits come out.

10 I think there are also some difference in
11 the -- the SGI product from the Manitoba product, as
12 well. So it's difficult to benchmark specifically, you
13 know, how the -- exact data across and I think that the
14 more compelling analysis I think in view of the -- in my
15 view and I won't speak for the external actuary is,
16 really, to look at your own data on the -- the -- the
17 claim payments and claims reserves that you are booking.

18 And it is just awfully difficult. And
19 they're not going to tell you a lot more either, simply
20 because they are of about the same duration as yours.

21 MR. REGIS GOSSELIN: I draw your -- your
22 attention to page 66 of the annual financial statement
23 for -- for MPI, the one that's part of the rate
24 application.

25 This is the -- page 66. I'm looking at

1 the paragraph that talks to the rate stabilization
2 reserve. It's the -- it would be the second paragraph
3 after the two (2) sets of bullets. They -- it starts by,
4 "basic retained earnings are comprised
5 of rate stabilization reserve."

6 That paragraph.

7 So, you -- you reported that, in his
8 report, the Corporation's internal actuary concluded a
9 minimum RSR level of 185 million would be required to bas
10 -- for Basic to achieve a satisfactory blah-blah. If you
11 had a SR -- RSR lo -- level lower than 185 million, it
12 would resul -- result in a not satisfactory opinion. Now
13 you -- you reported that information.

14 I guess my question is: Do you share the
15 view of the internal actuary? I -- and I'm assuming you
16 don't because otherwise you would -- you have -- would it
17 have caused you to qualify the financial statement?

18 MR. ROBERT KOWALCHUK: So, I would answer
19 that, you know, it was factual that the DCAT analysis did
20 come up with a not satisfactory rating. That, however,
21 does not mean that that would cause us to issue a
22 qualified opinion on the financial statements taken as a
23 whole.

24 I mean, it's a -- it's one (1) test used
25 to measure capital adequacy, but does not bear a direct

1 relation to an audit opinion that we are providing on the
2 financial statements.

3 MR. NEIL PARKINSON: I might just clarify
4 what a DCAT is, just to -- in case there is anyone who
5 doesn't know what that represents.

6 The actuary -- it stands for Dynamic
7 Capital Adequacy Testing, and it actually is a future
8 projection under both the business, or base case, of the
9 organization. So, call it your business plan. It also
10 then applies certain plausible adverse scenarios, like
11 claims liabilities, where claims costs would be a lot
12 worse, or investment performance will be bad, or things
13 like that.

14 So it's very much future oriented. We do
15 not audit it. It is very much a projection or a
16 forecasting exercise undertaken by the actuary in
17 cooperation with management. So it's not ex -- actually
18 expressly audited.

19 MR. REGIS GOSSELIN: Now, moving now to
20 the IT optimization fund. I -- I -- and I -- Mr.
21 Kowalchuk, you talked about the fact that other entities
22 will establish reserves for buildings, for example.

23 And, I believe that there was also
24 reference or a discussion about the IFRS reserve that had
25 been discussed at the audit committee. In that case,

1 that reserve was not retained, but the IT optimization
2 fund was established.

3 I guess the question is -- I'm trying to
4 understand why one (1) was retained -- and why I'm
5 questioning this is because IFRS was not retained because
6 you couldn't come up with a level of cost related to
7 IFRS, as I understand it but the IT optimization fund was
8 established.

9 So, it would suggest to me that you had a
10 pretty good fix on the amount of -- of the cost of -- of
11 the program that was going to be undertaken?

12 MR. ROBERT KOWALCHUK: Yeah, I would say,
13 certainly, that there was far less predictability on --
14 on any impact of the IFRS adjustment, if any, compared to
15 the IT optimization fund, you know, which would have had,
16 you know a budget prepared, et cetera.

17 So, there -- I would say that would be the
18 main difference between the two (2) is the level of
19 certainty on which you could estimate how much the -- the
20 reserve should be.

21 MR. REGIS GOSSELIN: I guess -- I'm --
22 what I'm wondering is there -- is there a particular set
23 of documents that you could point to that says this is --
24 this is why we need to have 75 million?

25 What did -- what did you base your

1 decision as to reasonableness in that particular case?

2 MR. ROBERT KOWALCHUK: I believe we would
3 have examined information that management would have put
4 together and presented to the audit committee, and
5 ultimately the Board, which would have been budgets and
6 forecasts of expenditures on the various IT projects. So
7 that would be primarily what -- what audit evidence we
8 would have obtained.

9 MR. REGIS GOSSELIN: Now, in -- in
10 relation to that, whether the level was sixty-five (65),
11 or seventy-five (75) or eighty-five (85), I mean -- that,
12 in your view, would have been a management decision, or -
13 - you say for example, you see a set of documents that
14 says we're going to spend, you know, there's a hundred
15 million dollars we could spend here.

16 The level of reserves that are set is a
17 management decision against that hundred million, right.
18 Or -- am I ...?

19 MR. ROBERT KOWALCHUK: Well, the level of
20 the reserve set was management's best estimate of,
21 ultimately, what would be spent on the various IT
22 projects. So it was that amount that was appropriated
23 from retained earnings.

24 THE CHAIRPERSON: Okay. Thank you very
25 much. I think now, we're ready to go to Ms. Grammond and

1 your line of questioning.

2 MS. CANDACE GRAMMOND: Yes. Thank you,
3 Madam Chair.

4

5 CROSS-EXAMINATION BY MS. CANDACE GRAMMOND:

6 MS. CANDACE GRAMMOND: I'll begin with
7 some questions with respect to Mr. Lam's report, so I'll
8 -- I'll come to that in a moment. Before we get to the
9 report specifically, I'd like to ask some questions about
10 the roles and responsibilities of the -- the actuarial
11 specialist.

12 We have at Tab 18, of the Board's book of
13 documents, the question posed at PUB/MPI 1-28(b), this is
14 where -- and if we look at page 3 of that, this is where
15 the Board had asked a question about the role and
16 responsibility of the -- the actuarial specialist. And
17 the Corporation provided an answer with three (3) bullet
18 points of the -- the role with respect to that.

19 I'm assuming that you've had a chance to
20 review that?

21 MR. NEIL PARKINSON: Yes.

22 MS. CANDACE GRAMMOND: And do you accept,
23 Mr. Parkinson, this description of the role of the
24 actuarial specialist?

25 MR. NEIL PARKINSON: Well, it's at a --

1 it's a fairly high level. There's -- I -- I think my
2 own answer earlier was probably a little more granular on
3 what the audit support actuary would do.

4 MS. CANDACE GRAMMOND: So together with
5 your earlier description you'd be comfortable with that
6 standing on the record?

7 MR. NEIL PARKINSON: Yes.

8 MS. CANDACE GRAMMOND: And before we go
9 to Mr. Lam, specifically, I just want to clarify, you
10 gave evidence that the auditing guideline 43 has been
11 replaced, and I think you said it was CAC-620.

12 Is that the -- the proper term for what
13 the -- the successor document is?

14 MR. NEIL PARKINSON: The successor
15 document is -- and if you'll just bear with me for a
16 moment I'll give you the --

17 MS. CANDACE GRAMMOND: You're not going
18 to say that long thing again, are you?

19 MR. NEIL PARKINSON: Yeah, it's in there
20 somewhere. You'll see it in the transcript. But what it
21 is is a joint -- CICA-CIA was a joint guidance note. The
22 reference to paragraphs 500 and 620 in Canadian Audit
23 Standards are general standards related to evidence and
24 the use of an expert.

25 They -- they would apply equally to a

1 mineralogist or geologist, use of a geologist in an
2 audit. But what wa -- the guidance note did was put it
3 entirely in the context of using actuarially determined
4 amounts, and so it is a good deal more detailed, and
5 focussed on insurance, in particular, than those -- those
6 CAS standards chapters are.

7 MS. CANDACE GRAMMOND: So just for the
8 purposes of our discussion, if we just continue to call
9 it auditing guideline 43 is that okay with you --

10 MR. NEIL PARKINSON: I'm -- that's --

11 MS. CANDACE GRAMMOND: -- in the context
12 of the evidence you've given?

13 MR. NEIL PARKINSON: I'm fine with that
14 code, yeah.

15 MS. CANDACE GRAMMOND: Okay. So we note
16 that Mr. Lam, the author of this year's actuarial
17 specialist report, is new. As you described, Mr.
18 Parkinson, previously, the role was filled by Mr.
19 Manktelow. And I know you said that Mr. Lam assisted Mr.
20 Manktelow in the past.

21 Can you give us a little bit more detail
22 in terms of Mr. Lam's previous experience in this audit
23 engagement?

24 MR. NEIL PARKINSON: Well, I couldn't
25 give you the exact number of years, but I believe he'd

1 worked in the role of providing a lot of the technical
2 checking, the computation testing, and the detailed work
3 under Mr. Manktelow's supervision for probably at least
4 four (4) years, probably five (5) previous.

5 He's very -- he was fully accredited as a
6 fellow the cas -- of the Canadian Institute of Actuaries
7 and the -- the Casualty Actuary Society I want to say
8 about two (2) years ago, by memory. And so he had
9 several years of experience in working specifically on
10 these liabilities.

11 MS. CANDACE GRAMMOND: And given his
12 relatively short time as a fully qualified actuary, is
13 there anything else other than his prior experience with
14 this engagement that you looked at to satisfy yourself
15 that he was properly qualified and experienced to fulfill
16 the role that he did this year?

17 MR. NEIL PARKINSON: Well, in part, I was
18 perhaps remiss in not referring to the fact that this --
19 these reports actually get peer reviewed internally on
20 our part, and so the -- our actuarial practice leader,
21 Jacquie Friedland, who is an actuary with something like
22 twenty-five (25) years experience, also reviewed this and
23 was sort of the mentor, if you like, on this one.

24 MS. CANDACE GRAMMOND: Thank you. If we
25 talk then about the report prepared by -- by Mr. Lam

1 specifically. And I know we've -- you've already
2 referred to the statement by Mr. Lam, that Mr. Christie's
3 estimates are within the range of reasonableness and the
4 -- the reference to the estimates being slightly
5 conservative.

6 Can you comment on that characterization
7 compared with the characterization in last year's report
8 prepared by Mr. Manktelow?

9 MR. NEIL PARKINSON: By memory there,
10 there were a handful of lines that were also identified
11 as being somewhat conservative, and I think we may have
12 given -- we may have given some percentage differences on
13 a couple of those, but I -- I do not recall the specific
14 numbers.

15

16 (BRIEF PAUSE)

17

18 MS. CANDACE GRAMMOND: All we're really
19 getting at, Mr. Parkinson, is that last year there was
20 bit -- a bit more of an issue of conservat and --
21 conserva -- conservatism expressed than there was this
22 year.

23 Would you agree with that?

24 MR. NEIL PARKINSON: Yes.

25 MS. CANDACE GRAMMOND: And can you tell

1 us to what the -- this change, if you will, in
2 characterization is -- to what that is attributable?

3 MR. NEIL PARKINSON: I don't think that
4 the level of conservatism referred to in either last
5 year's or this year's is sort of out of the ordinary. It
6 -- but I think in both instances they were certainly
7 relatively small as compared to the release year over
8 year.

9 MS. CANDACE GRAMMOND: Can you tell us...
10

11 (BRIEF PAUSE)
12

13 MS. CANDACE GRAMMOND: So would the --
14 the large release in the '10/'11 fiscal year have been a
15 factor in the -- the change in characterization?

16 MR. NEIL PARKINSON: No, I don't believe
17 so. I think that the -- the degree of conservatism
18 assessed in the memo last year did not reflect any kind
19 of guessing that there might be a large release in the
20 offing.

21 I think that the -- in the preceding year
22 we accepted the assessment of the external actuary, that
23 there wasn't enough credibility around the -- you know,
24 the data. And -- and so wasn't reflective at all of any
25 suggestion that there will be a very substantial release

1 coming in the current year.

2 MS. CANDACE GRAMMOND: Mr. Parkinson,
3 when Mr. Lam speaks about there being some slight
4 conservatism, can you clarify which lines of business
5 he's speaking about.

6 MR. NEIL PARKINSON: No, unfortunately I
7 can't tell you the specific lines. But I would simply
8 say that the -- I think they were probably pretty much
9 the same lines as last year. And again, we're talking
10 about levels of conservatism where we might have been a
11 couple of percentage points different.

12 MS. CANDACE GRAMMOND: Okay. And you --
13 you commented a little bit on this earlier, but when Mr.
14 Lam uses the phrase "range of reasonableness" -- like,
15 conservatism within the range of reasonableness.

16 How -- how do we define that range?

17 MR. NEIL PARKINSON: Well, the -- I -- I
18 would say a widely held view of what that relates to for
19 property causality insurance liabilities both here and in
20 the United States, and I understand as well in other
21 major econ -- economic jurisdictions like the UK and
22 Europe, is that a range of reasonableness around property
23 casualty reserves would typically be about plus or minus
24 5 percent around a central estimate.

25 MS. CANDACE GRAMMOND: And so would Mr.

1 Lam and Ms. Friedland on this review have used that plus
2 or minus 5 percent?

3 MR. NEIL PARKINSON: Yes, I believe they
4 would have done.

5 MS. CANDACE GRAMMOND: Okay. Do you
6 know, Mr. Parkinson, whether there would have been any
7 additional testing of either a assumptions or
8 methodologies undertaken by KPMG beyond those that are
9 described in Mr. Lam's document?

10 MR. NEIL PARKINSON: Well, this is summer
11 -- summary memo. And so there is certainly more detail
12 about what was done. I would say that, you know, in the
13 broader work papers and I think I touched in general on
14 what sort of things those would be.

15 I -- I think that we would plainly have
16 spent some time -- and I know because I was involved in
17 some of those discussions, understanding what the nature,
18 you know, of the release was, how it -- how it was
19 justified, and -- and what -- what it sprang -- sprang
20 from.

21 MS. CANDACE GRAMMOND: And would KPMG
22 have been aware at the time that the results of the
23 October 2010 evaluation were based on the selection of
24 methodologies that were different than those that had
25 previously been used in February of 2010?

1 MR. NEIL PARKINSON: I -- I believe we
2 became aware of the changes after the decision making
3 occurred between management and the external actuary.

4 MS. CANDACE GRAMMOND: So by the time Mr.
5 Lam would have been preparing this document, KPMG would
6 have been aware of that? It's dated April of 2011.

7 MR. NEIL PARKINSON: Well, certainly by
8 then we were, I think, aware of it before that because,
9 you know, we -- we were doing the -- the take both at
10 year end. This is the summary memo at the end of the
11 process after the February 28th audit was concluded, so
12 we were aware of it certainly before this date.

13 MS. CANDACE GRAMMOND: Thank you. And
14 would KPMG have taken steps to test the appropriateness
15 of the changes in the selection of result to the
16 different methodologies?

17 MR. NEIL PARKINSON: Yes.

18 MS. CANDACE GRAMMOND: And what were
19 those steps?

20 MR. NEIL PARKINSON: Well, review of the
21 analysis, pri -- primarily. And, you know, looking at
22 the -- the justification for the shift and what data was
23 considered to be credible and assessing whether that was
24 appropriate in the circumstances.

25 DR. LEN EVANS: Excuse me, could I ask

1 you exactly when were you aware?

2 MR. ROBERT KOWALCHUK: We were aware of
3 the potential release of the actuarial reserve -- I'm
4 going to, off the top of my head I believe it was in late
5 December that Mr. Palmer had -- had notified me about
6 that.

7 The number at that point wouldn't have
8 been quantified, or finalized, but he did make me aware
9 of -- of -- of that fact.

10 DR. LEN EVANS: You -- you referred to --
11 you used the term "release." What do you mean by that?

12 MR. ROBERT KOWALCHUK: Well, potential
13 release of the -- the claims liability. The reduction of
14 the liability.

15 MR. NEIL PARKINSON: Yeah, you'll have to
16 forgive us. We -- we were lapsing into actuary-speak and
17 we're not even actuaries, but actuaries conventionally
18 would talk about a reserve that they would hold and when
19 they reduce the reserve, they are releasing it. So,
20 different professional background, I guess. So it's just
21 a reduction.

22 DR. LEN EVANS: All right. Thank you. I
23 think I understand.

24 MR. NEIL PARKINSON: Yeah, you may be a
25 step ahead of me if you fully understand that.

1 CONTINUED BY MS. CANDACE GRAMMOND:

2 MS. CANDACE GRAMMOND: Just on that, with
3 respect to the timing, what is the typical schedule, if
4 you will, for when KPMG does its interim work over the
5 course of the MPI fiscal year?

6 MR. ROBERT KOWALCHUK: Typical timing
7 would be -- we would start some initial planning in
8 September, the month of September. Typically there is an
9 October audit committee meeting which we attend and
10 present our audit planning report to the audit committee.

11 Subsequent to that, we would usually
12 perform some interim work and it can vary from year to
13 year, but November, December, January time frame we would
14 be on site at MPI performing some interim work.

15 Typically, the year end field work is
16 concentrated, I'm going to say starting at the end of
17 March and all through the month of April, and then
18 typically, the audit committee meeting to review the
19 financial statements is end of April or early May.

20 MS. CANDACE GRAMMOND: Thank you. And --
21 and you said in this instance, with respect to the
22 significant releases that came in -- ultimately in the
23 2010/'11 fiscal year, that you and Mr. Kowalchuk were
24 informed in late December. I take it -- and that's of
25 2010.

1 I take it that neither MPI nor Ernst &
2 Young informed you of that any earlier?

3 MR. ROBERT KOWALCHUK: That is correct.

4 MS. CANDACE GRAMMOND: Okay. And this
5 question can be for -- for either of you. It may be for
6 Mr. Parkinson.

7 Given your experience with other
8 insurance, including automobile insurance companies, have
9 you seen IBNR adjustments of the percentage magnitude of
10 this that -- that MPI experienced in this instance, over
11 the last several years?

12 MR. NEIL PARKINSON: Well. I think there
13 was some reference made by Mr. Christie to what happened
14 with State Farm last year, for instance, and that is of a
15 broadly similar magnitude, although on -- on the bad side
16 of things.

17 There was another property casualty group
18 since -- largely defunct, which were the auditors for a
19 few -- a few years, called Kingsway that, you know, is a
20 matter of public record. If you look at the increases in
21 IBNR that were booked in stages in the US, there, I think
22 it would be of a broadly similar magnitude. Those were
23 both pretty adverse kind -- kinds of situations. In
24 other words, the adjustments were bad ones.

25 I would say that there are bound to be

1 instances where relatively new organizations have been
2 applying what Mr. Christie referred to as a Bornhuetter-
3 Ferguson method, which is kind of a -- you know, you book
4 what -- you're a priori assumption of what your loss
5 ratios are going to be, to oversimplify, on an immature
6 or new product line.

7 And there have been some smaller
8 organizations that have had, you know, in a percentage
9 sense, significant declines in claims liabilities as the
10 data matured. The numbers, of course, were smaller than
11 we're talking about.

12 But from a percentage magnitude
13 standpoint, yeah, it wouldn't be unprecedented. But it's
14 -- it's not particularly usual, I would say, either.

15 MS. CANDACE GRAMMOND: Any of the
16 instances that you've experienced, Mr. Parkinson, and I
17 know the ones you've been speaking about have involved
18 adverse development, what about another situation that
19 you're aware of involving an insurer that had the -- the
20 same on the positive side?

21 MR. NEIL PARKINSON: Actually, the -- the
22 last ones I talked about where someone was starting out
23 with a new line and was booking a conservative and fairly
24 high percentage and yearly going, and then settle down to
25 lower numbers over time, that -- those were positive,

1 okay.

2 The -- the first two (2) I mentioned by
3 name were adverse, but the other ones were tended more
4 normally to be favourable.

5 MS. CANDACE GRAMMOND: Thank you. Okay,
6 I have a couple of questions then relating to IFRS.
7 We've heard some evidence in this hearing with respect to
8 the implementation of IFRS as of this fiscal year. And
9 we know that MPI had to make some accounting adjustments
10 or some adjusting entries with respect to that
11 transition.

12 And I -- I assume that KPMG reviewed those
13 provisions in connection with the audits that were
14 conducted?

15 MR. ROBERT KOWALCHUK: Those adjustments
16 have not been subject to audit yet, but we have reviewed
17 those transitional adjustments, yes.

18 MS. CANDACE GRAMMOND: And did KPMG have
19 any comments with respect to the transitional adjustments
20 or did they agree or disagree with what was done?

21 MR. ROBERT KOWALCHUK: We were in
22 agreement with the transitional adjustments, yes.

23 MS. CANDACE GRAMMOND: So that would
24 include the reclassification of the bonds from 'available
25 for sale' to 'held for trading'?

1 MR. ROBERT KOWALCHUK: Yes, that was an
2 appropriate election under IFRS.

3 MS. CANDACE GRAMMOND: And we know that
4 some of the adjustments resulted in changes to the
5 retained earnings.

6 Did KPMG review the calculations in
7 support of those entries?

8 MR. ROBERT KOWALCHUK: Yes, we have
9 reviewed them, yes.

10 MS. CANDACE GRAMMOND: And were there any
11 issues with respect to those?

12 MR. ROBERT KOWALCHUK: There were no
13 issues discovered.

14

15 (BRIEF PAUSE)

16

17 MS. CANDACE GRAMMOND: Evidence was given
18 this afternoon, and I think it was from you, Mr.
19 Parkinson, about the possibility of a \$100 million
20 provision relating to IFRS 4 and the fact that that was
21 discussed but that it was not ultimately booked?

22 MR. ROBERT KOWALCHUK: I believe that
23 might have been myself speaking of that topic. It was a
24 50/50 chance.

25 MS. CANDACE GRAMMOND: Fair enough. Kind

1 of like flipping a coin. But let's not get into the
2 probabilities of -- of doing that. My question, Mr.
3 Kowalchuk, thank you, was going to be whether KPMG had a
4 view with respect to that particular provision that was
5 expressed to MPI?

6 MR. ROBERT KOWALCHUK: Well, in our view,
7 it was premature to record any sort of provision or
8 reserve just because of the inherent uncertainty on -- on
9 trying to estimate what, if any, amount might be required
10 to address any adverse for adjustments.

11 MS. CANDACE GRAMMOND: So KPMG was
12 supportive of the entry not being booked?

13 MR. ROBERT KOWALCHUK: That is correct.

14 MS. CANDACE GRAMMOND: Okay. I'm going
15 to turn then to a few questions relating to the
16 accounting for the rebate moneys that were -- that have
17 now been paid out to ratepayers, the -- the 45 percent
18 rebate ordered by this Board in the spring of this year.

19 As the evidence reflects, that was booked
20 within the 2010/'11 fiscal year?

21 MR. ROBERT KOWALCHUK: That is correct.

22 MS. CANDACE GRAMMOND: And what I -- what
23 I want to speak to you about, Mr. Kowalchuk, is the
24 concept of a constructive obligation in -- in accounting
25 and in -- in auditing relative to how, if at all, you

1 might see a constructive obligation arising in the event
2 that the retained earnings in Basic exceed the -- the
3 range determined by the Board.

4 And if that were to occur, would you
5 consider that to be a constructive obligation?

6 MR. ROBERT KOWALCHUK: I know that
7 management undertook an analysis of that -- of that very
8 topic enlisting the support of Deloitte, who was their
9 IFRS advisors. And, from memory, I recall that the
10 conclusions reached that it was that that would not
11 represent a constructive obligation.

12 MS. CANDACE GRAMMOND: And would you
13 agree with that conclusion?

14 MR. ROBERT KOWALCHUK: I would agree.

15 MS. CANDACE GRAMMOND: So from KPMG's
16 perspective, would it be fair to say that no obligation
17 would arise that should be recorded unless and until an
18 Order was made by the Board for a rebate?

19 MR. ROBERT KOWALCHUK: That has been the
20 past practice and likely what would still continue, yes.

21 MS. CANDACE GRAMMOND: Okay. Thank you.

22 I'm just going to take a moment, Madam
23 Chair, if you don't mind, to review my notes because
24 there were some things that have been covered off
25 already.

1 (BRIEF PAUSE)

2

3 THE CHAIRPERSON: Maybe we'll just take a
4 five (5) minute break while you do that.

5 MS. CANDACE GRAMMOND: Definitely. Thank
6 you.

7

8 --- Upon recessing at 4:27 p.m.

9 --- Upon resuming at 4:33 p.m.

10

11 THE CHAIRPERSON: Okay. Let's go ahead.

12

13 CONTINUED BY MS. CANDACE GRAMMOND:

14 MS. CANDACE GRAMMOND: Thank you, Madam
15 Chair. I just have a few more questions for -- for you -
16 - the two (2) of you.

17 Some evidence was given earlier with
18 respect to the cost allocations done within the
19 Corporation. Can you tell us what, if any, steps KPMG
20 took to review or satisfy itself as to the
21 appropriateness of the amounts being allocated to Basic?

22 MR. ROBERT KOWALCHUK: In terms of the
23 appropriateness of the amounts, I think I mentioned, for
24 example, some of the audit procedures that we subject the
25 allocations to; investigating any changes from prior

1 periods; ensuring that we feel that the allocation to a
2 various line of business is reasonable.

3 Besides that, the use of our information
4 risk management specialists in terms of the coding to
5 ensure that the, you know, the calculations themselves
6 are -- are being carried out correctly. So it's those
7 types of procedures that we subject the allocations to.

8 MS. CANDACE GRAMMOND: And does KPMG
9 undertake management interviews as part of that process?

10 MR. ROBERT KOWALCHUK: Management
11 interviews would be part of the process, yes.

12 MS. CANDACE GRAMMOND: Okay. And, in the
13 same vein, still with cost allocation, was there anything
14 different with respect to the cost of the business
15 process review that KPMG did than other costs being
16 allocated?

17 MR. ROBERT KOWALCHUK: I don't think
18 there was anything special about it. I think it was all
19 part of the cost -- or part of the allocation subject to
20 audit.

21 MS. CANDACE GRAMMOND: Those are my
22 questions, Madam Chair.

23 THE CHAIRPERSON: I guess we're ready for
24 Mr. Williams.

25 MR. BYRON WILLIAMS: Madam Chair, I

1 assure you there will be no loss triangles this
2 afternoon. I wasn't that hurt by your comments.

3 Just -- just for the Board, there's one
4 exhibit which we wish to distribute. I've shared that
5 with my colleagues from MPI and it's the -- the actuarial
6 consultant's report from last year to KPMG.

7 Subject to any comment by My Learned
8 Friend, Ms. Kalinowsky, I'd suggest that that be marked
9 as CAC Exhibit Number 10 and will ask the Board secretary
10 to distribute it. It hasn't been distributed to you yet.

11 Madam Chair, it hasn't been distributed
12 yet.

13 THE CHAIRPERSON: Okay.

14 MR. BYRON WILLIAMS: And I -- I think I'd
15 ask the Board secretary to -- to distribute it.

16 THE CHAIRPERSON: Yes. She's going to do
17 that.

18

19 (BRIEF PAUSE)

20

21 THE CHAIRPERSON: Yeah, I think she's
22 trying to keep up with her regular work and do this too.
23 Not that -- it's not that she's not paying attention.
24 She's got a heavy work load.

25 MR. BYRON WILLIAMS: And I have

1 distributed it to MPI, so I think -- and if there's
2 anyone else who needs copies, I have a few extra here.

3 And -- and, Madam Chair, I would mark --
4 suggest it be marked as CAC Exhibit Number 10.

5 THE CHAIRPERSON: So that's number 10?
6 Thank you.

7

8 --- EXHIBIT NO. CAC-10: Memo from Mr. Manktelow to
9 Mr. Neil Parkinson dated
10 April 22nd, 2010

11

12 CROSS-EXAMINATION BY MR. BYRON WILLIAMS:

13 MR. BYRON WILLIAMS: Yes, and -- and
14 these -- this -- this first question does not relate to
15 this -- this exhibit, but it's -- it's more a general one
16 (1) and I may be testing the memories of the KPMG
17 witnesses, for which I apologize. But -- but maybe this
18 one won't be that much of a test.

19 Mr. Kowalchuk or Mr. Parkinson, you've
20 heard the testimony throughout the day. Have you been
21 listening in to the testimony? I see your heads nodding.

22 MR. ROBERT KOWALCHUK: Yes.

23 MR. NEIL PARKINSON: Yes.

24 MR. BYRON WILLIAMS: And you were aware
25 of a discussion that -- or do you recall a discussion I

1 had with Mr. Christie about a statement appearing in his
2 actuarial report as of October 31st, 2010, that report,
3 talking about the -- when the new reserving method --
4 method was implemented, the case reserves on ABW and AB
5 other index benefit claims to which the new tabular
6 reserves were applied immediately decreased in aggregate
7 by approximately 250 million?

8 Do you re -- you recall that discussion to
9 some degree?

10 MR. NEIL PARKINSON: Yes.

11 MR. BYRON WILLIAMS: And my simple
12 question which may test your memory or not is, in terms
13 of that figure of \$250 million relating to the -- coming
14 to MPI's attention in 2005, at what point in time, if
15 ever, was -- did that figure come to the attention of
16 KPMG?

17 MR. NEIL PARKINSON: I'd have to say, for
18 my part, I simply do not recall if that -- you know, at
19 what point. You know, thinking back over the period of
20 2005, I'm just not -- not prepared. I don't remember and
21 haven't reviewed our files to see anything going back
22 into that time period.

23 MR. BYRON WILLIAMS: So -- so you're
24 unable to -- to recall whether that came to your
25 attention, sir?

1 MR. NEIL PARKINSON: That's correct.

2 MR. BYRON WILLIAMS: Mr. Kowalchuk...?

3 MR. ROBERT KOWALCHUK: No, I'll just add
4 I wasn't part of the MPI engagement team that far back,
5 so I -- I don't have a recollection either.

6 MR. BYRON WILLIAMS: One (1) question for
7 Mr. Kowalchuk, and then I think the rest are proba --
8 probably for Mr. Parkinson for the next five (5) or six
9 (6) anyways.

10 Mr. Kowalchuk, you testified that every
11 year since 2003 KPMG had given Manitoba Public Insurance
12 a clean audit.

13 Is that correct, sir?

14 MR. ROBERT KOWALCHUK: That is correct.

15 MR. BYRON WILLIAMS: Mr. Parkinson, if
16 you want to turn to CAC Exhibit number 10. I just want
17 to explore with you this document. And -- and you'll
18 agree me, first -- first of all, that in -- in terms of
19 the audit for last year this would have been one (1) of
20 the documents considered by KPMG.

21 Is that correct, sir?

22 MR. NEIL PARKINSON: Yes, it was.

23 MR. BYRON WILLIAMS: And I'll -- I'll
24 suggest to you that this is a memo from Mr. Manktelow to
25 you dated April 22nd, 2010.

1 hazard a guess.

2 THE CHAIRPERSON: As Chair, I'm saying
3 you're moving off topic.

4 MR. BYRON WILLIAMS: Thank you, Madam
5 Chair. I thought this late in the day it might be
6 welcome.

7

8 CONTINUED BY MR. BYRON WILLIAMS:

9 MR. BYRON WILLIAMS: The subject of Mr.
10 Manktelow's report was a review of the appointed
11 actuary's reports as of October 31st, 2009, and February
12 28th, 2010.

13 Is that fair, sir?

14 MR. NEIL PARKINSON: Yes.

15 MR. BYRON WILLIAMS: And I wonder if you
16 could turn, first of all, to page 3 of his report under
17 the heading of, "Concerns or Recommendations."

18 Do you have that, sir?

19 MR. NEIL PARKINSON: Yes, I do.

20 MR. BYRON WILLIAMS: That's page 3 under
21 the heading "Concerns or Recommendations." It may be two
22 (2) sided, I'm not sure. And we're just waiting for
23 Board members to get it.

24 And in terms of Mr. -- I -- directing your
25 attention, first of all, to the second sentence there.

1 Mr. Manktelow concluded that the -- I'll suggest to you:

2 "The approach followed by Mr. Christie
3 is a conservative approach that tends
4 to result in favourable development in
5 most years. In particular, he expected
6 the two (2) major lines in Basic
7 AutoPac, being accident benefits weekly
8 benefits and accident benefits -- other
9 benefits indexed, to continue having
10 favourable developments similar to the
11 outcomes in the last few years."

12 And he also suggested that Mr. Christie's
13 total claims liabilities estimate is closer to the top
14 end of our range of reasonableness.

15 Is that your understanding of his opinion,
16 sir?

17 MR. NEIL PARKINSON: Yes, it is.

18 MR. BYRON WILLIAMS: And in -- in your
19 conversation with My Learned Friend, Ms. Grammond,
20 earlier about Mr. Lam's report of this year end and --
21 and lines that might be slightly conservative, you
22 suggested that they might be the same lines as -- as last
23 year.

24 Do you remember that suggestion, sir?

25 MR. NEIL PARKINSON: Yes, I do.

1 Although, again, I don't -- the -- Mr. Lam's memo doesn't
2 specifically delineate which of the lines are in -- in
3 play and -- as this memo does.

4 MR. BYRON WILLIAMS: At the -- but, sir,
5 your understanding would be -- but -- or, let me try that
6 again.

7 In terms of the same lines as last -- last
8 year, you were referring to the PIPP -- or accident
9 benefits weekly benefits and accident benefits other
10 benefits.

11 Would that be fair, sir?

12 MR. NEIL PARKINSON: Yes.

13 MR. BYRON WILLIAMS: Now, I just again
14 want to direct you to Mr. -- Mr. Manktelow's report of --
15 again to Page 4 now and just above the heading, "Total
16 unpaid losses." And I'm -- I'm -- again, I'm directing
17 you to the head -- the paragraph just above the heading
18 "Total unpaid losses," and in particular the second and
19 thir -- third sentences.

20 Mr. -- again, Mr. -- he suggests:

21 "Mr. Christie tends to select
22 assumptions that result in estimates
23 that are an aggregate -- or, are at the
24 upper end of our range of
25 reasonableness. For some lines of

1 business Mr. Christie's selective
2 claims liabilities are above our range
3 of reasonableness."

4 Was -- was that your understanding of Mr.
5 Manktelow's opinion at that time, sir?

6 MR. NEIL PARKINSON: Yes, it was.

7 MR. BYRON WILLIAMS: And again, just to
8 confirm. In terms of the -- the lines where Mr.
9 Manktelow was of the -- the view that the selected claims
10 liabilities were above their range of reasonableness,
11 I'll suggest to you those were Basic accident benefits
12 weekly indemnity and Basic accident benefit others.

13 Would that be your understanding as well,
14 sir?

15 You performed an undertaking on that last year, I recall.

16 MR. NEIL PARKINSON: I -- I'm sorry --

17 MR. BYRON WILLIAMS: Sorry. Would that
18 be your understanding as well in terms of the line?

19 MR. NEIL PARKINSON: I -- I do not recall
20 the specific lines he was referring to as being above the
21 range. There were some lines where I think he'd identify
22 numbers that might have been, say, 6, 7, 8 percent over.
23 But the overall total he was giving was, you know, at the
24 upper end of the range of reasonableness, so it would
25 have been closer to about 5 percent.

1 MR. BYRON WILLIAMS: Mr. -- Mr.
2 Parkinson, we can -- just in terms of my question we can
3 do it in one (1) of two (2) ways. Last year you were
4 asked to do an undertaking in terms of which were the
5 lines where they -- they were above the range of
6 reasonableness, I could ask you to do that now.

7 Or, alternatively, I could ask you to
8 accept subject to your check and review that the -- the
9 select -- the lines of business in question were AB-WI
10 and AB Other.

11 I'll leave that. What would you -- would
12 -- would you be prepared to accept that subject to check,
13 or would you pre -- prefer to do an undertaking?

14 MR. NEIL PARKINSON: We -- we can accept
15 that sub -- subject to check. I think that the -- the
16 point is that the lines identified as being somewhat
17 above the range of reasonableness this year -- we're not
18 -- there were none this year that were considered to be
19 above the range of reasonableness. There were some that
20 were identified as being somewhat conservative which was
21 different than what was stated in last year's memorandum.

22 MR. BYRON WILLIAMS: Yes, and I
23 appreciate that, sir. And I guess a point that I'll
24 suggest to you and you can agree or disagree, is that
25 when one gets a clean audit that is not a representation

1 that the estimates for all lines of business are within a
2 range of reasonableness.

3 Would that be fair, sir?

4 MR. NEIL PARKINSON: Not on a line by
5 line basis. That's right. I think it -- the -- it is on
6 an aggregate basis that -- that that's what is implied,
7 that there's no material difference, you know, on an all
8 lines combined basis.

9 MR. BYRON WILLIAMS: Now, this question
10 can go to either Mr. Kowalchuk or Mr. Parkinson. And if
11 you don't recall I -- I won't be hurt. But you may
12 recall from last year we had an -- a fairly extensive
13 discussion about cost allocation.

14 Does that ring a bell?

15 MR. NEIL PARKINSON: Yes, it does.

16 MR. BYRON WILLIAMS: And, Mr. Parkinson,
17 you'll be glad to know I won't bore you with repeating
18 that conversation this year. But based on your many
19 years of experience, it would be fair to say that -- that
20 you've seen a variety of approaches of cost allocation
21 taken to -- to a variety of businesses.

22 Would that be fair, sir?

23 MR. NEIL PARKINSON: Yes.

24 MR. BYRON WILLIAMS: And certainly you
25 would agree with me that while there may be wrong ways of

1 allocating costs between different lines of business,
2 there are probably more than one (1) -- one (1) way of --
3 of reasonably allocating costs between different lines of
4 business.

5 Would that be fair?

6 MR. NEIL PARKINSON: Yeah, I would say
7 that there's typically more than one (1) reasonable
8 approach.

9 MR. BYRON WILLIAMS: Madam Chair, I have
10 no further questions.

11 THE CHAIRPERSON: Okay. Thank you for
12 that. Now, I'm wondering, do you have any questions?

13 No. Okay. I think maybe we have come to
14 the end of the day.

15 MS. CANDACE GRAMMOND: Unless Ms.
16 Kalinowsky has any re-direct?

17 MS. KATHY KALINOWSKY: No, I have no
18 further redirect.

19 THE CHAIRPERSON: Well, I'd like to thank
20 these witnesses for the time that they've spent with all
21 of us. And I think we're ready to adjourn. We'll be
22 back again tomorrow at 9:30.

23

24 (PANEL STANDS DOWN)

25

1 --- Upon adjourning at 4:49 p.m.

2

3

4

5 Certified correct,

6

7

8

9

10

11

12 Cheryl Lavigne, Ms.

13

14

15

16

17

18

19

20

21

22

23

24

25